Plenary:

T. Facon, J. Mary, J. Harousseau, F. Huguet, C. Berthou, B. Grosbois, B. Anglaret, A. Azzedine, P. Rodon, A. Peny Intergroupe Francophone du Myélome

Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma
J Clin Oncol (Meeting Abstracts) 2006 24: 1. [Abstract]  

Plenary Presentation:

P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrózek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, R. A. Larson, and C. D. Bloomfield

Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study
J Clin Oncol (Meeting Abstracts) 2006 24: 2. [Abstract]  

Genitourinary Cancer:

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. T. Kim, C. M. Baum, and R. A. Figlin

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA3. [Abstract]  

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, T. O’Toole, S. Kong, and L. Moore

A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA4. [Abstract]  

M. I. Milowsky, M. Galsky, D. J. George, J. M. Lewin, C. P. Rozario, T. Marshall, M. Chang, D. M. Nanus, I. J. Webb, and H. I. Scher

Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4500. [Abstract]  

B. Escudier, C. Szczylik, T. Demkow, M. Staehler, F. Rolland, S. Negrier, T. E. Hutson, U. J. Scheuring, B. Schwartz, and R. M. Bukowski

Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4501. [Abstract]  

A. Ravaud, J. Gardner, R. Hawkins, H. Von der Maase, N. Zantl, P. Harper, F. Rolland, B. Audhuy, J. Machiels, I. El-Hariry Tykerb Renal Cell Cancer Study Group and GSK CoreT

Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4502. [Abstract]  

B. T. Teh, X. J. Yang, M. Tan, H. L. Kim, W. Stadler, N. G. Vogelzang, R. Amato, R. Figlin, A. Belldegrun, and C. G. Rogers

Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis
J Clin Oncol (Meeting Abstracts) 2006 24: 4503. [Abstract]  

M. J. Donovan, H. Scher, P. Scardino, A. Kotsianti, and C. Cordon-Cardo

Systems pathology for building predictive models: The androgen receptor as a prototype biomarker in prostate cancer progression and targeted therapeutic response assessment
J Clin Oncol (Meeting Abstracts) 2006 24: 4504. [Abstract]  

P. M. Venner, C. Ryan, D. P. Petrylak, G. S. Chatta, J. Ruether, K. N. Chi, J. Curd, and T. M. Beer

Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants
J Clin Oncol (Meeting Abstracts) 2006 24: 4505. [Abstract]  

W. L. Dahut, C. D. Scripture, E. M. Posadas, S. Wu, P. M. Arlen, J. L. Gulley, J. Wright, C. C. Chen, E. Jones, and W. D. Figg

Bony metastatic disease responses to sorafenib (BAY 43–9006) independent of PSA in patients with metastatic androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4506. [Abstract]  

R. C. Chen, J. A. Clark, S. P. Mitchell, and J. A. Talcott

Long-term outcomes after local treatments for prostate cancer by functional categories: Late changes, different results
J Clin Oncol (Meeting Abstracts) 2006 24: 4507. [Abstract]  

S. D. Fosså, J. Chen, G. M. Dores, K. A. McGlynn, S. J. Schonfeld, L. B. Travis NCI Testicular Cancer Research Group

Long-term non-cancer mortality among 39,657 one-year testicular cancer survivors (TCSs)
J Clin Oncol (Meeting Abstracts) 2006 24: 4508. [Abstract]  

D. Raghavan, M. S. Davis, D. Tsao-Wei, R. Ross, and S. Groshen

Increased late toxicity in 12–20 year survivors of germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4509. [Abstract]  

D. F. Bajorin, C. R. Nichols, K. A. Margolin, J. Bacik, P. G. Richardson, N. J. Vogelzang, L. Einhorn, M. Mazumdar, G. J. Bosl, and R. J. Motzer

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB
J Clin Oncol (Meeting Abstracts) 2006 24: 4510. [Abstract]  

A. Lorch, O. Rick, J. T. Hartmann, C. Kollmannsberger, B. Metzner, I. Schmidt-Wolf, W. E. Berdel, R. Schirren, J. Beyer, C. Bokemeyer for the German Testicular Cancer Study Group

Single versus sequential high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ-cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4511. [Abstract]  

P. Albers, R. Siener, S. Krege, H. Schmelz, K. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, R. Fimmers, and M. Hartmann

One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): Results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German Testicular Cancer Study Group [GTCSG] Trial 01–94)
J Clin Oncol (Meeting Abstracts) 2006 24: 4512. [Abstract]  

F. M. Calais Da Silva, F. Calais Da Silva, A. Bono, M. Brausi, P. Whelan, A. Queimadelos, J. Portillo, J. Portillo, Z. Kirkali, C. Robertson South European Uroncological Group

Phase III intermittent MAB vs continuous MAB
J Clin Oncol (Meeting Abstracts) 2006 24: 4513. [Abstract]  

A. J. Stephenson, A. Pollack, M. W. Kattan, P. T. Scardino Post-Prostatectomy Radiotherapy Consortium

Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4514. [Abstract]  

M. D. Michaelson, H. Lee, D. S. Kaufman, P. W. Kantoff, J. Finkelstein, and M. R. Smith

Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4515. [Abstract]  

D. R. Berthold, G. Pond, R. De Wit, M. A. Eisenberger, and I. F. Tannock

Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study
J Clin Oncol (Meeting Abstracts) 2006 24: 4516. [Abstract]  

M. Hussain, C. M. Tangen, P. F. Schellhammer, E. D. Crawford, C. S. Higano, G. Wilding, A. Akdas, E. J. Small, B. Donnelly, and D. Raghavan

Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162)
J Clin Oncol (Meeting Abstracts) 2006 24: 4517. [Abstract]  

T. M. Beer, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. Chatta, J. Ruether, K. N. Chi, A. Arroyo, and F. W. Clow

Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT
J Clin Oncol (Meeting Abstracts) 2006 24: 4518. [Abstract]  

G. M. Mead, G. J. Rustin, S. P. Stenning, P. Vasey, N. Aass, R. Huddart, M. Sokal, and S. Kirk

Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis
J Clin Oncol (Meeting Abstracts) 2006 24: 4519. [Abstract]  

R. Huddart, M. O’Doherty, A. Padhani, G. Rustin, G. Mead, J. K. Joffe, P. Vasey, S. Hain, S. J. Kirk, S. P. Stenning National Cancer Research Institute Testis Cancer Clinical Studies Group

A prospective study of ¹⁸FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22
J Clin Oncol (Meeting Abstracts) 2006 24: 4520. [Abstract]  

M. De Wit, M. Hartmann, W. Brenner, L. Weißbach, H. Amthauer, C. Franzius, S. Kliesch, S. Krege, R. Heicappell, R. Bares, and C. Bokemeyer

[18F]-FDG-PET in germ cell tumors following chemotherapy: Results of the German multicenter trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4521. [Abstract]  

B. I. Rini, D. J. George, M. D. Michaelson, J. E. Rosenberg, R. M. Bukowski, J. A. Sosman, W. M. Stadler, K. Margolin, T. E. Hutson, and C. M. Baum

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4522. [Abstract]  

R. M. Bukowski, F. Kabbinavar, R. A. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, H. Drabkin, J. Dutcher, F. Scappaticci, and D. McDermott

Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4523. [Abstract]  

T. Eisen, R. M. Bukowski, M. Staehler, C. Szczylik, S. Oudard, W. M. Stadler, B. Schwartz, R. Simantov, M. Shan, B. Escudier for The Sorafenib TARGETs Clinical Trial Group

Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
J Clin Oncol (Meeting Abstracts) 2006 24: 4524. [Abstract]  

C. W. Ryan, B. H. Goldman, P. N. Lara, Jr., T. M. Beer, H. A. Drabkin, and E. Crawford

Sorafenib plus interferon-2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412
J Clin Oncol (Meeting Abstracts) 2006 24: 4525. [Abstract]  

G. V. Kondagunta, J. Bacik, N. Ishill, V. Reuter, L. H. Schwartz, J. Korkola, J. Deluca, S. Sweeney, R. S. K. Chaganti, and R. J. Motzer

Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response
J Clin Oncol (Meeting Abstracts) 2006 24: 4528. [Abstract]  

P. H. De Mulder, J. Roigas, S. Gillessen, S. Srinivas, P. Pisa, N. Vogelzang, G. Fountzilas, C. Peschel, C. Baum, and B. Escudier

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4529. [Abstract]  

R. J. Amato, A. Misellati, M. Khan, and S. Chiang

A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4530. [Abstract]  

B. E. Houk, M. Amantea, R. J. Motzer, M. D. Michaelson, B. I. Rini, D. J. George, B. G. Redman, G. R. Hudes, B. Poland, and C. L. Bello

Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4531. [Abstract]  

M. Tan, B. Teh International Kidney Cancer Study Group

The von Hippel-Lindau gene mutation is associated with the good-prognosis profiling subtype of clear cell renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4532. [Abstract]  

L. Marsh, M. Khan, M. Needle, and R. Amato

Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4533. [Abstract]  

R. Dhanda, K. Gondek, J. Song, D. Cella, R. M. Bukowski, and B. Escudier

A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo
J Clin Oncol (Meeting Abstracts) 2006 24: 4534. [Abstract]  

R. A. Figlin, G. V. Kondagunta, S. Yazji, R. J. Motzer, and R. M. Bukowski

Phase II study of volociximab (M200), an 5ß1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4535. [Abstract]  

S. Negrier, D. Perol, A. Ravaud, J. O. Bay, S. Oudard, P. Fargeot, R. Delva, G. Deplanque, G. Gravis, B. Escudier for The French Immunotherapy Intergroup

Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4536. [Abstract]  

E. A. Ronnen, G. V. Kondagunta, C. Lau, P. Fischer, M. S. Ginsberg, M. Baum, S. T. Kim, I. Chen, C. M. Baum, and R. J. Motzer

A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4537. [Abstract]  

J. Gollob, T. Richmond, J. Jones, W. K. Rathmell, G. Grigson, C. Watkins, B. Peterson, and J. Wright

Phase II trial of sorafenib plus interferon-alpha 2b (IFN-2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4538. [Abstract]  

T. K. Choueiri, R. Dreicer, B. I. Rini, P. Elson, J. Garcia, T. Mekhail, and R. M. Bukowski

Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4539. [Abstract]  

K. A. David, D. M. Nanus, M. I. Milowsky, J. Ritchey, A. Stewart, and P. R. Carroll

Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma (TCC) (1998–2003): A report from the National Cancer Data Base (NCDB)
J Clin Oncol (Meeting Abstracts) 2006 24: 4540. [Abstract]  

D. C. Smith, N. J. Mackler, M. H. Hussain, R. Dunn, J. E. Montie, D. Wood, C. T. Lee, D. Petrylak, D. Quinn, and U. Vaishampayan

Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report
J Clin Oncol (Meeting Abstracts) 2006 24: 4541. [Abstract]  

M. D. Galsky, A. Iasonos, S. Mironov, J. Scattergood, S. M. Donat, B. H. Bochner, H. W. Herr, P. Russo, M. G. Boyle, and D. F. Bajorin

Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell (non-TCC) carcinomas of the urothelial tract
J Clin Oncol (Meeting Abstracts) 2006 24: 4542. [Abstract]  

R. Dreicer, S. Li, J. Manola, N. Haas, B. Roth, and G. Wilding

Phase II trial of epothilone B analogue BMS-247550 in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group
J Clin Oncol (Meeting Abstracts) 2006 24: 4543. [Abstract]  

P. Sharma, E. Sato, D. Bajorin, Y. Shen, S. Wen, V. Reuter, A. Jungbluth, S. Gnjatic, and L. Old

CD8⁺ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4544. [Abstract]  

M. S. Zaghloul, H. M. Khaled, M. Lotayef, and H. William

Adjuvant chemoradiotherapy after radical cystectomy in advanced high risk bladder cancer: A prospective randomized trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4545. [Abstract]  

J. M. Martin, T. Panzarella, D. R. Zwahlen, P. W. Chung, and P. Warde

Stage one seminoma: Evidence based guidelines for follow up
J Clin Oncol (Meeting Abstracts) 2006 24: 4546. [Abstract]  

M. Brydoy, J. Oldenburg, O. Klepp, R. M. Bremnes, E. Wist, O. Dahl, S. D. Fossa NUCG III Study group

Self-reported paresthesias, Raynaud’s phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TC) survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4547. [Abstract]  

P. J. Wiechno, M. A. Sadowska, K. S. Kubiak, T. Demkow, and J. Kaminska

Hormonal status and the quality of life of testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4548. [Abstract]  

L. H. Einhorn, S. Williams, and R. Abonour

Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4549. [Abstract]  

D. S. Sharp, B. S. Carver, S. E. Eggener, G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld

Clinical outcome of patients managed for late relapse of germ cell tumor
J Clin Oncol (Meeting Abstracts) 2006 24: 4550. [Abstract]  

B. S. Carver, B. Shayegan, R. J. Motzer, D. Bajorin, G. V. Kondagunta, G. J. Bosl, and J. Sheinfeld

Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4551. [Abstract]  

J. Aparicio, J. Garcia-Puche, M. Lomas, F. Carabantes, S. Vazquez, C. Crespo, M. Climent, A. Murias, A. Oltra, E. Barrajon Spanish Germ Cell Cancer Group

Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases
J Clin Oncol (Meeting Abstracts) 2006 24: 4552. [Abstract]  

M. R. Smith, F. Chu, J. Forrest, S. B. Malkowicz, D. Price, P. Sieber, K. G. Barnette, S. Segal, and M. S. Steiner

Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4553. [Abstract]  

J. R. Flanagan, C. Carney-Doebbeling, L. Jones, and C. Sweeney

Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4554. [Abstract]  

F. Saad, R. E. Coleman, R. Cook, M. R. Smith, J. E. Brown, J. Y. Hei, and Y. M. Chen

Predictors of clinical outcome in patients with bone metastases from prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4555. [Abstract]  

S. Halabi, S. Ou, N. J. Vogelzang, and E. J. Small

An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4556. [Abstract]  

G. R. Pond, D. R. Berthold, R. Dewit, M. Eisenberger, and I. F. Tannock

Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study
J Clin Oncol (Meeting Abstracts) 2006 24: 4557. [Abstract]  

A. M. Lin, J. E. Rosenberg, V. K. Weinberg, W. K. Kelly, M. D. Michaelson, M. Hussain, G. Wilding, M. E. Gross, and E. J. Small

Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP)
J Clin Oncol (Meeting Abstracts) 2006 24: 4558. [Abstract]  

M. Taplin, W. Xie, D. Morganstern, G. Bubley, M. Ernstoff, and M. Regan

Chemo-hormonal therapy for biochemical progression of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4559. [Abstract]  

M. Pomerantz, J. Manola, M. Taplin, G. Bubley, M. Inman, J. Lowell, P. Kantoff, and W. K. Oh

Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4560. [Abstract]  

K. Fizazi, G. R. Hudes, W. R. Berry, W. K. Kelly, J. C. Eymard, C. Logothetis, A. Le Maitre, J. P. Pignon, and S. Michiels

A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4561. [Abstract]  

P. Mathew, P. F. Thall, M. M. Johnson, W. K. Oh, A. A. Meluch, M. J. Morris, P. Troncoso, C. D. Bucana, I. J. Fidler, and C. J. Logothetis

Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)
J Clin Oncol (Meeting Abstracts) 2006 24: 4562. [Abstract]  

P. Sooriakumaran, P. Macanas-Pirard, S. Fox, H. Coley, G. Bucca, D. Lovell, A. Henderson, C. Smith, S. Langley, and R. Laing

A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4563. [Abstract]  

J. A. Garcia, C. Magi-Galluzzi, J. Rothaermel, P. Elson, M. Zhou, E. Klein, and R. Dreicer

Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4564. [Abstract]  

F. Silva, F. M. Calais Da Silva, F. Gonçalves, T. Oliver South European Uroncological Group

Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4565. [Abstract]  

J. B. Nelson, D. J. Sleep, J. D. Isaacson, and M. A. Carducci

Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naive prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4566. [Abstract]  

A. V. D’Amico, J. Cullen, Y. Chen, and D. G. McLeod

Prostate-specific antigen velocity and the odds of detecting gleason 8 to 10 prostate cancer at biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 4567. [Abstract]  

S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, D. J. George, and A. W. Partin

Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival
J Clin Oncol (Meeting Abstracts) 2006 24: 4568. [Abstract]  

F. J. Bianco, Jr., J. A. Eastham, A. J. Vickers, A. M. Serio, J. Pontes, E. A. Kline, and P. T. Scardino

Impact of the radical prostatectomy surgical technique and surgeon experience on freedom from cancer recurrence
J Clin Oncol (Meeting Abstracts) 2006 24: 4569. [Abstract]  

O. K. MacDonald, A. V. D’Amico, N. Sadetsky, D. C. Shrieve, A. W. Bakst, and P. R. Carroll

Predicting men at high risk for PSA failure after salvage radiotherapy for rising PSA following prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4570. [Abstract]  

D. V. Makarov, B. J. Trock, E. B. Humphreys, L. A. Mangold, M. A. Carducci, A. W. Partin, M. A. Eisenberger, and P. C. Walsh

Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4571. [Abstract]  

H. K. Tsai, M. Chen, D. G. McLeod, P. R. Carroll, J. P. Richie, and A. V. D’Amico

Cancer-specific survival following radical prostatectomy or radiation therapy and short course hormonal therapy in men with localized, unfavorable-risk prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4572. [Abstract]  

J. Picus, S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang

Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782
J Clin Oncol (Meeting Abstracts) 2006 24: 4573. [Abstract]  

Z. A. Dotan, K. Sathyamoorthy, F. J. Bianco, Jr, A. J. Stephenson, J. A. Eastham, P. Fearn, H. Schöder, H. I. Scher, P. T. Scardino, and M. W. Kattan

The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4574. [Abstract]  

A. Berg, A. Berner, W. Lilleby, Ø. S. Bruland, S. D. Fosså, J. Nesland, and G. Kvalheim

Clinical impact of disseminated tumor cells in patients with non-metastatic prostate cancer treated by definitive radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4575. [Abstract]  

J. L. Wright, D. W. Lin, J. E. Cowan, J. Duchane, P. R. Carroll, M. S. Litwin the CaPSURE Investigators

Quality of life in young men after radical prostatectomy: Results from the CaPSURE registry
J Clin Oncol (Meeting Abstracts) 2006 24: 4576. [Abstract]  

B. Konety, J. Cowan, J. Duchane, P. Carroll CaPSURE Investigators

Patterns of primary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE
J Clin Oncol (Meeting Abstracts) 2006 24: 4577. [Abstract]  

G. Philips, B. Sanford, S. Halabi, D. Bajorin, and E. J. Small

Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102
J Clin Oncol (Meeting Abstracts) 2006 24: 4578. [Abstract]  

N. Shinohara, T. Harabayashi, S. Suzuki, K. Nagao, S. Nagamori, H. Matsuyama, K. Naito, and K. Nonomura

Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4579. [Abstract]  

D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald, and N. Glover

Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results
J Clin Oncol (Meeting Abstracts) 2006 24: 4580. [Abstract]  

Y. Mizutani, Y. N. Li, T. Shiraishi, T. Nakamura, T. Nomoto, K. Okihara, O. Ukimura, K. Yoneda, A. Kawauchi, and T. Miki

Prognostic significance of the level of serum osteoprotegerin in patients with bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4581. [Abstract]  

J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4582. [Abstract]  

E. Herrmann, S. Bierer, M. Boegemann, E. Eltze, L. Hertle, and C. Wülfing

Expression of the endothelin axis and microvessel density in bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4583. [Abstract]  

C. Belda Iniesta, J. De Castro Carpeño, E. Casado Saenz, J. Feliu Batlle, F. Bernabeu, J. Alves, P. Cejas, M. Sereno, R. Perona, and M. Gonzalez Baron

Erythropoietin receptor expression in bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4584. [Abstract]  

C. Sammler, J. Beyer, C. Bokemeyer, J. Hartmann, W. Siegert, and O. Rick

Evaluation of prognosis in relapsed germ cell tumors: Identification of patients who profit from high dose chemotherapy (HDCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4585. [Abstract]  

A. H. Kortsaris, N. Diamantopoulos, G. Galaktidou, C. Andreadis, A. L. Boutis, C. Zavos, and D. Mouratidou

Relationship between insulin-like growth factor-1 and human testicular cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4586. [Abstract]  

T. Miki, Y. Mizutani, T. Nomoto, T. Nakamura, A. Kawauchi, D. Oka, K. Nishimura, N. Nonomura, and A. Okuyama

Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for cisplatin refractory germ cell tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 4587. [Abstract]  

D. A. Lewis, M. J. Brames, and L. H. Einhorn

Can patients (pts.) with refractory germ cell tumors (GCT) be cured after progression following high dose chemotherapy (HDCT) with tandem transplant? Results with paclitaxel + gemcitabine
J Clin Oncol (Meeting Abstracts) 2006 24: 4588. [Abstract]  

J. H. Oh, D. D. Baum, J. Ensor, S. Pham, M. D. Muddiman, S. Nguyen, and I. Chen

Long-term complications of platinum in testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4589. [Abstract]  

S. J. Harland, G. Daugaard, A. Horwich, G. M. Mead, S. D. Fossa, M. Sokal, D. Morgenstern, R. Oliver, P. A. Cook, S. P. Stenning National Cancer Research Institute Testis Cancer Clinical Studies Group

The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2
J Clin Oncol (Meeting Abstracts) 2006 24: 4590. [Abstract]  

T. B. Dorff, R. Rupani, D. T. Wei, S. Groshen, J. Pinski, D. Raghavan, D. Quinn, and A. Aparicio

POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience
J Clin Oncol (Meeting Abstracts) 2006 24: 4591. [Abstract]  

S. C. Palmer, J. Carver, L. Jacobs, K. H. Schmitz, C. Fung, E. Mohler, and D. J. Vaughn

Assessment of coronary heart disease risk in testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4592. [Abstract]  

P. E. Spiess, G. A. Brown, P. Liu, N. M. Tannir, S. Tu, A. M. Kamat, and L. L. Pisters

Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissection
J Clin Oncol (Meeting Abstracts) 2006 24: 4593. [Abstract]  

D. S. Thompson, F. A. Greco, D. R. Spigel, J. A. Sosman, E. Burkett, T. J. O’Rourke, L. Hart, and J. D. Hainsworth

Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4594. [Abstract]  

D. T. Eton, D. Cella, J. Bacik, and R. J. Motzer

A brief symptom index for renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4595. [Abstract]  

J. Patard, N. Rioux-Leclercq, K. Bensalah, and P. Fergelot

Biological significance of serum VEGF measurement in renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4596. [Abstract]  

I. Tamaskar, P. Shaheen, L. Wood, S. Hodnick, C. Nemec, J. Garcia, R. Dreicer, B. Rini, and R. Bukowski

Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents
J Clin Oncol (Meeting Abstracts) 2006 24: 4597. [Abstract]  

G. V. Raj, A. Iasonos, A. Bach, L. Hann, and P. Russo

Predicting the histology of renal masses using pre-operative Doppler ultrasonography
J Clin Oncol (Meeting Abstracts) 2006 24: 4598. [Abstract]  

S. Collins, P. M. Pierorazio, J. M. McKiernan, and M. C. Benson

Fractional percentage of tumor volume removed is a predictor of outcome following cytoreductive nephrectomy for metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4599. [Abstract]  

S. Srinivas, W. M. Stadler, R. Bukowski, R. Figlin, T. Hayes, E. W. Yankee, and E. Jonasch

Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4600. [Abstract]  

A. Al Hazzouri, S. A. Vaziri, M. Lynch, B. Schwartz, B. I. Rini, R. Bukowski, and R. Ganapathy

Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia
J Clin Oncol (Meeting Abstracts) 2006 24: 4601. [Abstract]  

P. Fergelot, N. Rioux-Leclercq, S. Zerrouki, K. Bensalah, and J. Patard

Relationship between VHL mutation status, tumor VEGF expression and plasma VEGF measurement in sporadic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4602. [Abstract]  

A. G. García, Sr., E. Esteban, C. G. Girón, P. Maroto, R. Andrés, A. Canelas, J. Caballido, J. Carles, E. Espinosa, and A. J. Lacave

Observational study in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 (rIL-2)
J Clin Oncol (Meeting Abstracts) 2006 24: 4603. [Abstract]  

X. Gao, P. Reddy, R. Dhanda, K. Gondek, Y. C. Yeh, W. M. Stadler, and E. Jonasch

Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4604. [Abstract]  

P. E. Shaheen, I. R. Tamaskar, R. N. Salas, B. I. Rini, J. Garcia, L. Wood, R. Dreicer, and R. M. Bukowski

Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
J Clin Oncol (Meeting Abstracts) 2006 24: 4605. [Abstract]  

G. Hennig, H. Paus, D. Atkins, and S. Störkel

Comparative expression profiling with kinetic RT-PCR in paired fresh frozen and archived formalin-fixed, paraffin-embedded renal cell cancer and normal tissue
J Clin Oncol (Meeting Abstracts) 2006 24: 4606. [Abstract]  

S. M. Di Stasi, A. Giannantoni, M. Valenti, L. Storti, F. Attisani, T. Palloni, E. A. Jannini, M. Bibas, and G. Zampa

Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: An interim report
J Clin Oncol (Meeting Abstracts) 2006 24: 4607. [Abstract]  

A. Laplanche, P. Beuzeboc, J. Lumbroso, M. Di Palma, C. Theodore, D. Prapotnich, B. Escudier, J. Bouzy, V. Haddad, and K. Fizazi

A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine
J Clin Oncol (Meeting Abstracts) 2006 24: 4608. [Abstract]  

E. Small, C. Higano, N. Tchekmedyian, O. Sartor, B. Stein, R. Young, J. Vestal, W. Moseley, S. Fischkoff, and I. Lowy

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4609. [Abstract]  

J. Graff, M. Mori, H. Li, M. Garzotto, D. Penson, A. Potosky, and T. M. Beer

Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study
J Clin Oncol (Meeting Abstracts) 2006 24: 4610. [Abstract]  

D. Douglas, H. Zhong, J. Ro, C. Oddoux, M. Pincus, J. Satagopan, W. Gerald, H. Scher, P. Lee, and I. Osman

Novel mutations in tyrosine kinase domain of epidermal growth factor receptor in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4611. [Abstract]  

P. M. Pierorazio, S. M. Lambert, T. R. McCann, A. E. Katz, C. A. Olsson, M. C. Benson, and J. M. McKiernan

Evaluating high-grade prostatic intraepithelial neoplasia as a predictor of outcome following radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4612. [Abstract]  

M. J. Morris, M. I. Milowsky, N. Pandit-Taskar, C. Divgi, K. A. David, C. P. Rozario, S. Vallabhajosula, S. J. Goldsmith, H. I. Scher, and D. M. Nanus

Phase 2 trial of ¹⁷⁷Lutetium (¹⁷⁷Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4613. [Abstract]  

J. S. Chan, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. S. Chatta, J. Ruether, K. N. Chi, J. Young, C. Shen, and T. M. Beer

Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT
J Clin Oncol (Meeting Abstracts) 2006 24: 4614. [Abstract]  

S. Gogov, F. Hussain, G. Naglie, I. Tannock, N. E. Fleshner, M. D. Krahn, S. Duff Canning, P. Warde, and S. M. Alibhai

Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer?
J Clin Oncol (Meeting Abstracts) 2006 24: 4615. [Abstract]  

T. J. Daskivich, M. M. Regan, P. W. Kantoff, and W. K. Oh

Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4616. [Abstract]  

M. Garzotto, S. Mongoue-Tchokote, J. Shannon, L. Peters, M. H. Sokoloff, T. M. Beer, and M. Mori

Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4617. [Abstract]  

G. Liu, W. Wang, R. Dipaola, M. Carducci, and G. Wilding

A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803)
J Clin Oncol (Meeting Abstracts) 2006 24: 4618. [Abstract]  

A. Hung, L. P. Depaula, S. Mongoue-Tchokote, and M. Garzotto

Pre-treatment PSA velocity (PSAV) is not predictive of outcomes after radical prostatectomy (RP) in a referral cohort
J Clin Oncol (Meeting Abstracts) 2006 24: 4619. [Abstract]  

O. Sartor, C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino

Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry
J Clin Oncol (Meeting Abstracts) 2006 24: 4620. [Abstract]  

S. Wu, E. Jones, J. Gulley, P. Arlen, C. Chen, W. Figg, and W. Dahut

Routine interval computed tomography in detecting new soft tissue disease in patients with androgen-independent prostate cancer (AIPC) and only bone metastasis
J Clin Oncol (Meeting Abstracts) 2006 24: 4621. [Abstract]  

P. A. Johnstone, M. Goodman, K. Ward, V. Assikis, and K. Ogan

Salvage prostatectomy for prostate cancer (CaP): Data from the Surveillance Epidemiology and End Results (SEER) database
J Clin Oncol (Meeting Abstracts) 2006 24: 4622. [Abstract]  

D. Crawford, N. Serkova, E. Gamito, R. Jones, C. O’Donnell, and T. Hedlund

Nuclear magnetic resonance spectroscopy of expressed prostatic secretions: Metabolite citrate and derivatives are potential markers of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4623. [Abstract]  

W. A. See, D. G. McLeod, P. Iversen, M. P. Wirth, J. Armstrong, S. Navani on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: Results from the Early Prostate Cancer program
J Clin Oncol (Meeting Abstracts) 2006 24: 4624. [Abstract]  

O. Caffo, T. Sava, E. Comploj, A. Fariello, F. Zustovich, F. Valduga, M. Frisinghelli, R. Segati, C. Sacco, A. Perin, and G. Pappagallo

A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4625. [Abstract]  

C. J. Ryan, J. Rosenberg, A. Lin, L. Ruttner, V. Weinberg, and E. Small

Outcome of patients with non-metastatic versus metastatic hormone refractory prostate cancer (HRPC) treated with second-line hormonal therapy consisting of ketoconazole (keto) plus granulocyte macrophage colony stimulating factor (GM-CSF)
J Clin Oncol (Meeting Abstracts) 2006 24: 4626. [Abstract]  

B. Montgomery, D. Lin, C. Ryan, M. Garzotto, and T. M. Beer

Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4627. [Abstract]  

P. Iversen, M. P. Wirth, W. A. See, II, D. G. McLeod, T. Morris, J. Armstrong on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years
J Clin Oncol (Meeting Abstracts) 2006 24: 4628. [Abstract]  

M. P. Wirth, W. A. See, II, D. G. McLeod, P. Iversen, T. Morris, J. Armstrong on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

Delaying metastatic disease progression in locally advanced disease – Results from the Early Prostate Cancer program at a median follow-up of 7.4 years
J Clin Oncol (Meeting Abstracts) 2006 24: 4629. [Abstract]  

D. J. Sleep, J. B. Nelson, D. P. Petrylak, J. D. Isaacson, and M. A. Carducci

Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone
J Clin Oncol (Meeting Abstracts) 2006 24: 4630. [Abstract]  

M. R. McKenzie, K. N. Chi, A. Neville, S. Ellard, B. Baerg, D. Ruether, E. Winquist, R. Segal, and H. Lukka

Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)
J Clin Oncol (Meeting Abstracts) 2006 24: 4631. [Abstract]  

J. Domingo-Domenech, E. Gallardo, X. Filella, E. Fernandez, P. Fernandez, P. Gascon, and B. Mellado

Serum c-erbB-2 ectodomain (ECD) correlates with immunohistochemical c-erbB-2 expression and predicts an aggressive clinical outcome in hormone-independent prostate cancer (HIPC) patients (pts) treated with docetaxel (D)
J Clin Oncol (Meeting Abstracts) 2006 24: 4632. [Abstract]  

C. A. O’Brien, S. Mongoue-Tchokote, L. Collins, S. Spurgeon, L. Peters, T. M. Beer, M. Mori, and M. Garzotto

Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason 7 prostate cancer in a referral population
J Clin Oncol (Meeting Abstracts) 2006 24: 4633. [Abstract]  

S. Marur, L. Heilbrun, O. Kucuk, M. L. Cher, J. Forman, E. Heath, and U. Vaishampayan

Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4634. [Abstract]  

L. K. Aguilar, B. Teh, W. Mai, J. Caillouet, G. Ayala, E. Aguilar-Cordova, and E. Butler

Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4635. [Abstract]  

A. Andea, I. Osman, P. Scardino, H. Scher, and W. Gerald

Mutational profiling of protein kinases in prostate carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4636. [Abstract]  

R. K. Nam, K. W. Marshall, R. Zheng, H. W. Zhang, S. A. Narod, and C. C. Liew

Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 4637. [Abstract]  

L. Abetz, V. Barghout, R. Arbuckle, V. Bosch, N. Shirina, and F. Saad

Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4638. [Abstract]  

A. Banu, D. Helley, E. Banu, A. M. Fischer, F. Scotte, A. Bouziane, and S. Oudard

Platelet microparticles (PMP): A predictive factor of overall survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4639. [Abstract]  

M. M. Regan, T. J. Daskivich, P. W. Kantoff, and W. K. Oh

Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4640. [Abstract]  

O. Stoss, P. Albers, M. Werther, D. Zielinsky, N. Jost, J. Rueschoff, and T. Henkel

Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4641. [Abstract]  

P. Carlini, E. Bria, M. Ciccarese, M. Milella, G. Arcangeli, M. Gallucci, E. Ruggeri, E. Terzoli, F. Cognetti, and D. Giannarelli

Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials
J Clin Oncol (Meeting Abstracts) 2006 24: 4642. [Abstract]  

S. Kumar, C. Harrison, M. Shelley, and M. Mason

Meta-analysis of neo-adjuvant androgen deprivation therapy (AD) in localised prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4643. [Abstract]  

N. M. Hahn, C. Whalen, and C. J. Sweeney

Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group phase II study—Preliminary analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 4644. [Abstract]  

R. D. Nurani, K. E. Wallner, G. S. Merrick, P. Orio, J. Virgin, and L. True

The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4645. [Abstract]  

M. Nakabayashi, W. Xie, M. M. Regan, D. M. Jackman, P. W. Kantoff, and W. K. Oh

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4646. [Abstract]  

P. U. Moffett, M. A. Choudry, L. A. Ferguson, D. A. Williams, R. V. La Rocca, F. J. Hendler, and D. A. Laber

Update on a phase II study of cyclophosphamide, etoposide and estramustine in patients with androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4647. [Abstract]  

T. Kang, P. Nichols, E. Skinner, S. Groshen, G. Valin, W. Ye, and D. Raghavan

Functional heterogeneity of prostatic intra-epithelial neoplasia: Length of hormonal therapy influences response
J Clin Oncol (Meeting Abstracts) 2006 24: 4648. [Abstract]  

M. Saraiya, D. Werny, and T. Thompson

Relationship of body mass index and other anthropometric measures and prostate specific antigen, NHANES 2001–2002
J Clin Oncol (Meeting Abstracts) 2006 24: 4649. [Abstract]  

S. F. Slovin, L. Daigneault, H. Dulude, C. Panchal, J. Richardson, T. Curley, A. Delacruz, M. Fleisher, M. Morris, and H. Scher

Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC)—The US experience
J Clin Oncol (Meeting Abstracts) 2006 24: 4650. [Abstract]  

J. E. Michels, S. Ellard, L. Le, N. Murray, E. Guns, A. Hagey, and K. N. Chi

A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4651. [Abstract]  

N. J. Fitzsimons, S. Freedland, J. Presti, Jr., C. Amling, C. Kane, M. Terris, and W. Aronson

Is biopsy Gleason sum an independent predictor of biochemical progression following radical prostatectomy after adjusting for the pathological Gleason sum?
J Clin Oncol (Meeting Abstracts) 2006 24: 4652. [Abstract]  

T. Nelius, T. Klatte, F. Reiher, S. Filleur, R. Yap, and E. P. Allhoff

Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4653. [Abstract]  

K. Touijer, F. Rabbani, J. Romero Otero, F. Secin, and B. Guillonneau

Extended vs. limited laparoscopic pelvic lymph node dissection for prostate cancer: The value of Partin tables in selection of the need for and the extent of dissection
J Clin Oncol (Meeting Abstracts) 2006 24: 4654. [Abstract]  

J. Bahary, K. Bae, D. Taussky, M. Roach, III, H. M. Sandler, and W. U. Shipley

Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of Radiation Therapy Oncology Group protocol 9413
J Clin Oncol (Meeting Abstracts) 2006 24: 4655. [Abstract]  

C. R. Porter, J. Wright, L. Borden, K. Jason, and K. Latchemsetty

Are men with larger prostates and bothersome voiding symptoms less likely to have significant prostate cancer?
J Clin Oncol (Meeting Abstracts) 2006 24: 4656. [Abstract]  

A. C. Ferrari, L. Wang, X. Liu, and X. Liu

Androgen receptor (AR) modulation strategies for recurrent prostate cancer (PC) without androgen suppression
J Clin Oncol (Meeting Abstracts) 2006 24: 4657. [Abstract]  

A. Reichle, J. Grassinger, K. Bross, J. Wilke, T. Suedhoff, A. Berand, W. Wieland, and R. Andreesen

Effect of anti-inflammatory therapy in patients with metastatic renal cell carcinoma on clinical response
J Clin Oncol (Meeting Abstracts) 2006 24: 14500. [Abstract]  

S. Thakkar, T. Hutson, J. Garcia, J. Rothaermal, M. Bart, and R. Dreicer

A phase II trial of gemcitabine and docetaxel in hormone-refractory metastatic prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14501. [Abstract]  

S. A. North, S. Marwaha, and P. M. Venner

The importance of etoposide dose intensity in the management of metastatic germ cell tumours and the role of paclitaxel in salvage treatment of relapsing patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14502. [Abstract]  

A. J. Montero, C. Diaz-Montero, X. Wang, B. W. McIntyre, and N. Tannir

Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa)
J Clin Oncol (Meeting Abstracts) 2006 24: 14503. [Abstract]  

C. N. Moore, P. Creel, W. P. Petros, T. Torain, S. Yenser, J. Gockerman, H. Hurwitz, A. Garcia Turner, D. J. Sleep, and D. J. George

Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14504. [Abstract]  

M. A. Moyad and T. A. Kirk

National study of patients, caregivers and physicians reveals pain associated with advanced prostate cancer as the primary concern
J Clin Oncol (Meeting Abstracts) 2006 24: 14505. [Abstract]  

J. Y. Luh, S. J. Wang, C. D. Fuller, and C. R. Thomas, Jr

A SEER database analysis of conditional survival for prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14506. [Abstract]  

O. Yossepowitch, S. E. Eggener, B. H. Bochner, S. M. Donat, H. W. Herr, and G. Dalbagni

Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid-treated and immunocompromised patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14507. [Abstract]  

J. H. Hayes, W. K. Oh, P. W. Kantoff, J. B. Manola, M. R. Smith, E. P. Gelmann, G. Bubley, S. P. Balk, and M. Taplin

Mifepristone (RU-486) in androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14508. [Abstract]  

M. Zhou, I. Tamaskar, L. Sercia, B. I. Rini, and R. M. Bukowski

Expression of caveolin-1 in renal neoplasms
J Clin Oncol (Meeting Abstracts) 2006 24: 14509. [Abstract]  

I. Cordia, C. H. Ohlmann, U. Engelmann, and A. Heidenreich

Prognostic risk factors for survival following adjuvant chemotherapy for locally advanced urothelial bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14510. [Abstract]  

J. Pettus, D. Sharp, Y. Ofer, A. Bach, and P. Russo

Tumor location does not impact return of renal function following partial nephrectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 14511. [Abstract]  

D. P. Petrylak, S. G. Mohile, G. Shelton, R. A. Carr, J. Steinberg, D. Sleep, J. Melia, M. J. Rieser, D. Nanus, and M. I. Milowsky

Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14512. [Abstract]  

L. Hart, T. Ciuleanu, J. Hainsworth, S. Oudard, E. R. Berger, J. Alexandre, K. N. Chi, D. Ruether, J. R. MacDonald, and E. Cvitkovic

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 14513. [Abstract]  

H. Muniswamy, J. P. Dutcher, P. Mannam, S. Malik, V. Rusciano, L. Paul, and P. H. Wiernik

Role of prognostic factors in patients with metastatic renal cell carcinoma (MRCC) eligible for treatment with interleukin (IL2)
J Clin Oncol (Meeting Abstracts) 2006 24: 14514. [Abstract]  

B. Mellado, A. Font, L. A. Aparicio, E. Gallardo, J. R. Mel, A. Alcaraz, J. Areal, F. J. Gómez Veiga, N. Hannaoui, and P. Gascón

Phase II trial of weekly docetaxel (D) and complete androgen blockade (CAB) prior to radical prostatectomy (RP) in high-risk localized prostate cancer (PC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 14515. [Abstract]  

M. Gittelman, P. Pommerville, J. De La Rosette, B. E. Persson, J. K. Jensen, T. K. Olesen on behalf of the Degarelix Study Groups

Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14516. [Abstract]  

A. Misellati, S. Phan, and R. J. Amato

Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14518. [Abstract]  

B. Kasimis, V. Chang, J. Cogswell, N. Sambamoorthi, M. Gonzalez, S. Srinivas, F. Zhong, E. Morales, L. Duque, and M. Blumenfrucht

Combination therapy with docetaxel (D) and celecoxib (C) in patients (pts) with hormone resistant prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14519. [Abstract]  

D. R. Shaffer, L. E. Abrey, K. Beekman, C. Eicher, M. Morris, S. Slovin, J. Feldstein, S. Larson, N. Rosen, and H. I. Scher

A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2006 24: 14520. [Abstract]  

G. A. Gignac, M. J. Morris, L. H. Schwartz, E. Lis, and H. I. Scher

Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14521. [Abstract]  

C. Priolo, D. Tang, M. Brahmandam, B. Benassi, E. Sicinska, S. Ogino, A. Farsetti, A. Porrello, P. G. Febbo, J. Zimmermann, and M. F. Loda

USP2a is an oncogenic isopeptidase and a potential target in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14522. [Abstract]  

D. Sahi, C. H. Ohlmann, I. Cordia, U. Engelmann, and A. Heidenreich

PSA flare-up in patients with hormone-refractory prostate cancer (HRPCA) receiving docetaxel-based chemotherapy: Incidence and differentiation from progressive disease
J Clin Oncol (Meeting Abstracts) 2006 24: 14523. [Abstract]  

V. Tagalakis, H. Tamim, J. Collet, S. R. Kahn, M. Blostein, and J. A. Hanley

The effect of warfarin on the risk of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14524. [Abstract]  

T. Klatte, A. Ittenson, F. Röhl, M. Ecke, E. P. Allhoff, and M. Böhm

Perioperative immunomodulation with interferon-alpha in patients with renal cell carcinoma: Early results of a controlled phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14525. [Abstract]  

P. Jiang and C. S. Higano

Phase I study of interleukin 2 (IL2) maintenance after induction with weekly docetaxel and estramustine in patients with metastatic hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14526. [Abstract]  

M. Kohli, J. Huang, G. Palapattu, R. Dennis, J. Yao, T. Lester, and W. Ricke

Cellular localization of thrombin in prostate: Implications for thrombin targeted therapy in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14527. [Abstract]  

A. Mehta, M. Stein, S. Goodin, S. Yao, J. Shih, M. Todd, and R. S. Dipaola

Pre-treatment PSA doubling time (PSADT) predicts biochemical response to chemotherapy in patients with androgen sensitive PSA progression after local therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 14528. [Abstract]  

S. Vázquez Estévez, J. Mel Lorenzo, E. Álvarez Gómez, and G. Quintero Aldana

A phase II study of biweekly docetaxel and vinorelbine for hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14529. [Abstract]  

F. Honecker, S. Glaesener, T. Rohlfing, T. H. Brummendorf, C. Bokemeyer, and S. Balabanov

Comparative proteome analysis of gonadal and extragonadal germ cell tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 14530. [Abstract]  

M. C. Scholz, R. Lam, B. Guess, S. Strum, H. Johnson, and R. Jenrrich

Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression
J Clin Oncol (Meeting Abstracts) 2006 24: 14531. [Abstract]  

J. S. Lam, R. H. Goel, A. J. Pantuck, R. A. Figlin, and A. S. Belldegrun

Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14532. [Abstract]  

W. K. Oh, J. Manola, R. W. Ross, A. Berkowitz, C. W. Ryan, K. M. Eilers, and T. M. Beer

A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 14533. [Abstract]  

P. Sperone, M. Volante, A. Berruti, E. Bollito, E. Frangipane, F. Daffara, M. Terzolo, G. Gorzegno, L. Dogliotti, and M. Papotti

Matrix metalloproteinase type 2 (MMP2) is selective expressed in adrenocortical carcinoma but not in adrenal adenoma: An immunohistochemical study
J Clin Oncol (Meeting Abstracts) 2006 24: 14534. [Abstract]  

W. Kassouf, R. Sanchez-Ortiz, P. Tamboli, S. Matin, and D. Swanson

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology
J Clin Oncol (Meeting Abstracts) 2006 24: 14535. [Abstract]  

R. Shazer, A. Bharne, E. Nepomuceno, J. Mirocha, C. Ramirez, D. Luthringer, S. Holden, D. B. Agus, and M. Gross

Biomarkers and obesity in surgically treated patients with prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14536. [Abstract]  

A. J. Rodney, A. Siefker-Radtke, N. M. Tannir, S. Swisher, G. Walsh, R. E. Millikan, and L. C. Pagliaro

Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14538. [Abstract]  

A. J. Pantuck, P. Fergelot, J. Patard, J. Lam, A. S. Belldegrun, and R. A. Figlin

Pilot study of VHL mutation analysis to predict response to interleukin-2 in patients with metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14539. [Abstract]  

D. Huang, G. P. Casale, N. K. Wehbi, J. Tian, and G. P. Hemstreet, III

Altered expression of ß-catenin and UDP-glucose dehydrogenase in normal appearing acini of cancer-bearing prostate glands, detected by quantitative fluorescence imaging analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 14540. [Abstract]  

M. S. Wolf, J. A. Zagory, C. Chang, S. Knight, P. Ray, M. Kozloff, A. Starr, E. A. Lyons, S. Costello, and C. L. Bennett

Literacy and race predictors in localized prostate cancer treatment choice
J Clin Oncol (Meeting Abstracts) 2006 24: 14541. [Abstract]  

C. P. Evans, P. N. Lara, Jr, H. Kung, and J. C. Yang

Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14542. [Abstract]  

G. V. Masucci, E. Andersson, L. Egevad, K. Kälkner, U. Harmenberg, M. Ryberg, S. Nilsson, and P. Pisa

High frequency of human leucocyte antigen (HLA) A2 and HLA-B7, -B44, -B15 and -DRB1–4 haplotypes in Swedish prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14543. [Abstract]  

V. Barghout, L. Abetz, R. Arbuckle, V. Bosch, Y. Hei, and F. Saad

Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status
J Clin Oncol (Meeting Abstracts) 2006 24: 14544. [Abstract]  

G. Sonpavde, K. Slawin, J. M. Levitt, and L. Guariguata

Clinical experience with extended lymph node dissection during radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 14545. [Abstract]  

A. B. Jani, A. Shoushtari, and J. Feinstein

The role of androgen ablation with low dose rate brachytherapy in the treatment of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14546. [Abstract]  

L. A. Korde, A. Premkumar, J. L. Kramer, W. Linehan, S. Pfeiffer, G. Bratslavsky, and M. H. Greene

Testicular ultrasound (TU) screening in men from familial testicular cancer (FTC) kindreds
J Clin Oncol (Meeting Abstracts) 2006 24: 14547. [Abstract]  

K. Lang, N. Danchenko, K. Gondek, B. Schwartz, and D. Thompson

Burden of illness analysis of renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14548. [Abstract]  

T. A. Mays, J. Sarantopoulos, A. Tolcher, I. Lowy, G. Preston, E. Levy, M. D. Oslund, E. Manchen, A. Kelly, and W. M. Stadler

MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14549. [Abstract]  

T. E. Hutson, S. Vukelja, S. Nicol, K. E. Hood, A. Delgado, D. Ilegbodu, and W. R. Berry

Phase I study of gemcitabine and cisplatin followed by pemetrexed and gemcitabine in patients with metastatic transitional cell carcinoma of the urothelium: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 14550. [Abstract]  

T. R. Blom, R. A. Somer, W. Shih, M. Sarno, D. McNally, M. Todd, S. Yao, G. Lu-Yao, R. Dipaola, and M. N. Stein

Variation in local treatment of prostate cancer by hospital within New Jersey
J Clin Oncol (Meeting Abstracts) 2006 24: 14551. [Abstract]  

N. Sharifi, E. Hurt, and W. L. Farrar

TGFBR3 is lost in prostate cancer, contributing to malignant transformation
J Clin Oncol (Meeting Abstracts) 2006 24: 14552. [Abstract]  

D. E. Linstadt, M. Logsdon, D. Stickney, D. Chabra, M. Russo, and S. Workman

Permanent ¹²⁵I prostate brachytherapy outcome in patients younger than 60
J Clin Oncol (Meeting Abstracts) 2006 24: 14553. [Abstract]  

R. Molife, S. Patterson, C. Riggs, C. Higano, W. M. Stadler, D. Dearnaley, C. Parker, W. McCulloch, A. Shalaurov, and J. S. De-Bono

Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14554. [Abstract]  

T. McCann, P. M. Pierorazio, R. Mitchell, M. Desai, C. A. Olsson, M. C. Benson, and J. McKiernan

Pre-biopsy PSA and biopsy gleason sum; evaluating the independence of two independent variables
J Clin Oncol (Meeting Abstracts) 2006 24: 14555. [Abstract]  

T. Wiegel, G. Lohm, S. Hoecht, D. Bottke, K. Neumann, and W. Hinkelbein

Salvage radiotherapy (SR) in patients (pts) with prostate cancer (PC) and rising prostate specific antigen (PSA) after radical prostatectomy (RP): Results from a single-center study
J Clin Oncol (Meeting Abstracts) 2006 24: 14556. [Abstract]  

J. Stephenson, R. J. Amato, S. Hotte, J. Nemunaitis, B. Berman, K. Bélanger, T. A. Patterson, A. R. Macleod, G. K. Reid, and R. E. Martell

A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF) in nephrectomized patients (pts) with advanced renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14557. [Abstract]  

A. Bamias, E. Kastritis, G. Bozas, V. Koutsoukou, N. Antoniou, H. Katsifotis, K. Konstantinidis, A. Skolarikos, C. Deliveliotis, and M. A. Dimopoulos

Cisplatin versus carboplatin-based chemotherapy in inoperable or recurrent urothelial carcinoma: A retrospective analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 14558. [Abstract]  

S. Sewak, S. Kosmider, V. Ganju, A. Woollett, B. Le, E. Yeow, M. Henry, and R. Bell

A phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer (HRPC): Double tubulin targeting
J Clin Oncol (Meeting Abstracts) 2006 24: 14559. [Abstract]  

F. Merlin, M. Riolfi, T. Sava, F. Consoli, C. Griso, P. Manno, A. B. Porcaro, C. Ghimenton, L. Comunale, and G. Cetto

Upper urinary tract cancer: Prognostic factors for bladder tumours development and systemic relapse
J Clin Oncol (Meeting Abstracts) 2006 24: 14560. [Abstract]  

N. T. Karanikolas, F. P. Secin, J. Stasi, B. S. Carver, Z. Dotan, and J. Sheinfeld

Non-seminomatous retroperitoneal histology in patients with a pure testicular seminoma and an elevated serum alpha feto-protein
J Clin Oncol (Meeting Abstracts) 2006 24: 14561. [Abstract]  

G. Pomara, M. Simone, L. Fontana, S. Giusti, C. Bartolozzi, and F. Francesca

DHAIS (Diagnosis-Helping-Accuracy-Imaging-Study) study: Combined endorectal MR and MR spectroscopic imaging in the diagnosis of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14562. [Abstract]  

A. Flechon, N. Noel, M. Rivoire, F. Mithieux, and J. Droz

Thoracic surgery of residual masses after first-line chemotherapy in patients with testicular (T) or primary retroperitoneal (PR) non seminomatous germ cell tumors (NSGCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 14563. [Abstract]  

R. Oliver, T. Powles, P. Ell, U. Somasundram, and J. Shamash

22 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Potential for acceleration by a new surrogate end point, 72 hr PET scan response?
J Clin Oncol (Meeting Abstracts) 2006 24: 14565. [Abstract]  

J. Diallo, B. Péant, L. Lessard, N. Delvoye, C. Le Page, A. Mes-Masson, and F. Saad

A ligand-independent androgen receptor function protects from inositol hexakisphosphate-induced cell death
J Clin Oncol (Meeting Abstracts) 2006 24: 14566. [Abstract]  

F. Zhong, B. Kasimis, V. Chang, N. Sambamoorthi, S. Srinivas, J. Cogswell, E. Morales, M. Gonzalez, L. Duque, and M. Blumenfrucht

A phase II trial of epirubicin (E), estramustine phosphate (EP), and celecoxib (C) as second line treatment of patients (pts) with hormone resistant prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14567. [Abstract]  

V. R. Phooshkooru, H. J. Spencer, and M. Kohli

A phase II report of longitudinal bone marker time trends in racially diverse prostate cancer patients receiving zoledronic acid with androgen deprivation
J Clin Oncol (Meeting Abstracts) 2006 24: 14568. [Abstract]  

C. Joynson, P. Symonds, and S. Sundar

Anaemia in patients with transitional cell carcinoma (TCC) of the bladder treated with radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 14569. [Abstract]  

D. G. McNeel, E. J. Dunphy, L. E. Johnson, T. P. Frye, M. J. Staab, D. L. Horvath, J. Straus, D. Alberti, G. Liu, and G. Wilding

A plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) elicits antigen-specific T cells in patients with stage D0 prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14570. [Abstract]  

S. Bierer, M. E. Bode, O. A. Brinkmann, and L. Hertle

Interleukin-2, interferon alpha and 5-fluorouracil immunochemotherapy with and without 13-cis-retinoic acid in patients with metastatic renal cell carcinoma: Results of a prospective randomized trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14571. [Abstract]  

B. S. Teh, C. Bloch, A. C. Paulino, L. Doh, S. Chiang, S. Shen, D. Baskin, J. Jac, and R. J. Amato

The treatment of primary and metastatic renal cell carcinoma (RCC) with stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS)
J Clin Oncol (Meeting Abstracts) 2006 24: 14572. [Abstract]  

J. Blitstein and R. Macchia

Predicting the pathology of post-BCG lesions
J Clin Oncol (Meeting Abstracts) 2006 24: 14573. [Abstract]  

N. Androulakis, I. Boukovinas, V. Bozionelou, A. Kalykaki, A. Potamianou, A. Pallis, L. Vamvakas, I. Gkioulbasanis, I. Souglakos, and G. Sfakiotaki

Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 14574. [Abstract]  

A. E. Katz, P. M. Pierorazio, P. Masson, E. T. Goluboff, B. A. Stone, J. M. McKiernan, M. C. Benson, and C. A. Olsson

Results of a phase I trial administering Zyflamend to subjects with high-grade prostatic intraepithelial neoplasia
J Clin Oncol (Meeting Abstracts) 2006 24: 14575. [Abstract]  

C. Theodore, S. Droupy, A. Laplanche, P. Wibault, K. Fizazi, and M. Terrier-Lacombe

Risk of late relapse after surveillance for stage I mixed (M) or non seminomatous (NS) testicular germ cell tumors (TGCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 14576. [Abstract]  

E. D. Bernstein, K. Bae, L. A. Baldridge, S. Zhang, L. Cheng, H. Wolkov, M. Pilepich, A. P. Dicker, and C. J. Sweeney

Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610
J Clin Oncol (Meeting Abstracts) 2006 24: 14578. [Abstract]  

T. M. Feinstein, D. M. Friedland, K. E. McIntire, S. A. Jacobs, W. A. Ferri, M. F. Earle, K. D. Hyoung, L. M. Brown, and G. S. Chatta

A phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens
J Clin Oncol (Meeting Abstracts) 2006 24: 14580. [Abstract]  

M. Westergaard, H. F. Hansen, C. A. Thrue, J. B. Hansen, L. S. Kjaerulff, E. M. Straarup, O. Olsen, L. W. Dalby, L. Hildebrandt-Eriksen, and P. Kearney

SPC2968—A novel Hif-1 antagonist for treatment of clear cell renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14581. [Abstract]  

D. O. Henry, S. C. Chen, and M. K. Wong

Targeted molecular imaging of prostate cancer using tumor endothelium homing Arg-Arg-Leu peptides
J Clin Oncol (Meeting Abstracts) 2006 24: 14582. [Abstract]  

Y. Tsai, C. Lin, C. Hsu, K. Huang, C. Huang, A. Cheng, N. J. Vogelzang, and Y. Pu

Prognostic factors for patients with metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens
J Clin Oncol (Meeting Abstracts) 2006 24: 14583. [Abstract]  

S. Sharef, J. Jac, M. Khan, and R. J. Amato

Rapamycin for androgen-independent prostrate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14584. [Abstract]  

T. F. Wimpissinger, T. Felzmann, H. Hügel, P. Funovics, and W. Stackl

Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells
J Clin Oncol (Meeting Abstracts) 2006 24: 14585. [Abstract]  

R. Sanchez-Ortiz, P. Tamboli, M. L. Lozano, S. Matin, and C. G. Wood

Adjuvant thalidomide improves disease specific survival for patients with renal cell carcinoma at high risk for relapse following surgery
J Clin Oncol (Meeting Abstracts) 2006 24: 14586. [Abstract]  

B. Guix, T. M. Lacorte, and F. Guedea

Quality of life in intermediate or high risk prostate cancer patients treated by 3-D external beam radiotherapy and brachytherapy with or without androgen deprivation
J Clin Oncol (Meeting Abstracts) 2006 24: 14587. [Abstract]  

M. E. Martin, L. A. Ferguson, D. A. Williams, and D. A. Laber

A phase I/II study of docetaxel in combination with doxorubicin HCI liposome injection in advanced androgen-independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14588. [Abstract]  

E. C. De Haas, C. Meijer, N. Zwart, G. Van der Steege, H. M. Boezen, S. Sleijfer, F. E. Van Leeuwen, A. J. Smit, D. T. Sleijfer, and J. A. Gietema

Hemochromatosis gene (HFE) mutations and chemotherapy-related cardiovascular risk profile in testicular cancer survivors (TCS)
J Clin Oncol (Meeting Abstracts) 2006 24: 14589. [Abstract]  

R. Dienstmann, Sr, D. Herchenhorn, F. A. Peixoto, F. Campos, V. O. Santos, D. M. Moreira, D. M. Moreira, I. A. Small, H. Cardoso, and C. G. Ferreira

Phase II trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 14590. [Abstract]  

T. Steiner, J. Roigas, H. Kirchner, C. Doehn, H. Heynemann, M. Siebels, S. Loening, D. Jocham, P. Fornara, D. Rohde, and C. G. Stieff

Clinical course of patients with metastatic papillary renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14591. [Abstract]  

G. G. Fareau and R. Vassilopoulou-Sellin

Chemotherapeutic management of adrenocortical carcinoma: The M. D. Anderson Cancer Center experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14592. [Abstract]  

J. Mardiak, J. Lakota, Z. Sycova-Mila, J. Obertova, M. Reckova, M. Mego, M. Ladicka, T. Salek, K. Brozmanova, Z. Risnyovszka, and I. Koza

Miniautologous transplantation of lymphokine-activated killers (LAK) in cytokine-pretreated patients with metastatic renal cell carcinoma (RCC): A Slovak phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 14593. [Abstract]  

D. J. Vaughn, M. Powell, P. J. Catalano, P. Loehrer, C. Nichols, C. Sweeney, G. Wilding, and R. S. Dipaola

The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 14594. [Abstract]  

S. Chen, D. O. Henry, and M. K. Wong

The biologic therapy of prostate cancer using plasminogen activator inhibitor-1 (PAI-1)
J Clin Oncol (Meeting Abstracts) 2006 24: 14596. [Abstract]  

K. J. Minehan, K. Furutani, K. McNamara, D. Groshek, E. Mitchell, M. Price, M. Emme, and T. Harms

Prostate brachytherapy post implant dosimetry: Timing matters
J Clin Oncol (Meeting Abstracts) 2006 24: 14597. [Abstract]  

L. L. Porter, H. A. Burris, S. F. Jones, S. Calvert, V. A. Papadimitrakopoulou, K. Hazell, N. Shand, D. Lebwohl, J. Baselga, and I. Judson

Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus)
J Clin Oncol (Meeting Abstracts) 2006 24: 14599. [Abstract]  

A. Shamseddine, J. Makarem, Z. Abdel Khalik, M. Bulbul, A. Taher, R. Khawli, K. Hemadeh, and N. El-Saghir

Safety and efficacy of the combination of high-dose calcitriol, docetaxel and aoledronic acid in hormone-refractory prostate cancer (HRPC): Interim report of a phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14600. [Abstract]  

E. Silva and F. Silva

Phase II study of intravenous vinorelbine plus hormone therapy in hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14601. [Abstract]  

Y. Fujisaka, Y. Fujiwara, K. Yamada, T. Shimizu, A. Horiike, N. Yamamoto, Y. Yamada, N. Matsuoka, H. Fujimoto, and T. Tamura

Phase 1 study of atrasentan (ABT627), novel endothelin receptor-A antagonist, in Japanese patients with hormone refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14602. [Abstract]  

A. Gonçalves, B. Taylor, Y. Toiron, B. Esterni, N. Salem, F. Bladou, P. Viens, and G. Gravis

Serum pharmacoproteomics of erlotinib-treated advanced prostate cancer patients: A SELDI-TOF mass spectrometry analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 14603. [Abstract]  

D. G. Pernkopf, G. Untergasser, P. Berger, and E. Plas

Phosphodiesterase (PDE) inhibitors reduce in vitro proliferation of prostate primary cells but do not interfere with growth of prostate carcinoma cell lines
J Clin Oncol (Meeting Abstracts) 2006 24: 14604. [Abstract]  

G. Nabi, P. Cash, and J. N’Dow

Identification of urinary markers using proteomics analysis of urine in patients with bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14605. [Abstract]  

T. Neumann, R. Mark, P. J. Anderson, and M. Nair

Interstitial high dose rate (HDR) brachtherapy + IMRT vs. HDR monotherapy for early stage prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14606. [Abstract]  

M. Malkovsky, D. G. McNeel, M. Wallace, K. Schell, G. Wilding, J. Eikhoff, M. J. Staab, D. Horvath, J. Straus, and G. Liu

Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand V9V2 T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14607. [Abstract]  

H. Bailey, J. Kolesar, T. Fass, J. Weiss, J. Heideman, D. Alberti, and S. Morgan-Meadow

A phase I study of LR-103 (1,24(OH)₂D₂) in patients with refractory malignancies
J Clin Oncol (Meeting Abstracts) 2006 24: 14608. [Abstract]  

W. L. Barrett

Undetectable PSA level following prostate brachytherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 14609. [Abstract]  

R. A. Miksad, G. Bubley, P. Church, A. Cooper, N. Rofsky, I. Kaplan, and M. Sanda

Analysis of hormonal receptor status in tissue from prostate cancer that developed 26 years after bilateral orchiectomy and following 41 years of estrogen therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 14610. [Abstract]  

A. Dufresne, A. Fléchon, P. Pommier, and J. Droz

Retrospective study of patients with advanced upper urinary tract transitional cell carcinoma (UUT-TCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14611. [Abstract]  

V. J. Sinibaldi, M. A. Carducci, K. Elza-Brown, E. Rosenbaum, S. Denmeade, R. Pili, J. Walczak, E. Garrett-Mayer, S. Moore-Cooper, and M. A. Eisenberger

A phase II evaluation of imatinib mesylate (G) in stage M0 prostate cancer (PC) patients (pts) on hormonal therapy (HT) with evidence of biochemical relapse
J Clin Oncol (Meeting Abstracts) 2006 24: 14612. [Abstract]  

P. Thirion

A randomised phase II trial assessing the impact of the addition of gefitinib to the combination of radiotherapy and short-term maximal androgen blockage in high-risk localised prostate cancer: Safety evaluation
J Clin Oncol (Meeting Abstracts) 2006 24: 14613. [Abstract]  

S. Sharma, N. Vogelzang, B. Wong, C. Adams, P. Manno, K. Welborne, and Y. Giraud

Preclinical and clinical investigation of histone deacetylase inhibitor valproic acid given orally in androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14614. [Abstract]  

R. Ben-Yosef, I. Barnea, D. Sarid, A. Vexler, S. Marmor, A. Starr, Y. Greif, M. Inbar, and N. Barak

ErbB1–4 expression in prostate cancer patients and its correlation to patients’ ethnicity and outcome
J Clin Oncol (Meeting Abstracts) 2006 24: 14615. [Abstract]  

J. Jac, Q. Zhai, M. Kareidy, J. Hernandez, L. Marsh, and R. J. Amato

Interferon-alpha (INF) and gefitinib or imatinib in patients (pts) with metastatic renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14616. [Abstract]  

N. T. Rich, B. J. Smith, and D. A. Vaena

Correlation of statin use and duration with increased survival in hormone refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14617. [Abstract]  

R. A. Moss, G. Shelton, J. Melia, S. G. Mohile, and D. P. Petrylak

A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14618. [Abstract]  

A. W. Levinson, D. B. Samadi, S. M. Collins, A. E. Urdaneta, E. T. Goluboff, and M. C. Benson

Robotic-assisted laparoscopic prostatectomy in obese patients: The Columbia University experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14619. [Abstract]  

L. Lamphere, F. Obermayr, M. Caligiuri, G. Unteregger, M. S. Rudoltz, K. Wosikowksi, and A. M. Casazza

Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models
J Clin Oncol (Meeting Abstracts) 2006 24: 14620. [Abstract]  

J. A. Zagory, C. Chang, S. Knight, E. A. Lyons, and C. L. Bennett

Urinary dysfunction appears to be the primary determinant of castration versus observation for prostate cancer patients with PSA failure
J Clin Oncol (Meeting Abstracts) 2006 24: 14621. [Abstract]  

M. Shum, E. Bodofsky, Z. Skaff, M. El-Khoury, S. Kankipati, C. Dalsania, V. Khemka, R. Parra, S. Dibiase, and R. Somer

The incidence of prostate cancer in patients under the age of 60 from an urban setting
J Clin Oncol (Meeting Abstracts) 2006 24: 14622. [Abstract]  

F. M. Calais Da Silva and F. E. Calais Da Silva

Zoledronic acid in patients with adenocarcinoma of the prostate M1
J Clin Oncol (Meeting Abstracts) 2006 24: 14623. [Abstract]  

M. Khan, S. Sharef, and R. J. Amato

Phase II study of xyotax (PPX) for androgen independent prostate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14624. [Abstract]  

E. Maydanski Murphy, J. Douglas, K. Thompson, and L. A. Wood

Application of the International Germ Cell Consensus Classification (IGCCC) to the Nova Scotia population of patients with germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 14625. [Abstract]  

Z. Allibhai and S. M. Alibhai

The effect of androgen deprivation therapy (ADT) on cognition in men with prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14626. [Abstract]  

A. Gidron, J. Eklund, B. Mortone, A. W. Rademaker, C. Goolsby, and T. Kuzel

T_reg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinphilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell cancer (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14627. [Abstract]  

S. Tucker, S. Binder RN, C. Chua RN, A. C. Houts PhD, B. V. Fortner PhD, and L. S. Schwartzberg

Zoledronic acid (ZA) to prevent bone loss during combined androgen blockade with finasteride (CAB+F) for clinically localized or recurrent non-osseous prostate cancer (PC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14628. [Abstract]  

C. H. Ohlmann, T. Schneider, S. Wille, U. Engelmann, and A. Heidenreich

Prognostic factors for the recurrence of renal cell carcinoma after radical nephrectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 14629. [Abstract]  

Z. Shklar, R. Rubinov, M. Steiner, A. Rabkin, M. Leviov, S. Keren, and K. Sinatzky

Primary hormonal therapy for patients with localized or locally advanced prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14630. [Abstract]  

K. E. Nietupski, T. Demkow, I. Skoneczna, M. Pilichowska, P. Peczkowski, E. Kraszewska, M. Ligaj, G. Poniatowska, A. Sieczych, A. Chaladaj-Kujawska, and B. Sikora

Diagnosis of local relapse after radical radiotherapy (RRTH) of prostate cancer by biochemical PSA kinetics and transrectal ultrasonography (TRUS) verified by prostate biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 14631. [Abstract]  

F. Zustovich, G. Cartei, R. Ceravolo, F. Salmaso, S. Zovato, G. Artioli, S. Cingarlini, S. Binato, and D. Pastorelli

Fixed infusion rate (FIR) gemcitabine (G) based treatment for advanced renal cell carcinoma (ARCC): Efficacy and toxicity data from a phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 14632. [Abstract]  

R. J. Mark, P. J. Anderson, T. Neumann, and M. Nair

Interstitial high dose rate (HDR) brachytherapy alone for early stage prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14633. [Abstract]  

D. Shasha

Weekly (QW) epoetin alfa (EPO) in prostate cancer (PC) patients (pts) with anemia not receiving chemotherapy (CT) or radiation therapy (RT)
J Clin Oncol (Meeting Abstracts) 2006 24: 14634. [Abstract]  

B. D. Curti, I. Assman, T. Moudgil, T. Ratzow, D. Haley, E. Walker, K. Hege, N. Sacks, W. J. Urba, and B. A. Fox

Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14635. [Abstract]  

D. Farray, J. I. Clark, T. Kuzel, and J. P. Dutcher

A multicenter phase II study of thalidomide in combination with interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14636. [Abstract]  

T. Shu, J. Hernandez, M. Karediy, M. Khan, and R. J. Amato

Trial of chemotherapy (CHT) plus hormonal therapy an initial treatment for prostate cancer (PC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14637. [Abstract]  

H. K. Dadhich, S. V. Attili, K. S. Saini, U. Batra, L. A. Jacob, G. Anupama, N. Singhal, and B. Pp

Retrospective comparison of treatment outcome and cost effective analysis of BEP and VIP for poor-prognosis metastatic germ cell tumors in India
J Clin Oncol (Meeting Abstracts) 2006 24: 14638. [Abstract]  

D. White, R. Mark, P. J. Anderson, T. Neumann, and M. Nair

Interstitial high dose rate (HDR) brachytherapy under local anesthesia for early stage prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14639. [Abstract]  

C. Simonelli, R. Talamini, A. Bearz, M. Berretta, P. Monini, C. Sgadari, I. Sartor, B. Ensoli, E. Vaccher, and U. Tirelli

Evaluation of angiogenis activation during interleukin-2 infusion in patients with renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14640. [Abstract]  

M. R. Cruz, R. A. Nakamura, C. R. Monti, J. C. Prestes, F. A. Trevisan, and R. Ferrigno

Increasing overall survival with neoadjuvant and concomitant hormonal therapy plus conformal radiotherapy for high risk prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14641. [Abstract]  

A. Gary, L. Marsh, M. McDonald, S. Naylor, R. Harrop, D. Bernard, and R. J. Amato

A phase II trial to assess the activity of MVA5T4 plus interleukin-2 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14642. [Abstract]  

R. Y. Lam, M. Scholz, B. Guess, and T. Trilling

Oral bisphosphonates fail to prevent bone loss from androgen deprivation therapy in men with prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14643. [Abstract]  

W. Witjes, T. Tammela, and M. Wirth

Effectiveness of zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients: A randomised, open label, multicenter study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). An initial report of the "ZEUS" study
J Clin Oncol (Meeting Abstracts) 2006 24: 14644. [Abstract]  

T. A. Leslie, R. O. Illing, J. E. Kennedy, M. F. Wu, G. R. Ter Haar, R. R. Phillips, A. S. Protheroe, and D. W. Cranston

High intensity focused ultrasound in the treatment of small kidney tumours— The Oxford experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14645. [Abstract]  

E. M. Posadas, S. Undevia, A. D. Colevas, E. Manchen, E. E. Vokes, and W. M. Stadler

A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14646. [Abstract]  

R. A. Nakamura, C. R. Monti, R. Ferrigno, F. A. Trevisan, L. N. Castilho, and J. A. Reinato

Post-operative conformal radiotherapy on prostate cancer after radical prostatectomy. Results and dose constraint on bladder volume
J Clin Oncol (Meeting Abstracts) 2006 24: 14647. [Abstract]  

A. Varadhachary, M. Spadaro, J. Engelmayer, P. Blezinger, T. Valli, K. Petrak, F. Pericle, M. B. Mokyr, G. Forni, and T. G. Hayes

Talactoferrin alfa is an anti-cancer agent with activity in renal cell cancer (RCC) patients and a novel immunomodulatory mechanism of action
J Clin Oncol (Meeting Abstracts) 2006 24: 14648. [Abstract]  

W. R. Berry, R. K. Fairbanks, R. H. Gersh, S. M. Mull, D. Ilegbodu, and L. Asmar

Docetaxel in combination with radiation in prostate cancer: A phase I dose-finding study
J Clin Oncol (Meeting Abstracts) 2006 24: 14649. [Abstract]  

H. Akaza, I. Ikemoto, M. Namiki, M. Usami, M. Kobayashi, H. Fujimoto, T. Tsukamoto, and S. Naito

A phase II study of S-1 in patients with hormone-refractory prostate cancer: The S-1 Cooperative Study Group (Prostate Cancer) study
J Clin Oncol (Meeting Abstracts) 2006 24: 14650. [Abstract]  

Y. Kakehi, T. Kamoto, O. Ogawa, K. Tobisu, Y. Saito, H. Fukuda, and T. Kakizoe

Prospective evaluation of a "Watchful Waiting" program using initial pathology criteria and PSA-doubling time monitoring for patients with stage T1c prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14651. [Abstract]  

H. T. Tsai, M. Datta, H. Frierson, Jr, X. Dong, Y. Qiu, S. Sun, and J. Dong

Increased cytoplasmic localization of KLF5 in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14652. [Abstract]  

R. M. Hoffman, M. Zhao, J. Geller, M. Yang, H. Ma, X. Tan, and X. Li

Genetically altered Salmonella typhimurium profoundly increases survival in nude mice with metastatic PC-3 prostate tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 14653. [Abstract]  

K. Kakimoto, T. Kinouchi, Y. Ono, N. Meguro, O. Maeda, M. Usami, N. Nonomura, D. Oka, T. Miki, and Y. Mizutani

Clinical outcome of postchemotherapy salvage surgery for metastatic germ cell tumors in Japan
J Clin Oncol (Meeting Abstracts) 2006 24: 14654. [Abstract]  

T. Akimoto, K. Hiroyuki, K. Shirai, K. Harada, T. Ebara, K. Ito, T. Yamamoto, and T. Nakano

HDR brachytherapy combined with hypofractionated EBRT for intermediate-high risk prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14655. [Abstract]  

H. Astudillo-De La Vega, E. Ruiz-Garcia, M. Salcedo, A. Torres, J. A. De La Cruz, A. Benitez, P. Gariglio, and F. Gutierrez-Delgado

Outcomes associated with retinoblastoma and c-myc gene expression in patients with testicular cancer: A ten-year experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14656. [Abstract]  

J. Martinez-Cedillo, J. L. Aguilar, A. Morán-Mendoza, O. Arrieta, J. Cruz-Lòpez, G. Calderillo, A. Rivera-Lamas, M. Torreblanca-Montaño, F. Lara-Medina, and J. G. De La Garza

Survival of patients with testicular germ-cell tumors with poor prognosis secondary to liver metastases
J Clin Oncol (Meeting Abstracts) 2006 24: 14657. [Abstract]  

M. A. Sadowska, P. J. Wiechno, L. Greszata, B. Paluchowska, and T. Demkow

Late cardiovascular toxicity of BEP regimen among testicular cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14658. [Abstract]  

V. Vuaroqueaux, P. Diener, S. Eppenberger-Castori, M. Labuhn, C. Horica, T. Németh, M. Sulmoni, G. Fürstenberger, U. Eppenberger, and R. Morant

Molecular profiles of prostate cancer versus today’s diagnostic tools
J Clin Oncol (Meeting Abstracts) 2006 24: 14659. [Abstract]  

M. Botteman, V. Barghout, and K. El Ouagari

Cost-effectiveness of zoledronic acid vs. pamidronate in the management of hormone refractory prostate cancer (HRPC) patients with bone metastases
J Clin Oncol (Meeting Abstracts) 2006 24: 14660. [Abstract]  

Breast Cancer:

D. L. Wickerham, J. P. Costantino, V. Vogel, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, W. McCaskill-Stevens, and N. Wolmark

The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study
J Clin Oncol (Meeting Abstracts) 2006 24: LBA5. [Abstract]  

R. T. Chlebowski, K. C. Johnson, C. Kooperberg, A. Hubbell, D. Lane, M. O’Sullivan, S. Cummings, T. Rohan, S. Yasmeen, J. Khandekar The Women’s Health Initiative Investigators

The Women’s Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias
J Clin Oncol (Meeting Abstracts) 2006 24: LBA6. [Abstract]  

S. M. Ali, F. J. Esteva, M. Fornier, J. Gligorov, L. Harris, W. J. Kostler, D. Luftner, M. F. Pichon, C. Tse, and A. Lipton

Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 500. [Abstract]  

S. Modi, A. Stopeck, M. S. Gordon, D. Solit, W. Ma, J. Wheler, G. Cropp, R. G. Johnson, A. L. Hannah, and C. Hudis

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)
J Clin Oncol (Meeting Abstracts) 2006 24: 501. [Abstract]  

N. L. Spector, K. Blackwell, J. Hurley, J. L. Harris, D. Lombardi, S. Bacus, S. B. Ahmed, H. Boussen, M. Frikha, and F. B. Ayed

EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response
J Clin Oncol (Meeting Abstracts) 2006 24: 502. [Abstract]  

N. U. Lin, L. A. Carey, M. C. Liu, J. Younger, S. E. Come, E. Bullitt, A. D. Van Den Abbeele, X. Li, F. H. Hochberg, and E. P. Winer

Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 503. [Abstract]  

S. K. Knox, J. N. Ingle, V. J. Suman, J. M. Rae, D. A. Flockhart, D. Zeruesenay, M. M. Ames, D. W. Visscher, E. A. Perez, and M. P. Goetz

Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam)
J Clin Oncol (Meeting Abstracts) 2006 24: 504. [Abstract]  

J. L. Grabinski, L. S. Smith, G. B. Chisholm, R. Drengler, G. I. Rodriguez, A. S. Lang, S. P. Kalter, A. M. Garner, L. M. Fichtel, B. H. Pollock, and J. G. Kuhn

Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment
J Clin Oncol (Meeting Abstracts) 2006 24: 505. [Abstract]  

K. F. Lau, A. Wang, K. Chew, H. Dai, T. Hastie, B. Brandt, F. Waldman, and J. Sninsky

An RT-PCR-based multi-gene prognostic signature predicts distant metastasis of node negative, ER positive breast cancer from FFPE sections
J Clin Oncol (Meeting Abstracts) 2006 24: 506. [Abstract]  

C. Sotiriou, P. Wirapati, S. Loi, B. Haibe-Kains, C. Desmedt, A. Tutt, P. Ellis, M. Buyse, M. Delorenzi, and M. Piccart

Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 507. [Abstract]  

M. J. Kandel, Z. Stadler, S. Masciari, L. Collins, S. Schnitt, L. Harris, A. Miron, A. Richardson, and J. E. Garber

Prevalence of BRCA1 mutations in triple negative breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 508. [Abstract]  

J. Jacquemier, F. Penault-Llorca, H. Mnif, E. Charafe-Jauffret, S. Marque, A. Martin, J. Genève, and H. Roché

Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA)
J Clin Oncol (Meeting Abstracts) 2006 24: 509. [Abstract]  

D. F. Hayes, A. Thor, L. Dressler, D. Weaver, G. Broadwater, L. Goldstein, S. Martino, J. Ingle, I. C. Henderson, and D. Berry

HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344
J Clin Oncol (Meeting Abstracts) 2006 24: 510. [Abstract]  

R. E. Coleman ATAC Trialists’ Group

Effect of anastrozole on bone mineral density: 5-year results from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial
J Clin Oncol (Meeting Abstracts) 2006 24: 511. [Abstract]  

A. Lipton, C. Alvarado, R. De Boer, G. G. Steger, K. S. Tonkin, A. Kinsey, M. Fan, and S. Jun

Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP)
J Clin Oncol (Meeting Abstracts) 2006 24: 512. [Abstract]  

M. F. Rimawi, H. L. Weiss, P. Bhatia, G. Chamness, and R. M. Elledge

EGFR expression in breast cancer: Association with biologic phenotype, prognosis, and resistance to adjuvant therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 513. [Abstract]  

R. S. Finn, J. Dering, C. Ginther, M. Press, J. Forbes, J. Mackey, T. French, M. South, M. Rupin, D. J. Slamon BCIRG 103 Study Group

ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies
J Clin Oncol (Meeting Abstracts) 2006 24: 514. [Abstract]  

M. Dowsett, I. Smith, A. Skene, A. Llombart, J. Mayordomo, S. Detre, J. Salter, E. Beresford, P. Magill Study 0223 Trialists

Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223)
J Clin Oncol (Meeting Abstracts) 2006 24: 515. [Abstract]  

J. F. Forbes, T. Pienkowski, V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, M. Smylie, J. M. Crown, N. Noel, M. Pegram On behalf of the BCIRG007 investigators

BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA516. [Abstract]  

H. Lueck, G. V. Minckwitz, A. Du Bois, I. Schrader, J. Huober, V. Heilmann, M. Beckmann, A. Stähle, C. Jackisch, C. Marth, and B. Richter

Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group
J Clin Oncol (Meeting Abstracts) 2006 24: 517. [Abstract]  

A. H. Partridge, A. C. Wolff, P. K. Marcom, P. A. Kaufman, C. Moore, D. Lake, G. Fleming, H. S. Rugo, D. Collyar, and E. P. Winer

Study participants’ perceptions of the process and impact of receiving results of N9831
J Clin Oncol (Meeting Abstracts) 2006 24: 518. [Abstract]  

J. P. Crown, P. Francis, A. Di Leo, M. Buyse, A. Balil, M. Anderson, B. Nordenskjöld, R. Jakesz, J. Gutierrez, and M. Piccart

Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2–98 Trial at 5 years median follow-up (MFU)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA519. [Abstract]  

A. R. Bianco, A. De Matteis, L. Manzione, C. Boni, S. Palazzo, M. Di Palma, C. Iacono, S. De Placido, P. Papaldo, F. Cognetti Taxit216 Study Group

Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial
J Clin Oncol (Meeting Abstracts) 2006 24: LBA520. [Abstract]  

S. H. Giordano, M. Pinder, Z. Duan, G. Hortobagyi, and J. Goodwin

Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C)
J Clin Oncol (Meeting Abstracts) 2006 24: 521. [Abstract]  

L. E. Shepherd, W. Parulekar, K. I. Pritchard, M. Trudeau, N. Paul, D. Tu, and M. Levine

Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience
J Clin Oncol (Meeting Abstracts) 2006 24: 522. [Abstract]  

M. Y. Halyard, T. M. Pisansky, L. J. Solin, L. B. Marks, L. J. Pierce, A. Dueck, and E. A. Perez

Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831
J Clin Oncol (Meeting Abstracts) 2006 24: 523. [Abstract]  

M. N. Pollak, J. W. Chapman, L. Shepherd, D. Meng, P. Richardson, C. Wilson, B. Orme, and K. I. Pritchard

Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial
J Clin Oncol (Meeting Abstracts) 2006 24: 524. [Abstract]  

P. E. Goss, I. N. Bondarenko, G. N. Manikhas, K. B. Pendergrass, W. H. Miller, D. Blanchett, W. Lang, P. Langecker for the 777 CLP-29 Study Group

Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: LBA525. [Abstract]  

C. L. Loprinzi, J. W. Kugler, D. L. Barton, A. C. Dueck, L. K. Tschetter, R. A. Nelimark, E. P. Balcueva, M. D. Carlson, S. F. Duane, and S. W. Corso

Phase III randomized trial to evaluate the use of gabapentin alone vs with continuing an antidepressant in women failing an antidepressant for the treatment of hot flashes: North Central Cancer Treatment Group Study N00C3
J Clin Oncol (Meeting Abstracts) 2006 24: 526. [Abstract]  

R. C. Coombes, R. Paridaens, J. Jassem, C. J. Van de Velde, T. Delozier, S. E. Jones, E. Hall, L. S. Kilburn, C. F. Snowdon, J. M. Bliss for the Intergroup Exemestane Study (IES)

First mature analysis of the Intergroup Exemestane Study
J Clin Oncol (Meeting Abstracts) 2006 24: LBA527. [Abstract]  

H. T. Mouridsen, A. Keshaviah, L. Mauriac, J. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. Gelber, I. Smith, B. Thuerlimann, and A. Goldhirsch

BIG 1–98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: LBA528. [Abstract]  

F. Vicini, P. Beitsch, C. Quiet, A. Keleher, D. Garcia, H. Snider, M. Gittleman, V. Zannis, H. Kuerer, and E. Whitacre

Two year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI)
J Clin Oncol (Meeting Abstracts) 2006 24: 529. [Abstract]  

C. E. Carr, E. F. Conant, M. A. Rosen, M. D. Schnall, and R. Davidson

The impact of FDG PET in the staging of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 530. [Abstract]  

H. E. Kohrt, R. A. Olshen, W. H. Goodson, III, R. V. Rouse, L. Bailey, V. Philben, F. M. Dirbas, F. E. Stockdale, R. W. Carlson, S. S. Jeffrey Bay Area SLN Study Group

Predicting non-sentinel lymph node involvement in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 531. [Abstract]  

A. Knoop, H. Knudsen, E. Balslev, B. B. Rasmussen, J. Overgaard, M. During, K. V. Nielsen, J. T. Jørgensen, H. Mouridsen, and B. Ejlertsen

TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D)
J Clin Oncol (Meeting Abstracts) 2006 24: 532. [Abstract]  

F. P. O’Malley, S. Chia, D. Tu, L. E. Shepherd, M. N. Levine, D. G. Huntsman, V. H. Bramwell, I. L. Andrulis, and K. I. Pritchard

Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
J Clin Oncol (Meeting Abstracts) 2006 24: 533. [Abstract]  

U. Euler, C. Meisner, C. Friedel, M. Schmidt, M. Untch, B. Lisboa, F. Jaenicke, M. Schmitt, C. Thomssen, and N. Harbeck

Comparison of outcome prediction in node-negative breast cancer based on biomarkers uPA/PAI-1 or Adjuvant Online using the 10-year follow-up of the randomized multicenter Chemo N0 trial
J Clin Oncol (Meeting Abstracts) 2006 24: 534. [Abstract]  

C. Creighton, J. Rae, A. Chinnaiyan, and M. Lippman

Improved prediction of disease-free survival in tamoxifen-treated patients using an expression signature of estrogen-regulated genes as compared to progesterone receptor
J Clin Oncol (Meeting Abstracts) 2006 24: 535. [Abstract]  

W. Symmans, F. Peintinger, C. Hatzis, H. Kuerer, V. Valero, B. Hennessy, M. Green, E. Singletary, G. Hortobagyi, and L. Pusztai

A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 536. [Abstract]  

G. K. Ellis, W. E. Barlow, C. A. Russell, M. E. Royce, E. A. Perez, and R. B. Livingston

SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: LBA537. [Abstract]  

J. C. Chang, A. Makris, S. G. Hilsenbeck, J. R. Hackett, J. Jeong, M. Liu, J. Baker, K. Sexton, C. K. Osborne, and S. Shak

Gene expression profiles in formalin-fixed, paraffin-embedded (FFPE) core biopsies predict docetaxel chemosensitivity
J Clin Oncol (Meeting Abstracts) 2006 24: 538. [Abstract]  

S. Badve, D. Turbin, A. Morimiya, T. Nielsen, C. Perou, S. Dunn, D. Huntsman, and H. Nakshatri

Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 539. [Abstract]  

A. S. Doane, M. Danso, P. Lal, M. Donaton, J. Wheler, M. Moynahan, L. Zhang, C. Hudis, and W. Gerald

Distinct PIK3CA mutation profiles in estrogen receptor (ER) negative breast cancer (BC) subsets
J Clin Oncol (Meeting Abstracts) 2006 24: 540. [Abstract]  

B. T. Hennessy, A. M. Gonzalez-Angulo, Y. Lu, R. Tibes, D. Siwak, A. Sahin, S. Kau, G. N. Hortobagyi, V. Valero, and G. B. Mills

Proteomic prediction in hormone receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 541. [Abstract]  

Q. C. Ru, L. A. Zhu, J. Silberman, R. Mural, and C. D. Shriver

Proteomic profiling of breast cancer serum via two-dimensional liquid-chromatography—tandem mass spectrometry
J Clin Oncol (Meeting Abstracts) 2006 24: 542. [Abstract]  

A. M. Gown, L. C. Goldstein, P. L. Porter, R. B. Livingston, S. Tam, I. Yeh, W. E. Barlow, J. R. Gralow, and D. F. Hayes

Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim
J Clin Oncol (Meeting Abstracts) 2006 24: 543. [Abstract]  

L. N. Harris, S. Carter, F. You, A. Eklund, S. Hilsenbeck, Z. Szallasi, and J. Chang

High level analysis of genomic data reveals complex predictors of response to trastuzumab (T) and chemotherapy for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 544. [Abstract]  

F. J. Esteva, K. Anderson, F. Lin, R. Nahta, J. Mejia, K. Altundag, A. U. Buzdar, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai

Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 545. [Abstract]  

M. Kaufmann, W. Jonat, J. Hilfrich, H. Eidtmann, G. Gademann, I. Zuna, G. Von Minckwitz German Adjuvant Breast Cancer Group

Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study
J Clin Oncol (Meeting Abstracts) 2006 24: 547. [Abstract]  

F. M. Boccardo, P. Guglielmini, A. Rubagotti GROCTA 4 and ITA trials

Mortality benefit of switching to an aromatase inhibitor in early breast carcinoma: Pooled analysis of two consecutive trials
J Clin Oncol (Meeting Abstracts) 2006 24: 548. [Abstract]  

J. Ingle, D. Tu, L. Shepherd, M. Palmer, J. Pater, and P. Goss

NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months
J Clin Oncol (Meeting Abstracts) 2006 24: 549. [Abstract]  

N. J. Robert, P. E. Goss, J. N. Ingle, D. Tu, L. Shepherd, M. Palmer, and J. Pater

Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding
J Clin Oncol (Meeting Abstracts) 2006 24: 550. [Abstract]  

A. U. Buzdar ATAC Trialists’ Group

Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial
J Clin Oncol (Meeting Abstracts) 2006 24: 551. [Abstract]  

J. M. Dixon, L. Renshaw, O. Young, J. Murray, E. J. Macaskill, M. McHugh, E. Folkerd, D. Cameron, and M. Dowsett

Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 552. [Abstract]  

R. Largillier, A. Savignoni, J. Gligorov, P. Chollet, M. Guillaume, M. Spielmann, E. Luporsi, B. Asselain, B. Coudert, and M. Namer

Effect of pregnancy, in the year prior and after treatment for breast carcinoma, on survival and recurrence in women with breast cancer younger than 35 years. GETNA GROUP
J Clin Oncol (Meeting Abstracts) 2006 24: 553. [Abstract]  

P. Lonning, J. Geisler, L. E. Krag, E. Løkkevik, T. Risberg, A. I. Hagen, E. Schlichting, G. E. Eide, and E. Di Salle

Vitamin D deficiency: A threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors
J Clin Oncol (Meeting Abstracts) 2006 24: 554. [Abstract]  

E. McCloskey, R. Hannon, G. Lakner, G. Clack, A. Miyamoto, and R. Eastell

The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women
J Clin Oncol (Meeting Abstracts) 2006 24: 555. [Abstract]  

R. Aft, M. Naughton, K. Trinkuas, M. Watson, and K. Weilbaecher

Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid
J Clin Oncol (Meeting Abstracts) 2006 24: 556. [Abstract]  

B. Mincey, M. Duh, S. Thomas, E. Moyneur, M. Marynchencko, S. Boyce, and E. Perez

Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors
J Clin Oncol (Meeting Abstracts) 2006 24: 557. [Abstract]  

L. Orlando, A. Cardillo, R. Ghisini, N. Rotmensz, G. Peruzzotti, P. Maisonneuve, G. Viale, A. Goldhirsch, and M. Colleoni

Role of endocrine responsiveness and adjuvant therapy in very young women (< 35 years) with operable breast cancer and node negative disease
J Clin Oncol (Meeting Abstracts) 2006 24: 558. [Abstract]  

H. Muss, D. Berry, C. Cirrincione, D. Budman, I. Henderson, M. Citron, L. Norton, E. Winer, and C. Hudis

Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience
J Clin Oncol (Meeting Abstracts) 2006 24: 559. [Abstract]  

D. A. Patt, Z. Duan, G. Hortobagyi, and S. H. Giordano

Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 560. [Abstract]  

P. A. Ganz, S. R. Land, D. L. Wickerham, M. Lee, M. Ritter, V. Vogel, E. Pajon, J. L. Wade, J. P. Costantino, and N. Wolmark

The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study
J Clin Oncol (Meeting Abstracts) 2006 24: LBA561. [Abstract]  

B. F. Kimler, G. Ursin, C. J. Fabian, J. R. Anderson, C. Chamberlain, M. S. Mayo, J. A. O’Shaughnessy, H. T. Lynch, K. A. Johnson, and D. Browne

Effect of the third generation selective estrogen receptor modulator arzoxifene on mammographic breast density
J Clin Oncol (Meeting Abstracts) 2006 24: 562. [Abstract]  

A. Howell ATAC Trialists’ Group

Analysis of fracture risk factors from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data
J Clin Oncol (Meeting Abstracts) 2006 24: 563. [Abstract]  

L. Chen, T. L. Nikolas, G. Markowitz, J. Green, N. Wintfeld, M. Neary, and M. Duh

Retrospective analysis of renal toxicity in breast cancer patients following zoledronic acid or pamidronate treatment
J Clin Oncol (Meeting Abstracts) 2006 24: 564. [Abstract]  

G. Freyer, M. Debled, J. F. Geay, T. Bachelot, E. Blot, J. Cretin, T. Delozier, D. Mille, J. M. Ferrero, P. Romestaing, and E. Pujade-Lauraine

Celecoxib (Ce) + exemestane (Ex) versus placebo + Ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): A double-blind phase III GINECO study
J Clin Oncol (Meeting Abstracts) 2006 24: 565. [Abstract]  

H. M. Linden, S. Stekhova, J. M. Link, R. B. Livingston, J. R. Gralow, G. K. Ellis, L. M. Peterson, E. K. Schubert, K. A. Krohn, and D. A. Mankoff

Understanding resistance to hormonal therapy in estrogen avid breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 566. [Abstract]  

S. Braun, F. D. Vogl, and K. Pantel

Presence of bone marrow micrometastasis (BMM) in breast cancer patients predicts a poor-prognosis pattern of first distant metastasis: Results from the pooled analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 567. [Abstract]  

E. Azambuja, M. Paesmans, C. Bernard-Marty, M. Beauduin, A. Vindevoghel, N. Cornez, C. Focan, A. Tagnon, J. M. Nogaret, and M. Piccart-Gebhart

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide (EC or HEC) with cyclophosphamide, methotrexate, and fluorouracil (CMF) in 777 women with node-positive (N+) breast cancer (BC): 10-year follow-up results
J Clin Oncol (Meeting Abstracts) 2006 24: 568. [Abstract]  

A. Gennari, M. Sormani, M. Costantini, P. Pronzato, R. Rosso, and P. Bruzzi

Anthracycline regimens versus CMF in the adjuvant treatment of early breast cancer (EBC): A matter of difference
J Clin Oncol (Meeting Abstracts) 2006 24: 569. [Abstract]  

C. Soto, L. Torrecillas, S. Reyes, M. Ramirez, L. Perez, G. Cervantes, F. Gonzalez, E. Tellez, P. Cortes, and H. Benitez

Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2006 24: 570. [Abstract]  

S. Beslija, N. Obralic, H. Basic, A. Tatarevic, M. Naila, M. Banjin, A. Cardzic, A. Sosevic, A. Pasic, T. Ceric, and B. Salkic

Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 571. [Abstract]  

G. Frasci, G. D’Aiuto, P. Comella, R. Thomas, G. Botti, M. Rubulotta, G. Iodice, R. Costanzo, M. Di Bonito, and G. Comella

Weekly cisplatin-epirubicin-paclitaxel (PET) with granulocyte-colony stimulating factor support versus tri-weekly epirubicin-paclitaxel in locally advanced breast cancer: Final comprehensive and subgroup analysis of a SICOG phase III study
J Clin Oncol (Meeting Abstracts) 2006 24: 572. [Abstract]  

R. Lambert-Falls, M. A. Deutsch, C. Desch, K. Zhou, and E. Perez

Phase III adjuvant trial of concurrent epirubicin/taxane vs. sequential epirubicin/cyclophosphamide followed by taxane for node positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 573. [Abstract]  

E. Rivera, J. A. Mejia, B. Arun, R. Adinin, R. Walters, A. Brewster, K. Broglio, G. Yin, F. J. Esteva, G. N. Hortobagyi, and V. Valero

Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results
J Clin Oncol (Meeting Abstracts) 2006 24: 574. [Abstract]  

M. Muñoz, M. Martín, A. Ruiz, A. Balil, J. García-Mata, L. Calvo, C. Jara, E. Alba, F. Salas, and C. Soto

Phase III study of gemcitabine plus vinorelbine (VG) versus vinorelbine (V) in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracyclines (A) and taxanes (T). Final results of GEICAM 2000–04 study
J Clin Oncol (Meeting Abstracts) 2006 24: 575. [Abstract]  

G. Von Minckwitz, J. Blohmer, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. Costa, and M. Kaufmann

Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study
J Clin Oncol (Meeting Abstracts) 2006 24: 576. [Abstract]  

A. Moreno-Aspitia, D. W. Hillman, M. Wiesenfeld, T. J. Hobday, K. M. Rowland, D. W. Northfelt, K. S. Tenner, F. M. Palmieri, and E. A. Perez

BAY 43–9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane
J Clin Oncol (Meeting Abstracts) 2006 24: 577. [Abstract]  

S. E. Deprimo, C. Friece, X. Huang, J. Smeraglia, L. Sherman, M. Collier, C. Baum, A. D. Elias, H. J. Burstein, and K. D. Miller

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 578. [Abstract]  

P. Spadaro, M. Ingemi, G. Dottore, G. Toscano, and R. Maisano

Changes in circulating endothelial cells (CEL) in patients receiving trastuzumab for metastatic breast cancer predict response to treatment
J Clin Oncol (Meeting Abstracts) 2006 24: 579. [Abstract]  

S. Stanway, A. Purohit, L. W. Woo, R. H. Wilson, F. Z. Stanczyk, N. Dobbs, P. Delavault, B. V. Potter, M. J. Reed, and R. C. Coombes

Endocrine and clinical responses to steroid sulfatase inhibition: Results from the first phase I trial in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 580. [Abstract]  

C. E. Geyer, Jr., J. L. Bryant, E. H. Romond, M. S. Ewer, D. L. Keefe, R. P. Shannon, T. B. Levine, P. Rastogi, S. M. Swain, and N. Wolmark

Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)paclitaxel (T) vs. ACT with trastuzumab (H)
J Clin Oncol (Meeting Abstracts) 2006 24: 581. [Abstract]  

C. DangK. Smith, M. Fornier, S. Sugarman, T. Troso-Sandoval, D. Lake, G. D’Andrea, A. Seidman, N. Sklarin, L. Norton, and C. Hudis

Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
J Clin Oncol (Meeting Abstracts) 2006 24: 582. [Abstract]  

E. A. Perez, J. A. Byrne, I. W. Hammond, R. Rafi, A. M. Martin, M. S. Berger, T. Z. Zaks, C. R. Oliva, D. F. Roychowdhury, and S. H. Stein

Results of an analysis of cardiac function in 2,812 patients treated with lapatinib
J Clin Oncol (Meeting Abstracts) 2006 24: 583. [Abstract]  

C. E. Scott-Conner, P. A. Romitti, C. F. Lynch, N. Wilkinson, G. Lal, L. Zhou, and B. J. Smith

Influence of pregnancy on breast cancer tumor characteristics and mortality in Iowa women
J Clin Oncol (Meeting Abstracts) 2006 24: 584. [Abstract]  

W. Y. Chen, G. A. Colditz, and B. Rosner

Breast cancer epidemiologic risk factors by HER2/neu status
J Clin Oncol (Meeting Abstracts) 2006 24: 585. [Abstract]  

I. M. Lipkus, G. G. Kimmick, S. Y. Chui, D. L. Fifield, L. A. Werner, and P. K. Marcom

Relationship between numeracy and breast cancer patients’ estimates of adjuvant treatment benefit
J Clin Oncol (Meeting Abstracts) 2006 24: 586. [Abstract]  

Z. Nahleh, R. Srikantiah, R. Komrokji, M. Safa, J. Pancoast, A. Muhleman, and A. Jazieh

Male breast cancer (MBC) in the VA population: A gender issue?
J Clin Oncol (Meeting Abstracts) 2006 24: 587. [Abstract]  

M. Sandhu, B. Zagorski, K. Sykora, G. Booth, and C. Brezden-Masley

Autoimmune hypothyroidism protects against breast cancer development in the elderly
J Clin Oncol (Meeting Abstracts) 2006 24: 588. [Abstract]  

S. K. Kang, B. W. Ely, R. H. Riffenburgh, T. S. Chung, A. D. Chan, and J. S. Hu

Breast cancer treatment patterns of Asian-American women in an equal access system
J Clin Oncol (Meeting Abstracts) 2006 24: 589. [Abstract]  

J. A. Ligibel, W. Chen, A. Keshaviah, K. Adloff, A. Partridge, T. Salinardi, and E. P. Winer

The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 590. [Abstract]  

V. Bonadona, N. Voirin, O. Sinilnikova, H. Mignotte, A. Bremond, P. Mathevet, P. Romestaing, D. Raudrant, G. Lenoir, and C. Lasset

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort
J Clin Oncol (Meeting Abstracts) 2006 24: 591. [Abstract]  

L. Dumasia, C. Lobocki, A. Couturier, C. Lebeis, and A. Drelichman

Use of statins and breast carcinoma: A case-control study
J Clin Oncol (Meeting Abstracts) 2006 24: 592. [Abstract]  

N. S. Wong, F. Gao, S. B. Tan, D. Machin, and E. H. Ng

Confirmation of double-peaked time distribution of mortality for breast cancer in a population-based study
J Clin Oncol (Meeting Abstracts) 2006 24: 593. [Abstract]  

B. G. Haffty, Q. Yang, M. Reiss, T. Kearney, W. Hait, and D. Toppmeyer

Local-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 594. [Abstract]  

W. F. Anderson, R. M. Pfeiffer, G. M. Dores, and M. E. Sherman

Bimodal breast cancer incidence patterns provide support for a dualistic model of mammary carcinogenesis
J Clin Oncol (Meeting Abstracts) 2006 24: 595. [Abstract]  

T. Aiti, S. McDunn, L. Hussein, I. Ashkenazi, A. Jajeh, Y. Wang, and H. A. Zaren

Race as a risk factor for developing osteonecrosis of the jaw after long term bisphosphonate therapy in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 596. [Abstract]  

S. Saji, N. Ishizuka, K. Horiguchi, E. Suzuki, H. Bando, T. Aruga, I. Takahashi, T. Tominaga, and M. Toi

Age frequency distribution of joint ER/PR phenotypes in primary breast cancer patients: An analysis of 3,620 cases at a single Japanese institute
J Clin Oncol (Meeting Abstracts) 2006 24: 597. [Abstract]  

W. B. Al-Refaie, J. N. Cormier, Y. Xing, K. K. Hunt, G. Fearmonti, R. Ghandi, H. M. Kuerer, F. Meric-Bernstam, I. Bedrosian, and A. Lucci

Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care
J Clin Oncol (Meeting Abstracts) 2006 24: 598. [Abstract]  

E. E. Harris, S. L. Urtishak, W. Hwang, B. Kinosian, and L. J. Solin

Comorbidity and outcomes in elderly women treated with breast-conserving therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 599. [Abstract]  

S. Saha, S. Chitneni, R. Sehgal, M. Arora, B. Desouza, S. David, and T. Singh

Comparative analysis of MRI vs mammography in evaluation of size, number of lesions and nodal status of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 600. [Abstract]  

A. M. Leitch, L. McCall, P. Beitsch, P. Whitworth, D. Reintgen, P. Blumencranz, S. Saha, T. Bauer, K. K. Hunt, and A. Giuliano

Factors influencing accrual to ACOSOG Z0011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 601. [Abstract]  

J. S. Jeruss, G. D. Ayers, M. Cristofanilli, M. I. Ross, G. Babiera, F. Meric-Bernstam, H. M. Kuerer, B. W. Feig, M. Yi, and K. K. Hunt

Postive sentinel nodes after neoadjuvant chemotherapy: What factors predict additional disease in the axilla?
J Clin Oncol (Meeting Abstracts) 2006 24: 602. [Abstract]  

M. J. Lund, O. W. Brawley, J. W. Eley, K. C. Ward, J. L. Young, and J. M. Liff

Racial differences in treatment for breast cancer among black and white women in Atlanta
J Clin Oncol (Meeting Abstracts) 2006 24: 603. [Abstract]  

L. A. Vallow, S. Packianathan, E. R. Deperi, M. D. McDonough, J. D. Earle, and E. A. Perez

Pre-operative breast magnetic resonance imaging (MRI) influences patient selection for partial breast irradiation
J Clin Oncol (Meeting Abstracts) 2006 24: 604. [Abstract]  

A. Goyal, A. Douglas-Jones, R. G. Newcombe, and R. E. Mansel

Objective assessment of sentinel node tumor burden and its impact on sentinel node localisation in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 605. [Abstract]  

C. Chung, M. Keyes, W. Kwa, L. Weir, and C. Parsons

Adjuvant axillary radiotherapy for breast cancer: Is CT planning with nodal contouring better than traditional planning?
J Clin Oncol (Meeting Abstracts) 2006 24: 606. [Abstract]  

J. C. Boughey, J. N. Cormier, Y. Xing, F. Meric-Bernstam, M. I. Ross, G. V. Babiera, F. C. Ames, K. K. Hunt, and I. Bedrosian

Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: A decision analysis model
J Clin Oncol (Meeting Abstracts) 2006 24: 607. [Abstract]  

T. Ofuchi, A. Amemiya, M. Ono, J. Hatayama, and A. Takeda

Salvage surgery for local recurrence after breast conservation therapy—Is re-lumpectomy an appropriate treatment?
J Clin Oncol (Meeting Abstracts) 2006 24: 608. [Abstract]  

K. L. Foley, F. Camacho, E. A. Levine, G. Kimmick, R. Balkrishnan, and R. Anderson

The influence of radiation therapy on survival among Medicaid-enrolled breast cancer patients treated with breast conserving surgery
J Clin Oncol (Meeting Abstracts) 2006 24: 609. [Abstract]  

S. Alberti, P. Querzoli, M. Pedriali, R. Rinaldi, E. Biganzoli, P. Boracchi, M. Piantelli, S. Iacobelli, E. Marubini, and I. Nenci

Axillary lymph node nanometastases are prognostic factors for metastatic relapse in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 610. [Abstract]  

B. Taback, N. Hansen, K. Conway, and A. Giuliano

Method of detection of local recurrence in patients following breast conserving surgery and its utility for surveillance
J Clin Oncol (Meeting Abstracts) 2006 24: 611. [Abstract]  

S. M. Maskery, H. Hu, R. Mural, J. Hooke, C. D. Shriver, and M. N. Liebman

Separate DCIS progression pathways derived from breast disease heterogeneity data
J Clin Oncol (Meeting Abstracts) 2006 24: 612. [Abstract]  

L. M. Kenny, R. C. Coombes, A. Al-Nahhas, S. Osman, C. Lowdell, and E. Aboagye

A feasibility study of [¹¹C]choline for the molecular imaging of human breast cancer in vivo using positron emission tomography (PET)
J Clin Oncol (Meeting Abstracts) 2006 24: 613. [Abstract]  

K. Tanaka, D. Shimizu, H. Kuramochi, J. Cooc, M. Williams, R. Li, P. Chen, K. D. Danenberg, P. V. Danenberg, and H. J. Lenz

Molecular signatures generated with RNA Isolated from formalin-fixed paraffin-embedded tumor specimens differentiate metastatic and non-metastatic primary breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 614. [Abstract]  

M. Cristofanilli, V. Guarneri, V. Valero, H. A. Fritsche, K. R. Broglio, J. M. Reuben, J. Lara, S. Krishnamurthy, and G. N. Hortobagyi

Circulating tumor cells (CTCs) in metastatic breast cancer: Biological value beyond tumor burden
J Clin Oncol (Meeting Abstracts) 2006 24: 615. [Abstract]  

R. Naik, D. Jin, E. Chuang, E. Gold, E. Tousimis, P. Christos, T. De Dalmas, D. Donovan, S. Rafii, and L. Vahdat

Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 616. [Abstract]  

K. Pachmann, O. Camara, K. Lobodasch, R. Dengler, I. Runnebaum, K. Hoeffken, and U. Pachmann

Circulating tumor cells: Tools for monitoring and targets for therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 617. [Abstract]  

D. G. Generali, S. Fox, F. M. Buffa, A. Berruti, M. Brizzi, G. Allevi, S. Bonardi, L. Dogliotti, A. Bottini, and A. Harris

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
J Clin Oncol (Meeting Abstracts) 2006 24: 618. [Abstract]  

A. H. Al-Hajj, M. V. Yezhelyev, T. Liu, and R. M. O’Regan

Simultaneous, quantitative detection of multiple biomarkers in human breast cancers using multicolor nanoparticles
J Clin Oncol (Meeting Abstracts) 2006 24: 619. [Abstract]  

V. Goodell, B. Macleod, M. Slota, and M. L. Disis

Performance characteristics of common immunologic biomarkers used in clinical trials
J Clin Oncol (Meeting Abstracts) 2006 24: 620. [Abstract]  

B. Park, H. Kim, J. Oh, S. Kim, K. Kim, and J. Sohn

Elevated preoperative serum level of tumor markers CEA and CA 15–3 in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 621. [Abstract]  

A. Rody, U. Holtrich, V. Müller, R. Gaetje, R. Diallo, M. Gehrmann, G. Von Minckwitz, K. Engels, T. Karn, and M. Kaufmann

c-kit: Identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features
J Clin Oncol (Meeting Abstracts) 2006 24: 622. [Abstract]  

K. H. Tkaczuk, N. S. Tait, K. Chua, F. Feldman, S. A. Lesko, Z. Lun, M. Tan, and P. O. Ts’o

Serial monitoring for circulating cancer cells in blood samples of stage 1–4 breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 623. [Abstract]  

J. Wu, D. Mirchandani, J. A. Smith, G. Inghirami, D. Roses, A. Zeleniuch-Jacquotte, and F. Muggia

Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers
J Clin Oncol (Meeting Abstracts) 2006 24: 624. [Abstract]  

C. Thussbas, J. Nahrig, S. Streit, J. Bange, R. Kates, K. Ulm, M. Kiechle, H. Hoefler, A. Ullrich, and N. Harbeck

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 625. [Abstract]  

L. A. Fernandez-Morales, E. Dalmau, S. Martinez, A. Arcusa, C. Pericay, J. M. Lain, J. Font, L. Tortajada, E. Saigi, and M. A. Segui-Palmer

Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status
J Clin Oncol (Meeting Abstracts) 2006 24: 626. [Abstract]  

M. S. Barsoum, R. M. Gafar, M. M. Nazmy, and A. Niazy

Randomized phase II trial evaluating the efficacy of adding sequential half body irradiation (SHBI) to adjuvant chemotherapy in high-risk breast cancer patients with >10 positive lymph nodes
J Clin Oncol (Meeting Abstracts) 2006 24: 627. [Abstract]  

J. Norum and J. A. Olsen

Trastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 628. [Abstract]  

V. Guarneri, D. J. Lenihan, V. Valero, J. Durand, K. Broglio, L. Boehnke-Michaud, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva

Long term cardiac tolerability of trastuzumab in HER-2-overexpressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 629. [Abstract]  

Y. Belkacemi, J. Gligorov, H. Laharie-Mineur, H. Marsiglia, M. Ozsahin, and D. Azria

Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities
J Clin Oncol (Meeting Abstracts) 2006 24: 630. [Abstract]  

S. A. Limentani, M. Campone, T. Dorval, E. Tan-Chiu, G. Curigliano, R. De Boer, J. Canon, T. Bachelot, J. Louahed, and V. G. Brichard

Evaluation of a recombinant HER2 vaccine: Induction of specific antibodies, T-cells and preliminary activity in metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 631. [Abstract]  

M. Spielmann, H. Roché, T. Delozier, G. Romieu, H. Bourgeois, D. Serin, J. Canon, B. Asselain, L. Roca, and J. Genève

Safety analysis from PACS 04—A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 632. [Abstract]  

S. Nakamura and O. Abe

Postoperative adjuvant therapy with tamoxifen, tegafur-uracil (UFT), or both in women with node-negative breast cancer: A pooled analysis of six randomized controlled trials (relapse-free survival data)
J Clin Oncol (Meeting Abstracts) 2006 24: 633. [Abstract]  

H. Lim, H. Lee, K. Lee, E. Lee, I. Jang, and J. Ro

CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 634. [Abstract]  

M. Ciccarese, E. Bria, D. Giannarelli, F. Cuppone, C. Nuzzo, C. Nistico’, E. Terzoli, F. Cognetti, and P. Carlini

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8,794 patients
J Clin Oncol (Meeting Abstracts) 2006 24: 635. [Abstract]  

W. C. Dooley, C. Hendricks, Y. Gusev, and L. Shockney

Internet based double-blind cross-over clinical trial to test efficacy of high dose isoflavone soy in controlling breast cancer survivor hot flashes
J Clin Oncol (Meeting Abstracts) 2006 24: 636. [Abstract]  

R. J. Pietras, D. C. Marquez, H. Chen, M. X. Sliwkowski, and D. J. Slamon

Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells
J Clin Oncol (Meeting Abstracts) 2006 24: 637. [Abstract]  

J. Mayordomo, A. Llombart, M. Martín, A. Antón, A. Barnadas, S. Antolín, J. Alés-Martínez, and I. Álvarez

Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001–03 study
J Clin Oncol (Meeting Abstracts) 2006 24: 638. [Abstract]  

M. Santarpia, G. Altavilla, M. Margeli, M. Mesiti, V. Cavallari, B. Cirauqui, N. Reguart, A. Barnadas, M. Taron, and R. Rosell

PIK3CA mutations in breast cancer: A potential predictive marker
J Clin Oncol (Meeting Abstracts) 2006 24: 639. [Abstract]  

J. Eng-Wong, S. Chang, S. Hursting, S. N. Perkins, N. Núñez, H. L. Hill, M. Bondy, D. Li, and S. E. Singletary

Premenopausal breast cancer and the association between estrogen receptor status, insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3) and leptin
J Clin Oncol (Meeting Abstracts) 2006 24: 640. [Abstract]  

J. F. Robertson, A. Agrawal, E. Gutteridge, K. Cheung, and A. J. Evans

Correlation of CA15.3 levels with clinical response in advanced breast cancer (ABC) patients receiving fulvestrant
J Clin Oncol (Meeting Abstracts) 2006 24: 641. [Abstract]  

J. J. Wheler, A. S. Doane, I. Linkov, C. A. Hudis, and W. Gerald

High expression of the chemokine receptor CXCR4 is associated with estrogen receptor-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 642. [Abstract]  

K. Neuss, D. Elling, I. Cascorbi, and D. Lueftner

Association between breast cancer and estrogen receptor gene polymorphism PVU II
J Clin Oncol (Meeting Abstracts) 2006 24: 643. [Abstract]  

R. Kim, M. Kaneko, K. Arihiro, M. Emi, K. Tanabe, S. Murakami, A. Osaki, and K. Inai

Clinical significance of extranuclear expression of hormone receptors in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 644. [Abstract]  

S. Mitsuyama, Y. Yanagida, H. Doihara, K. Komaki, M. Kusama, T. Ikeda, M. Kimura, M. Sano, and K. Miyauchi

A multi-center study of the effects of toremifene (TOR) and anastrozole (ANA) on serum lipids and bone metabolism in postmenopausal patients with estrogen receptor (ER) positive breast cancer: Interim report
J Clin Oncol (Meeting Abstracts) 2006 24: 645. [Abstract]  

A. A. Calabró, M. S. Portella, and M. Garcia

A budget impact analysis of extended adjuvant letrozole following five years of tamoxifen in postmenopausal women with early breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 646. [Abstract]  

J. Ragaz, J. J. Spinelli, A. Coldman, and C. Mihalcioiu

Is tamoxifen prevention in younger women underutilized? Analysis of competing causes of mortality
J Clin Oncol (Meeting Abstracts) 2006 24: 647. [Abstract]  

C. Owusu, D. Buist, T. Field, T. L. Lash, S. Thwin, and R. Silliman

Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 648. [Abstract]  

B. S. Abdulkarim, Z. Gabos, R. Sinha, J. Hanson, N. Chauhan, J. Hugh, and J. Mackey

Prognostic significance of HER-2/neu over-expression on the incidence of brain metastasis in newly diagnosed breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 649. [Abstract]  

H. J. Burstein, A. Keshaviah, A. Baron, R. Hart, R. Lambert-Falls, P. K. Marcom, R. Gelman, and E. P. Winer

Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study
J Clin Oncol (Meeting Abstracts) 2006 24: 650. [Abstract]  

N. Denduluri, J. J. Lee, J. M. Walshe, S. X. Yang, U. Vatas, C. K. Chow, S. M. Steinberg, M. C. Cox, J. A. Low, and S. M. Swain

Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes
J Clin Oncol (Meeting Abstracts) 2006 24: 651. [Abstract]  

C. Ishioka, S. Takahashi, T. Ishida, T. Moriya, and N. Ohuchi

Expression signature of p53 status (p53 signature) for the prediction of TP53 mutation and prognosis in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 652. [Abstract]  

J. BlumL. Forero, M. K. Heiskala, N. Meneses, K. Chandrawansa, F. Fang, G. Shapiro, S. Z. Fields, S. Silberman, and L. Vahdat

E7389, a novel anti-tubulin, in patients with refractory breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 653. [Abstract]  

T. N. Fehm, S. Becker, D. Wallwiener, G. Gebauer, and E. Solomayer

Apoptotic disseminated tumor cells reflect response to primary chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 654. [Abstract]  

F. Puglisi, M. Mansutti, A. Minisini, S. Russo, G. Cardellino, C. Andreetta, E. Rijavec, S. Pizzolitto, M. Pandolfi, and C. Di Loreto

Changes in thymidine phosphorylase expression in response to neoadjuvant chemotherapy for primary breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 655. [Abstract]  

N. K. Ibrahim, G. Nguyen, D. Suki, B. Hennessy, A. Montero, J. E. Sarriera, F. Symmans, V. Valero, R. Sawaya, and K. Aldape

Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM)
J Clin Oncol (Meeting Abstracts) 2006 24: 656. [Abstract]  

A. Kuciejewska, U. Banerji, G. Walsh, S. Ashley, M. O’Brien, S. Johnston, and I. Smith

A study of factors determining outcome of patients receiving third line chemotherapy for metastatic breast cancer: The Royal Marsden Hospital experience
J Clin Oncol (Meeting Abstracts) 2006 24: 657. [Abstract]  

D. Mavroudis, A. Ardavanis, I. Boukovinas, I. Varthalitis, K. Syrigos, A. Potamianou, C. Kouroussis, and V. Georgoulias

A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report
J Clin Oncol (Meeting Abstracts) 2006 24: 658. [Abstract]  

S. R. Amin, V. Valero, E. Rivera, R. Adinin, R. Banay, R. Arbuckle, K. Do, and B. Esmaeli

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel
J Clin Oncol (Meeting Abstracts) 2006 24: 659. [Abstract]  

E. Thomas, E. A. Perez, P. Mukhopadhyay, G. Lerzo, X. Pivot, L. D. Bosserman, B. Mullaney, L. Vahdat, and G. N. Hortobagyi

Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine
J Clin Oncol (Meeting Abstracts) 2006 24: 660. [Abstract]  

S. L. Moulder, N. Valkov, S. Minton, P. Munster, J. Gump, M. Lacevic, C. Rocha-Lima, J. Horton, R. Lush, D. Sullivan Sponsored by the National Comprehensive CancerNet

A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors?
J Clin Oncol (Meeting Abstracts) 2006 24: 661. [Abstract]  

P. Mariani, A. Moliterni, G. Da Prada, D. Hess, T. Gamucci, A. Zaniboni, A. Malossi, P. Barbieri, S. Marsoni, and L. Gianni

A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 662. [Abstract]  

M. A. Doz, C. D. Le Tourneau, M. S. Guilhaume, V. Dieras, A. Vincent-Salomon, M. Courbard, B. Le Vu, C. C. Buron, and A. Livartowski

The financial impact of trastuzumab in metastatic breast cancer: The experience of the Institut Curie
J Clin Oncol (Meeting Abstracts) 2006 24: 663. [Abstract]  

M. Bellet, M. Muñoz, B. Bellosillo, J. Corominas, T. Pena, M. Suárez, M. Maristany, J. Perich, I. Tusquets, and X. Fabregat

Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates
J Clin Oncol (Meeting Abstracts) 2006 24: 664. [Abstract]  

U. A. Nitz, O. Gluz, A. Herr, E. Ting, S. Mohrmann, M. Frick, C. Jackisch, C. Poremba, W. Lindemann, and R. Diallo-Danebrock

Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study
J Clin Oncol (Meeting Abstracts) 2006 24: 665. [Abstract]  

L. W. Jones, M. Haykowsky, C. J. Peddle, A. A. Joy, E. N. Pituskin, L. M. Tkachuk, K. S. Courneya, D. J. Slamon, and J. R. Mackey

Cardiovascular risk profile of breast cancer patients treated with anthracycline-taxane containing adjuvant chemotherapy and/or trastuzumab
J Clin Oncol (Meeting Abstracts) 2006 24: 666. [Abstract]  

M. J. Beresford, Y. Chin, R. Burcombe, M. Ah-See, and A. Makris

Clinical response assessment after 2 cycles of neoadjuvant chemotherapy for primary breast cancer fails to predict for final clinical response, but does predict for pathological complete response
J Clin Oncol (Meeting Abstracts) 2006 24: 667. [Abstract]  

I. Chirivella, B. Bermejo, A. Insa, A. Perez-Fidalgo, A. Magro, S. Rosello, E. Garcia-Garre, P. Martin, A. Bosch, and A. Lluch

Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 668. [Abstract]  

D. Shen, J. He, J. Gornbein, Z. Chen, K. F. Faull, J. P. Whitelegge, and H. R. Chang

Biomarkers detected by proteomic analysis predicts breast cancer response to neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 669. [Abstract]  

K. Lee, B. Kim, S. Lee, W. Han, D. Kim, S. Im, T. Kim, I. A. Park, D. Noh, and Y. Bang

Prognostic significance of bcl-2 expression in stage III breast cancer patients who received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 670. [Abstract]  

K. T. Vance and J. Carpenter

Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 671. [Abstract]  

A. R. Zander, N. Kroeger, C. Schmoor, W. Krueger, V. Moebus, N. Frickhofen, B. Metzner, W. Schultze, W. Berdel, M. Koenigsmann, and E. Thiel

Randomized trial of high-dose chemotherapy with autologous haematopoietic stem cell support vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow up
J Clin Oncol (Meeting Abstracts) 2006 24: 672. [Abstract]  

O. Tacca, F. Penault-Llorca, C. Abrial, I. Raoelfils, M. A. Mouret-Reynier, P. Bougnoux, J. L. Achard, J. Dauplat, P. Chollet, and H. Curé

Neoadjuvant chemotherapy (NCT) in 710 patients for operable breast cancer: Variation changing in hormonal receptors (HR) status
J Clin Oncol (Meeting Abstracts) 2006 24: 673. [Abstract]  

M. J. Naughton, L. Gu, X. F. Wang, A. D. Seidman, E. Winer, and A. B. Kornblith

Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 674. [Abstract]  

M. A. Gordon, W. Zhang, D. Yang, D. Spicer, J. Doroshow, K. Margolin, T. Synold, K. Albain, H. Chew, D. Gandara, and H. J. Lenz

Polymorphisms of DNA-repair genes associated with clinical outcome in metastatic breast cancer (MBC) patients treated with gemcitabine/cisplatin (GC) (California Cancer Consortium)
J Clin Oncol (Meeting Abstracts) 2006 24: 675. [Abstract]  

T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa

10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 676. [Abstract]  

A. Bottini, D. Generali, A. Berruti, M. Tampellini, M. Torta, S. Tedoldi, S. Bonardi, M. Tucci, G. Gorzegno, and L. Dogliotti

Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases
J Clin Oncol (Meeting Abstracts) 2006 24: 677. [Abstract]  

Y. Hei, A. Lipton, N. Shirina, Y. M. Chen, and T. Xie

Effect of zoledronic acid (Zol) compared with pamidronate (Pam) on disease progression in breast cancer (BC) patients with bone metastases stratified by baseline characteristics
J Clin Oncol (Meeting Abstracts) 2006 24: 678. [Abstract]  

G. Dranitsaris, M. Clemons, W. Ooi, and D. Cole

Urinary n-telopeptide (NTX) predicts palliative pain response in metastatic breast cancer patients receiving second-line zoledronic acid
J Clin Oncol (Meeting Abstracts) 2006 24: 679. [Abstract]  

A. Agrawal, R. A. Hannon, K. L. Cheung, R. Eastell, and J. F. Robertson

Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant
J Clin Oncol (Meeting Abstracts) 2006 24: 680. [Abstract]  

M. E. Trudeau, H. L. Lickley, L. Zhang, G. Hawker, S. Narod, and C. Sawka

Bone and cardiac status in 10-year survivors of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 681. [Abstract]  

P. Fumoleau, G. Romieu, S. Chan, J. Huober, M. Tubiana-Hulin, A. Schneeweiss, A. Lluch, and P. Bougnoux

Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 682. [Abstract]  

S. H. Kim, B. W. Park, S. H. Ahn, D. Y. Noh, S. J. Nam, E. S. Lee, and Y. H. Yun

Prevalence and correlates of fatigue and depression in breast cancer survivors: Breast cancer quality care study
J Clin Oncol (Meeting Abstracts) 2006 24: 683. [Abstract]  

C. Rousseau, C. Bodet-Milin, J. Bennouna, L. Ferrer, L. Campion, B. Bridji, C. Sagan, M. Ricaud, I. Resche, F. Kraeber-Bodere, and M. Campone

Evaluation of FDG PET in early axillary lymph node response to neoadjuvant chemotherapy in locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10500. [Abstract]  

S. Ménard, S. De Placido, S. Scalone, A. Molino, M. Mottolese, F. Perrone, P. Querzoli, A. Sapino, M. Venturini, G. Viale on behalf of the OMERO group

Biology and prognosis of 1,685 recently diagnosed HER2-positive breast carcinomas
J Clin Oncol (Meeting Abstracts) 2006 24: 10501. [Abstract]  

F. Penault-Llorca, C. Abrial, I. Raoelfils, S. Amat, M. Mouret-Reynier, M. Leheurteur, X. Durando, J. Dauplat, H. Curé, and P. Chollet

Neoadjuvant chemotherapy (NCT) in 710 patients for operable breast cancer: Comparison of 2 pathological classifications
J Clin Oncol (Meeting Abstracts) 2006 24: 10502. [Abstract]  

D. M. Paepke, F. Herbst, K. Annecke, N. Gaskill, F. Sweep, C. Meisner, M. Schmitt, F. Jaenicke, N. Harbeck, and C. Thomssen

Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients—A status report of the prospective clinical trial NNBC 3-Europe
J Clin Oncol (Meeting Abstracts) 2006 24: 10503. [Abstract]  

C. A. Adebamowo, T. Ogundiran, and E. Akang

Epidemiology of triple negative breast cancer in Nigerian women
J Clin Oncol (Meeting Abstracts) 2006 24: 10504. [Abstract]  

P. Conte, E. Thomas, M. Martin, J. Klimovsky, and J. Tabernero

Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report
J Clin Oncol (Meeting Abstracts) 2006 24: 10505. [Abstract]  

M. E. Abusief, S. A. Missmer, E. S. Ginsburg, J. C. Weeks, E. P. Winer, and A. H. Partridge

Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density
J Clin Oncol (Meeting Abstracts) 2006 24: 10506. [Abstract]  

P. Meijnen, M. C. Van Rijk, H. S. Oldenburg, C. E. Loo, R. A. Valdés Olmos, O. E. Nieweg, J. L. Peterse, M. J. Van de Vijver, and E. J. Rutgers

Lymphatic mapping of ductal carcinoma in situ diagnosed by stereotactic core needle biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 10507. [Abstract]  

R. Duchnowska, B. Czartoryska-Arlukowicz, B. Radecka, B. Szostakiewicz, K. Sosinska, A. Karpinska, R. Dziadziuszko, T. Kubiatowski, E. Staroslawska, and C. Szczylik

Predictors of brain relapse in HER-2 positive metastatic breast cancer (MBC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 10508. [Abstract]  

J. Hernandez, M. Mathieu, E. Taranchon, M. Spielmann, S. Delaloge, J. Soria, and F. André

hTert, MMP1, Her2 expressions by preneoplastic lesions and breast cancer risk
J Clin Oncol (Meeting Abstracts) 2006 24: 10510. [Abstract]  

C. A. Bunnell, J. Klimovsky, and E. Thomas

Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline
J Clin Oncol (Meeting Abstracts) 2006 24: 10511. [Abstract]  

J. Tchou, S. Sonnad, M. Sargen, B. Weber, K. Nathanson, and S. Domchek

Contralateral prophylactic mastectomy in affected carriers of deleterious BRCA1 or BRCA2 mutations: Does timing of genetic testing matter?
J Clin Oncol (Meeting Abstracts) 2006 24: 10512. [Abstract]  

R. Le Scodan, C. Massard, E. Fourme, J. Guinebretiere, A. Goupil, B. De Lalande, C. Cohen-Solal, P. Moisson, J. Floiras, and A. Labib

Pejorative factors identification for survival in patients with brain metastases from breast carcinoma treated with whole brain radiation therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10513. [Abstract]  

D. Tripathy, L. Jiang, N. Rao, R. McColl, X. Xie, P. Weatherall, M. Story, L. Ding, and R. Mason

Blood oxygen level dependent (BOLD) contrast MRI and breast cancer chemotherapy response
J Clin Oncol (Meeting Abstracts) 2006 24: 10514. [Abstract]  

H. R. Chang, D. Slamon, R. Prati, J. Glaspy, M. D. Pegram, F. C. Kass, L. D. Bosserman, J. Taguchi, R. Dichmann, and D. Chung

A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity
J Clin Oncol (Meeting Abstracts) 2006 24: 10515. [Abstract]  

S. Gori, V. De Angelis, S. Rimondini, A. M. Mosconi, G. Moretti, G. Bisagni, A. Sidoni, C. Aristei, E. Franceschi, M. Colozza, and L. Crino

Incidence and risk factors for central nervous system (CNS) metastases in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 10516. [Abstract]  

M. Berliere, F. Dalenc, N. Malingret, A. Vindevogel, J. Kerger, H. Roche, M. Symann, J. Donnez, and J. Machiels P

Incidence of reversible amenorrhea in women with early-stage breast cancer undergoing adjuvant anthracyclin-based chemotherapy with or without docetaxel
J Clin Oncol (Meeting Abstracts) 2006 24: 10517. [Abstract]  

M. Ionta, F. Atzori, D. Nonnis, M. Deidda, A. Contu, A. Farris, A. Catino, S. Palmeri, L. Minerba, and B. Massidda

Long-term effect in outcomes of intensified primary chemotherapy in poor prognosis LABC T4 patients: Results of a multicenter Italian study
J Clin Oncol (Meeting Abstracts) 2006 24: 10518. [Abstract]  

F. E. Frankenne, C. Munaut, F. Wijzen, J. Planellas Gomez, L. Kloosterboer, and J. Foidart

Effect of tibolone on tumor angiogenesis parameters in short-term treated women
J Clin Oncol (Meeting Abstracts) 2006 24: 10519. [Abstract]  

K. S. Lee, H. C. Chung, S. A. Im, Y. H. Park, S. B. Kim, C. S. Kim, and J. Ro

Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10520. [Abstract]  

M. Danova, K. Bencardino, D. Grasso, M. Manzoni, E. Collovà, S. Ferrari, E. Travaglino, B. Rovati, C. Porta, and R. Invernizzi

Biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10521. [Abstract]  

J. R. Gralow, D. Chielens, G. Schuster, B. Storer, M. J. McCleod, R. E. Smith, N. M. Chowhan, V. Gressler, and G. Miletello

UW-01: A randomized comparison of three doses of weekly docetaxel as 1st-line chemotherapy in stage IV breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10522. [Abstract]  

G. Hudelist, C. Singer, K. Pischinger, K. Kaserer, M. Manavi, E. Kubista, and K. Czerwenka

Proteomic analyses of normal and malignant breast tissue—Identification of a tumor-specific protein expression profile
J Clin Oncol (Meeting Abstracts) 2006 24: 10524. [Abstract]  

M. Litwiniuk, V. Filas, J. Moczko, R. Kaleta, and J. Breborowicz

Expression of hormone receptors ER, ERß and PgR in HER2-positive breast cancers
J Clin Oncol (Meeting Abstracts) 2006 24: 10525. [Abstract]  

M. Lopez, M. Brandi, P. Foggi, F. Giotta, N. Gebbia, B. Massidda, G. Filippelli, G. Cicero, P. Vici, G. Colucci Gruppo Oncologico Dell’italia Meridionale(goim)

Toxicity of epirubicin and cyclophosphamide (EC) vs. docetaxel (D) followed by EC in the adjuvant (adj) treatment of node positive breast cancer. A multicenter randomized phase III study (GOIM9902)
J Clin Oncol (Meeting Abstracts) 2006 24: 10526. [Abstract]  

V. Bar Ad, A. Cheville, N. Amin, J. Booty, L. J. Solin, and E. E. Harris

Minimal arm lymphedema after breast conservation therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10527. [Abstract]  

L. T. Vahdat, J. Klimovsky, and C. A. Bunnell

Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data
J Clin Oncol (Meeting Abstracts) 2006 24: 10528. [Abstract]  

H. K. Chew, W. E. Barlow, K. S. Albain, D. Lew, G. T. Budd, G. Allen, J. Gralow, R. Livingston Southwest Oncology Group

SWOG 0338: A phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10529. [Abstract]  

M. B. Rodin, J. A. Wallace, M. Lacy, K. Kuball, B. Pykkonen, and G. Fleming

Does adjuvant chemotherapy (CT) exacerbate cognitive impairment in elderly breast cancer (BC) patients? Results of a prospective, longitudinal study
J Clin Oncol (Meeting Abstracts) 2006 24: 10530. [Abstract]  

V. Guillem, A. Llombart-Cussac, J. Lopez Guerrero, A. Guerrero, C. Fuster, A. Ruiz, M. A. Climent, I. Tena, C. Vazquez, and A. Llombart-Bosch

Clinical response at 4 months to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II-III ER/PgR-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10531. [Abstract]  

J. Geisler, H. Helle, D. Ekse, N. K. Duong, D. Evans, and P. E. Lønning

Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting
J Clin Oncol (Meeting Abstracts) 2006 24: 10532. [Abstract]  

L. J. Tafe, G. J. Tsongalis, P. A. Kaufman, C. P. Moore, and W. A. Wells

Breast sentinel lymphadenectomy—Is immediate intra-operative assessment warranted?
J Clin Oncol (Meeting Abstracts) 2006 24: 10533. [Abstract]  

J. Wright, S. Dimitry, J. Sussman, and T. J. Whelan

Understanding decision supports (DS) for women with breast cancer eligible for clinical trials (CT)
J Clin Oncol (Meeting Abstracts) 2006 24: 10534. [Abstract]  

Y. J. Wang, Q. Fu, Q. Wu, F. X. Su, L. Z. Zhou, Z. B. Ye, and J. Q. Yang

Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for treatment of advanced breast cancer (CHN TAX-618)
J Clin Oncol (Meeting Abstracts) 2006 24: 10535. [Abstract]  

R. Bartsch, S. Muschitz, C. Wenzel, K. Roessler, K. Dieckmann, H. Weitmann, U. Pluschnig, R. Poetter, C. C. Zielinski, and G. G. Steger

Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10536. [Abstract]  

A. Lluch, I. Chirivella, A. Insa, F. Martinez-Ruiz, A. Santaballa, C. Herranz, J. Ibañez, J. Miranda, C. Pons, and D. Sala

Impact of mammographic screening in staging, treatment and prognosis of breast cancer: Early assessment
J Clin Oncol (Meeting Abstracts) 2006 24: 10537. [Abstract]  

C. Andreetta, S. Russo, V. Londero, M. Mansutti, A. Minisini, G. Cardellino, F. Valent, C. Zuiani, M. Bazzocchi, and F. Puglisi

Comparison of mammography, sonography and MRI in patients receiving neoadjuvant chemotherapy for breast cancer: Final results of a prospective study
J Clin Oncol (Meeting Abstracts) 2006 24: 10538. [Abstract]  

R. V. Raghupathy, C. W. Seidler, S. Emani, and J. Rooney

A retrospective pilot study of serum lipid levels and the risk of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10539. [Abstract]  

A. Katz, E. D. Saad, and L. Pusztai

Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)?
J Clin Oncol (Meeting Abstracts) 2006 24: 10541. [Abstract]  

E. Mrozek, J. Kolesar, J. Allen, D. Young, D. Angus, K. Kendra, C. A. Rhoades, M. A. Villalona-Calero, and C. L. Shapiro

Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10542. [Abstract]  

S. Djahansouzi, V. Rostock, D. Niederacher, W. Rath, H. Bender, and B. Hanstein

Changes to the hormone receptor expression in patients treated with either tamoxifen or aromatase inhibitors as endocrine therapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10543. [Abstract]  

P. McGowan, M. C. Perry, J. E. Hewett, B. Ge, and K. Sanfilippo

Weight gain in breast cancer patients: Tamoxifen versus anastrazole
J Clin Oncol (Meeting Abstracts) 2006 24: 10544. [Abstract]  

N. Cook, C. A. Parkinson, R. Jagsi, S. Patel, and L. Hughes-Davies

The International Core Literature Consensus (ICLC) : A tool for Resident training
J Clin Oncol (Meeting Abstracts) 2006 24: 10545. [Abstract]  

M. Brandi, A. Calascibetta, D. Cabibi, A. Martorana, F. Aragona, F. Fulfaro, M. Valerio, J. Dispenza, and R. Sanguedolce

Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy(CMF) versus docetaxel (TXT) in locally advanced carcinoma of the breast
J Clin Oncol (Meeting Abstracts) 2006 24: 10546. [Abstract]  

E. Angelidou, G. Sotiropoulou, E. Poulianou, E. Politi, and H. Koutselini

Preoperative prediction of the axillary lymph nodes status in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10547. [Abstract]  

D. Miura, D. Kitagawa, and K. Tsutsumi

Adding paclitaxel to trastuzumab enhances antibody-dependent cell-mediated cytotoxicity via increment of natural killer cells in patients with Her-2 overexpressing breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10548. [Abstract]  

E. N. Pituskin, B. Williams, K. Martin-Mcdonald, and H. Au

The experience of a sample of Canadian men with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10549. [Abstract]  

I. Wolf, J. O’kelly, T. Rubinek, M. Tong, B. T. Lin, H. Tai, B. Y. Karlan, and H. P. Koeffler

15-Hydroxyprostaglandin dehydrogenase (PGDH) is an aberrant tumor suppressor in human breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10550. [Abstract]  

S. Biggs, P. J. Anderson, R. Mark, T. Neumann, and M. Nair

Interstitial high dose rate (HDR) brachytherapy for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10551. [Abstract]  

I. Gisterek, R. Matkowski, E. Suder, A. Lacko, D. Ramsey, J. Szelachowska, and J. Kornafel

Prognostic role of c-met tyrosine kinase receptor expression in breast carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 10552. [Abstract]  

S. Gray, K. A. Dakin-Hache, P. J. Barnes, R. Dewar, T. Younis, and D. Rayson

Clinical and pathological correlations in male breast cancer (MBC): Intratumoral aromatase expression (ITA) via tissue microarray (TMA)
J Clin Oncol (Meeting Abstracts) 2006 24: 10553. [Abstract]  

P. Stieber, D. Nagel, and V. Heinemann

Tumor markers in metastatic breast cancer: High tumor specificity within the reference range
J Clin Oncol (Meeting Abstracts) 2006 24: 10554. [Abstract]  

R. Gutt, S. Yovino, L. Chin, W. Regine, P. Amin, K. Tkaczuk, and Y. Kwok

Gamma Knife stereotactic radiosurgery in the treatment of brain metastases from breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10555. [Abstract]  

I. Carreca, G. Iodice, G. D’Aiuto, R. Thomas, R. Costanzo, M. Licenziato, A. Petrillo, L. Maiorino, G. Frasci, and G. Comella

Tailored vinorelbine-capecitabine treatment in elderly metastatic breast cancer patients. A SICOG phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10556. [Abstract]  

A. D. Chan, G. A. Luiken, M. M. Quigley, M. Xu, and R. M. Hoffman

Induced fluorescence of breast cancer in the mouse model: A simple technology to improve visualization of malignant tissue during breast cancer surgery
J Clin Oncol (Meeting Abstracts) 2006 24: 10557. [Abstract]  

C. Bengala, C. Zamagni, P. Pedrazzoli, P. Matteucci, A. Ballestrero, G. Da Prada, M. Martino, G. Rosti, M. Danova, G. Jovic, and P. Conte

Cardiac tolerability of trastuzumab in metastatic breast cancer (MBC) patients previously treated with high-dose chemotherapy (HDC) with autologous hemopoietic support: Retrospective analysis from Gruppo Italiano Trapianto Midollo Osseo (GITMO) Solid Tumor Working Party
J Clin Oncol (Meeting Abstracts) 2006 24: 10558. [Abstract]  

N. Kohno, K. Aogi, H. Minami, and S. Takashima

Efficacy of zoledronic acid versus placebo on biochemical markers of bone metabolism in patients with breast cancer metastatic to bone
J Clin Oncol (Meeting Abstracts) 2006 24: 10559. [Abstract]  

J. D. Jhaveri, I. Savetsky, J. L. Bosworth, and S. C. Rush

Clinical outcomes following immediate reconstruction and post-mastectomy radiation therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10560. [Abstract]  

E. Barrajon, A. Lopez, and E. Adrover

Screening mammography in old women saves lives: A simulation model
J Clin Oncol (Meeting Abstracts) 2006 24: 10561. [Abstract]  

S. Walker, J. Franciose, P. G. Vashi, C. Lammersfeld, J. F. Grutsch, C. G. Lis, D. Gupta, and S. Williams

A prospective survey evaluating the use of soy products in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10562. [Abstract]  

F. André, C. Massard, H. Assi, B. Besse, J. Sabourin, and L. Zitvogel

Toll like receptor 3 expression and efficacy of adjuvant treatment with polyadenylic-polyuridylic acid in patients with axillary node positive breast cancer: Results from two randomized trials
J Clin Oncol (Meeting Abstracts) 2006 24: 10563. [Abstract]  

E. L. Mayer, L. N. Harris, A. H. Partridge, R. S. Gelman, S. T. Schumer, R. S. Comanaru, M. Long, E. Sampson, H. J. Burstein, and E. P. Winer

Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial
J Clin Oncol (Meeting Abstracts) 2006 24: 10564. [Abstract]  

S. M. Benn, G. Jha, T. W. Ratliff, K. Spiers, R. Baskin, F. Yunus, R. Osarogiagbon, B. Boston, S. Minhas, and M. Jahanzeb

Adjuvant trastuzumab (T) therapy in HER2+ breast cancer after ASCO 2005: Patients’ attitudes and immediate economic burden
J Clin Oncol (Meeting Abstracts) 2006 24: 10565. [Abstract]  

I. Frahm

National HER2 testing program for breast cancer patients in Argentina
J Clin Oncol (Meeting Abstracts) 2006 24: 10566. [Abstract]  

M. V. Karamouzis, S. A. Perez, A. D. Gritzapis, A. Ardavanis, D. V. Skarlos, C. N. Baxevanis, G. Rigatos, and M. Papamichail

Circulating regulatory T cells in advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10567. [Abstract]  

A. Larke, A. O’Doherty, and C. Quinn

High malignancy yield in core needle biopsy of BIRADS 3 breast lesions with calcification
J Clin Oncol (Meeting Abstracts) 2006 24: 10568. [Abstract]  

A. M. Ingle, P. Kumar, B. Baney, K. Day, T. Dagen, A. S. Galley, and R. H. Dixon

Effect of microscopic residual tumor (MRT) at surgical margin of resection (SMR) in invasive breast cancer (IBC) on survival of non-Hispanic white women in central Pennsylvania (PA)
J Clin Oncol (Meeting Abstracts) 2006 24: 10569. [Abstract]  

M. A. Koike Folgueira, S. T. Honda, T. T. Benvenuti, P. B. Rozenchan, R. P. Santos, H. Brentani, D. M. Carraro, M. H. Katayama, E. C. Lyra, and M. M. Brentani

Differential gene profiling of malignant cells and fibroblasts from the primary and metastatic sites from breast cancer patients upon stroma-epithelial cell interaction
J Clin Oncol (Meeting Abstracts) 2006 24: 10570. [Abstract]  

F. Nolè, E. Verri, G. Sanna, E. Munzone, C. Catania, G. Ascione, L. Adamoli, S. Dellapasqua, M. Colleoni, and A. Goldhirsch

Pegylated liposomal doxorubicin (PLA) at a metronomic schedule for patients with advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10571. [Abstract]  

L. P. Branco, R. Dienstmann, and J. Bines

Megestrol acetate after aromatase inhibitor failure in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10572. [Abstract]  

J. Fareed, D. A. Hoppensteadt, M. Demir, O. Iqbal, W. Jeske, M. Tobu, and R. Bick

Nitric oxide and asymmetric dimethylarginine (ADMA) in malignancy associated thrombosis and their modulation by anticoagulants
J Clin Oncol (Meeting Abstracts) 2006 24: 10573. [Abstract]  

I. E. Krop, M. Kosh, I. Fearen, J. Savoie, A. Dallob, C. Matthews, J. Stone, E. Winer, S. J. Freedman, and P. Lorusso

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 10574. [Abstract]  

C. D. Moussallem, A. Lopez, A. Gauthier, S. Moore, M. Johnson, J. L. Murray, III, and N. K. Ibrahim

Fulvestrant (F) in metastatic breast cancer: Standard dose (Std) vs loading dose (Ld)—A retrospective study
J Clin Oncol (Meeting Abstracts) 2006 24: 10575. [Abstract]  

M. C. Green, L. Pusztai, R. L. Theriault, R. B. Adinin, M. Hofweber, M. Fukushima, A. Mita, N. Bindra, and G. N. Hortobagyi

Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10576. [Abstract]  

T. E. Delea, J. Karnon, V. Barghout, S. K. Thomas, and N. L. Papo

Cost-effectiveness of letrozole and anastrozole as adjuvant therapy for hormone receptor positive early breast cancer in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2006 24: 10577. [Abstract]  

I. Laurent, C. Balleyguier, R. Rouzier, F. André, H. Marsiglia, M. Spielmann, P. Vielh, and S. Delaloge

A mathematical model to predict for pre-malignant or malignant diagnosis among patients with Birad 4 breast lesions
J Clin Oncol (Meeting Abstracts) 2006 24: 10578. [Abstract]  

C. Zanon, M. Airoldi, and F. Pedani

Hepatic intra-arterial infusion (HAI) for liver metastases in pretreated metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10579. [Abstract]  

M. Margelí, B. Cirauqui, V. Vallejos, C. Sánchez, A. Mariscal, E. Castellà, M. Rull, A. Torrente, M. Fraile, and A. Barnadas

Monitorization of primary therapy (PT) by additional imaging methods in locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10580. [Abstract]  

N. Fazio, M. Medici, M. Colleoni, A. Rocca, R. Torrisi, F. Orsi, P. Della Vigna, G. Bonomo, L. Monfardini, and A. Goldhirsch

Hepatic intra-arterial chemotherapy in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10581. [Abstract]  

G. Ferretti, A. Felici, M. Pino, P. Carlini, A. Fabi, C. Nuzzo, I. Sperduti, F. Cognetti, and P. Papaldo

Incidence of brain metastases after first line chemotherapy in breast cancer patients treated with or without trastuzumab
J Clin Oncol (Meeting Abstracts) 2006 24: 10582. [Abstract]  

R. S. Mehta, T. Schubbert, and K. Kong

Paclitaxel, carboplatin and trastuzumab (TCH) achieves high pathological complete remission rate after in vivo response directed 2–4 cycles of doxorubicin and cyclophosphamide (AC) in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10583. [Abstract]  

R. E. Mansel and F. McNeill

Quality assurance in surgical trials of new techniques
J Clin Oncol (Meeting Abstracts) 2006 24: 10584. [Abstract]  

D. Azria, M. Tubiana-Hulin, M. Spielmann, B. Coudert, A. Monnier, D. Serin, T. Altweeg, M. Namer, and J. Gligorov

Prognostic facctor for early versus late relapse in hormonodependant non metastatic breast cancers treated by tamoxifen: PROFARE study results from GETNA group
J Clin Oncol (Meeting Abstracts) 2006 24: 10585. [Abstract]  

M. Gil-Delgado, H. Boostan, E. Garcia-Giralt, G. Auclair, F. Biville, and D. Khayat

Oral vinorelbine in combination with capecitabine in advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10586. [Abstract]  

M. N. Fornier, M. Martin, J. Klimovsky, and C. A. Bunnell

Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report
J Clin Oncol (Meeting Abstracts) 2006 24: 10587. [Abstract]  

F. Sperandi, S. Fanti, R. Franchi, and A. Martoni

The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET) on the decision-making process in breast cancer patients: The experience of Bologna’s S.Orsola-Malpighi Hospital
J Clin Oncol (Meeting Abstracts) 2006 24: 10588. [Abstract]  

J. P. Guastalla, R. Largillier, J. F. Geay, A. C. Hardy-Bessard, S. Kirsher, B. Slama, J. Cretin, H. Orfeuvre, Y. Goubely, and E. Pujade-Lauraine

Docetaxel (Do) and liposomal pegylated doxorubicin in metastatic breast cancer (MBC) patients (pts): The French GINECO group experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10589. [Abstract]  

D. A. Yardley, N. W. Peacock, D. Shipley, D. Waterhouse, R. Landgdon, L. Simons, S. Thomas, J. D. Hainsworth, D. R. Spigel, and H. A. Burris, III

Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10590. [Abstract]  

A. M. Brufsky, K. Fox, M. Orlando, J. Abraham, E. Tan-Chiu, L. Haney, and Y. Wang

Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression
J Clin Oncol (Meeting Abstracts) 2006 24: 10591. [Abstract]  

J. Jeong, S. Lee, S. Yoon, W. Jung, H. Lee, and I. Lee

Clinical availability of chemotherapy response assay using adenosine triphosphate in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10592. [Abstract]  

V. Mari, E. Chamorey, A. Italiano, F. Van Den Bos, R. Ferri-Dessens, J. Ferrero, R. Largillier, F. Ettore, A. Courdi, P. Paquis, and M. Frenay

Clinical significance of brain metastases occurrence in HER2 overexpressing metastatic breast cancer patients treated with trastuzumab
J Clin Oncol (Meeting Abstracts) 2006 24: 10593. [Abstract]  

U. S. Kraus-Tiefenbacher, C. Herskind, L. Bauer, F. Melchert, and F. Wenz

Long-term follow-up after intraoperative radiotherapy (IORT) for breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10594. [Abstract]  

F. A. Holmes, J. A. O’Shaughnessy, B. Hellerstedt, J. Pippen, S. Vukelja, D. Kocs, L. Asmar, E. Fenske, F. Lin, W. F. Symmans, and L. Pusztai

Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10595. [Abstract]  

A. Z. Bluming

Hormone replacement therapy (HRT) in women with previously treated primary breast cancer: Update XII
J Clin Oncol (Meeting Abstracts) 2006 24: 10596. [Abstract]  

C. Massacesi, L. Zepponi, M. B. Rocchi, S. Rossini, and L. Burattini

Tamoxifen-related endocrine symptoms in early breast cancer patients are relieved when it is switched to anastrozole
J Clin Oncol (Meeting Abstracts) 2006 24: 10597. [Abstract]  

S. Iacobelli, E. Cianchetti, C. Ficorella, D. Angelucci, S. Grossi, E. Ricevuto, G. Castrilli, M. Zilli, N. Tinari, and C. Natoli

Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with early breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10598. [Abstract]  

S. Cresta, A. Perotti, L. Merlini, M. Mansutti, A. Marchianã, G. Grasselli, G. Bianchini, C. Ferrario, G. Capri, and L. Gianni

Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10599. [Abstract]  

L. P. Gold, Z. Cheng, L. Tafra, K. Sawyer, K. Verbanac, and M. Rosman

The risk of breast cancer recurrence in the sentinel lymph node era
J Clin Oncol (Meeting Abstracts) 2006 24: 10600. [Abstract]  

S. Terstriep, K. Amrami, R. Spinner, and T. Moynihan

Brachial plexopathy in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10601. [Abstract]  

G. Masci, L. Di Tommaso, I. Del Prato, S. E. Orefice, G. Gullo, A. Rubino, M. W. Eboli, E. Morenghi, M. Roncalli, and A. Santoro

Micrometastasis in sentinel (SLN) and non-sentinel lymph nodes of breast cancer: An update including clinico-pathologic impact and survival
J Clin Oncol (Meeting Abstracts) 2006 24: 10602. [Abstract]  

M. Gaui, G. Amorim, R. Arcuri, G. Pereira, D. Moreira, and C. Djahjah

Mature data on neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10603. [Abstract]  

N. A. Haideri, J. Moormeier, and N. Arora

Positive predictive factors for residual disease in re-excision specimens of early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10604. [Abstract]  

J. Finek, L. Holubec, L. Elgrova, M. Pesta, M. Votavova, I. Pavlikova, M. Frank, I. Bustova, H. Siffnerova, and M. Sediva

The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10605. [Abstract]  

M. E. Melisko, C. A. Millerick, P. Maniar, D. Moore, M. Rosenwein, H. S. Rugo, and L. Esserman

Impact of taxanes on weight gain during neoadjuvant chemotherapy (Ctx) for breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10606. [Abstract]  

A. Chan, N. Tubiana, V. Ganju, P. Conte, P. Bougnoux, D. Aubert, T. Bourlard, and D. Becquart

Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety Results of two international multicenter studies
J Clin Oncol (Meeting Abstracts) 2006 24: 10607. [Abstract]  

A. Thomas, S. Kümmel, S. Landt, M. Warm, F. Fritzsche, W. Lichtenegger, and T. Fischer

Improved differentiation of 300 breast lesions using real-time elastography
J Clin Oncol (Meeting Abstracts) 2006 24: 10608. [Abstract]  

A. Rosenberg, L. P. Burke, P. W. Vos, and M. Brinson

Factors predicting tumor size at presentation in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10609. [Abstract]  

J. Ahn, S. Kim, B. Son, S. Ahn, and W. Kim

Adjuvant CAF versus AC followed by paclitaxel for operable breast cancer with 4 or more involved axillary lymph nodes: Retrospective analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 10610. [Abstract]  

S. Massarut, G. Baldassarre, B. Belletti, A. Colombatti, S. D'Andrea, E. Candiani, T. Perin, S. Reccanello, M. Roncadin, and J. S. Vaidya

Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid
J Clin Oncol (Meeting Abstracts) 2006 24: 10611. [Abstract]  

A. M. Maarraoui, A. Utamachandani, A. I. Mattamona, C. A. Lazaro, L. S. Mathews, V. Saxen, D. Uttamchandani, Y. Maarraoui, H. Abdulatif, and N. M. Attia

Breast cancer in United Arab Emirates: Younger patients and more aggressive histology
J Clin Oncol (Meeting Abstracts) 2006 24: 10612. [Abstract]  

R. Tashima and R. Nishimura

An evaluation of changes in biological markers (ER, PgR, or Ki67) after neoadjuvant chemotherapy (ET: epirubicin and docetaxel) in operable breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10613. [Abstract]  

M. Mundia and M. F. Ali

Anastrazole treatment in breast cancer does not cause androgenic effect
J Clin Oncol (Meeting Abstracts) 2006 24: 10614. [Abstract]  

L. Xu, S. Song, J. Zhu, R. Luo, L. Li, S. Jiao, L. Chen, M. Tao, Y. Su, and D. Liu

A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10615. [Abstract]  

X. Jiang, A. Israyeeyan, E. Boykin, L. Lomax, J. F. Head, and R. L. Elliott

Antisense oligonucleotide targeted to the transferrin receptor gene suppresses tumor growth and lung metastases in 4T1 mammary adenocarcinoma mouse model
J Clin Oncol (Meeting Abstracts) 2006 24: 10616. [Abstract]  

J. Garcia-Saenz, M. Martin, C. Bueno, T. Sampedro, S. Lopez-Tarruella, J. Puente, L. Villalobos, L. Rodriguez, B. Garcia, A. Casado, and E. Diaz-Rubio

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10617. [Abstract]  

O. E. Silva, G. Lopes, D. Morgensztern, C. Lobo, S. Abdullah, P. Doliny, J. Slingerland, S. Gluck, E. Santos, C. Welsh, and J. Hurley

Split, low-dose docetaxel (D) and low-dose capecitabine (C) is an active regimen in metastatic breast cancer with minimal toxicity
J Clin Oncol (Meeting Abstracts) 2006 24: 10618. [Abstract]  

S. E. Clare, H. Neubauer, C. Schuetz, R. Kurek, E. Solomayer, D. Wallwiener, D. F. Dye, J. M. Zaleski, R. J. Goulet, Jr, and T. Fehm

Raman spectroscopy to distinguish progression stages in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10619. [Abstract]  

M. Castiel, S. Masakhalia, M. Krychman, B. Stier, A. Amsterdam, M. Gemignani, and N. Kauff

Usage trends of minimally absorbed vaginal estrogens in breast cancer patients versus patients with non-breast malignancies
J Clin Oncol (Meeting Abstracts) 2006 24: 10620. [Abstract]  

R. Matkowski, I. Gisterek, E. Suder, A. Lacko, J. Szelachowska, D. Ramsey, and J. Kornafel

Correlation between vascular endothelial growth factor and c-met expressions in breast carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 10621. [Abstract]  

S. A. McDaniel, H. Krontiras, J. T. Carpenter, Jr, L. M. Nabell, K. I. Bland, M. M. Urist, C. I. Falkson, and A. Forero

Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10622. [Abstract]  

H. Kaur, P. Silverman, D. Singh, B. W. Cooper, P. Fu, S. Krishnamurthi, S. Remick, and B. Overmoyer

Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10623. [Abstract]  

C. L. Vogel, E. Tan-Chiu, and F. Gokce

Capecitabine plus docetaxel (XT): A first line, phase II clinical trial in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10624. [Abstract]  

S. A. Russo, M. Akbari, V. R. Grann, J. S. Jacobson, and C. Chen

Oral adjuvant treatment choices and local recurrence risk in early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10625. [Abstract]  

G. Mavligit, R. Kurzrock, A. Cheung, S. Gupta, D. C. Madoff, M. Wallace, E. Kim, S. A. Curley, G. N. Hortobagyi, and L. H. Camacho

Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients (Pts) with breast carcinoma metastatic to the liver
J Clin Oncol (Meeting Abstracts) 2006 24: 10626. [Abstract]  

T. A. Vandenberg, M. Trudeau, L. Provencher, L. C. Panasci, L. Yelle, D. Rayson, J. Latreille, M. Clemons, M. Giroux, and J. Pouliot

Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1^st-line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines
J Clin Oncol (Meeting Abstracts) 2006 24: 10627. [Abstract]  

A. G. Alidina, A. Lal, and S. Khan

Impact of pre-operative three different regimens on breast-conservation surgery (BCS) and pathological complete response rates (pCR) in locally advanced breast cancer (LABC) in Pakistani patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10628. [Abstract]  

M. S. Lenhard, S. Kahlert, I. Himsl, N. Ditsch, M. Untch, K. Friese, and I. Bauerfeind

A clinical review of 33 cases of breast phyllodes tumor over the last 20 years
J Clin Oncol (Meeting Abstracts) 2006 24: 10629. [Abstract]  

R. Varadarajan, G. Das, B. Janarthanan, M. Desouki, S. Kulkarni, and J. Geradts

Study of association between p53 mutation and tamoxifen therapy in women with hormone receptor positive invasive ductal cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10630. [Abstract]  

Z. I. Tomasevic, D. Jovanovic, L. Radosevic-Jelic, Z. Tomasevic, S. Vasovic, L. Stamatovic, S. Jelic, and J. Spasic

HER-2 status of the primary breast cancer in patients with relapse at least five years after the initial diagnose
J Clin Oncol (Meeting Abstracts) 2006 24: 10631. [Abstract]  

O. Arrieta, T. Ceron-Lizarraga, D. Morales-Espinoza, G. Vizcaino, A. Gamboa, and B. Pineda

Detection of the AT1 and AT2 receptors of angiotensin II in malignant breast tumors and its correlation to cellular proliferation, hormonal profile and prognosis
J Clin Oncol (Meeting Abstracts) 2006 24: 10632. [Abstract]  

P. Pronzato, M. E. Cazzaniga, G. Mustacchi, A. De Matteis, F. Di Costanzo, C. Verusio, N. Marzano, E. Rulli, and I. Floriani

Factors influencing the switch from Tamoxifen (TAM) to Aromatase Inhibitors (AIs) as adjuvant therapy in early breast cancer (EBC) patients (pts). Results from the NORA study
J Clin Oncol (Meeting Abstracts) 2006 24: 10633. [Abstract]  

J. J. Doyle, D. L. Hershman, A. I. Neugut, L. S. Stern, L. M. Katz, and M. Dolgitser

Chemotherapy-related adverse events among breast cancer patients: A retrospective analysis of the SEER-Medicare database
J Clin Oncol (Meeting Abstracts) 2006 24: 10634. [Abstract]  

D. Laessig, U. Vehling-Kaiser, P. Fasching, F. Melchert, H. Koelbl, M. Stauch, P. Maubach, A. Scharl, J. Stemmler, and V. Heinemann

Gemcitabine plus carboplatin for patients with pretreated, metastatic breast cancer: A phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 10635. [Abstract]  

G. Romieu, F. Bibeau, S. Culine, S. Gourgou-Bourgade, C. Guillemare, and A. Kramar

Phase II trial of 4 cycles dose dense docetaxel (D) 100mg/m² every 2 weeks with G-CSF support, followed by 3 cycles of 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) every 3 weeks as neoadjuvant treatment of operable > 2cm breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10636. [Abstract]  

J. Y. Pierga, C. Mathiot, J. M. Extra, P. Tresca, J. Asselah, B. Sigal-Zafrani, E. Brain, V. Diéras, L. Mignot, and M. Marty

Circulating tumor cells (CTCs) detection in a randomized phase II trial of neoadjuvant chemotherapy for large operable and locally advanced breast cancer (REMAGUS 02): Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 10637. [Abstract]  

N. Sauter, H. Minami, N. Kohno, K. Aogi, and S. Takashima

Analysis of skeletal morbidity in breast cancer (BC) patients treated with zoledronic acid (Zol) or placebo: Time to first pathologic fracture
J Clin Oncol (Meeting Abstracts) 2006 24: 10639. [Abstract]  

H. L. McArthur, J. Barnett, and S. Chia

A population-based study of trastuzumab-mediated cardiotoxicity among early stage breast cancer patients treated with adjuvant trastuzumab
J Clin Oncol (Meeting Abstracts) 2006 24: 10640. [Abstract]  

F. Franke, M. Agnoletto, J. Saffi, and T. Guecheva

Expression of critical genes used as prognostic biomarkers and DNA damage in lymphocytes from breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10641. [Abstract]  

D. A. Donat, Sr., J. Pesic, J. Trifunovic, L. Muzikravic, S. Tesanovic, and D. D. Donat

Efficacy and tolerability of biweekly paclitaxel combined with cisplatin in the treatment of metastatic breast cancer (MBC) patients previously treated with anthracyclines
J Clin Oncol (Meeting Abstracts) 2006 24: 10642. [Abstract]  

A. I. Saito, C. Vargas, R. Benda, C. G. Morris, and N. P. Mendenhall

Is the Berg axillary lymph node categorization useful in the 3D Era
J Clin Oncol (Meeting Abstracts) 2006 24: 10643. [Abstract]  

J. Zhang, R. Hui, P. Liu, Y. Yu, Y. Liu, and X. Hao

Clinical pathologic status and expression of tumor markers in 5,000 Chinese breast cancers
J Clin Oncol (Meeting Abstracts) 2006 24: 10644. [Abstract]  

M. Ghosn, F. El Karak, J. Kattan, F. Farhat, F. Nasr, F. Younes, G. Chahine p. For The Cancer Research Group / Collaborative Grou

Gemcitabine and pegylated liposomal doxorubicin as salvage therapy in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10645. [Abstract]  

F. Giotta, V. Lorusso, G. Monticelli, P. Calabrese, G. Filippelli, M. Valerio, E. Maiello, M. Quaranta, and G. Colucci

Liposome-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: A phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10646. [Abstract]  

K. L. Cheung, M. W. Ying, A. R. Green, A. Agrawal, C. E. Paish, L. Winterbottom, and I. O. Ellis

Primary endocrine therapy with anastrozole for early operable primary breast cancer in the elderly: Early clinical and biological data
J Clin Oncol (Meeting Abstracts) 2006 24: 10647. [Abstract]  

M. R. Kell, C. Healy, Z. Martin, R. Downey, S. Potter-Bierne, T. F. Gorey, F. Flannigan, and M. Stokes

Routine staging radiology is not needed for all breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10648. [Abstract]  

J. Chacon, L. López, T. Quintanar, G. Rubio, M. Blanca, J. Andrade, I. Carbonero, C. G Esteban, and M. A. Cruz

Every-other week capecitabine (C7) combinations: An active and well tolerated treatment in heavily pretreated patients (p) with advanced solid tumours
J Clin Oncol (Meeting Abstracts) 2006 24: 10649. [Abstract]  

A. D. Seidman, M. Danso, A. Bach, M. Smith, M. Liu, M. Dickler, M. Robson, M. E. Moynahan, D. Lake, and C. A. Hudis

Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10650. [Abstract]  

R. Colomer, I. Tusquets, L. Calvo, J. Dorca, E. Adrover, P. Sanchez-Rovira, J. Rifa, J. De La Haba, J. A. Virizuela, and M. Beltran

Liposomal doxorubicin (M) plus gemcitabine (G) as first line treatment in metastatic breast carcinoma: A phase I-II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10651. [Abstract]  

C. Nistico’, F. Cuppone, E. Bria, D. Giannarelli, M. Mottolese, F. Novelli, G. Natoli, P. Astorre, and E. Terzoli

Ten-year experience with weekly chemotherapy in metastatic breast cancer patients: Multivariate analysis of prognostic factors
J Clin Oncol (Meeting Abstracts) 2006 24: 10652. [Abstract]  

K. Aogi, N. Kohno, H. Minami, and S. Takashima

Benefits of zoledronic acid compared with placebo in breast cancer patients with bone metastases based on analysis of pain, analgesic use, and performance status
J Clin Oncol (Meeting Abstracts) 2006 24: 10653. [Abstract]  

K. Armstrong, S. Gray, and S. Domchek

Internet use is associated with utilization of genetic counseling for BRCA 1/2 mutations in women with a family history of breast or ovarian cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10654. [Abstract]  

H. Roché, R. Deporte, D. Berton-Rigaud, B. Coudert, N. Tubiana-Mathieu, J. Ferrero, H. Orfeuvre, B. Audhuy, L. Bobadilla, and P. Fumoleau

Capecitabine + epirubicin + cyclophosphamide (CEX) has comparable safety to 5-FU + epirubicin + cyclophosphamide (FEC) as neoadjuvant therapy in patients (pts) with operable breast cancer (BC): Early safety findings from a randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2006 24: 10655. [Abstract]  

E. Cramer, C. Moers, V. Zarghooni, K. Bosse, P. Mallmann, and M. Warm

Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin (E) and cyclophosphamide (C) followed by docetaxel (T) in primary breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10656. [Abstract]  

J. Abraham, A. Hossain, and A. Sehbai

Epidemiologic characteristics of breast cancer (BC) in Asian Indian and Pakistani population living in the US compared to US white population in SEER database from 1988 to 2002
J Clin Oncol (Meeting Abstracts) 2006 24: 10657. [Abstract]  

W. B. Carter and M. Sekharam

Human chorionic gonadotropin (HCG) induction of apoptosis in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10658. [Abstract]  

L. Cals, P. Nouyrigat, X. Tchiknavorian, N. Dohollou, F. Bertrand, C. Bressac, P. Gomez, T. Facchini, M. Besset, and J. Gligorov

Non-pegylated liposomal doxorubicin and docetaxel as front line treatment in HER2-neu negative metastatic breast cancer: Safety and efficacy results
J Clin Oncol (Meeting Abstracts) 2006 24: 10659. [Abstract]  

R. Nishimura, Y. Rai, S. Mitsuyama, S. Toyoshima, H. Iwasaki, I. Ichinose, K. Tamura, F. Matsuo, S. Hara, H. Yano ET Study Group in Kyushu of Japan

Phase II study of an epirubicin and docetaxel (ET) combination as pre and post-operative systemic therapy in patients with early stage breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10660. [Abstract]  

A. N. Budrukkar, R. Sarin, R. Jalali, R. Badwe, V. Parmar, M. Nadkarni, D. Deshpande, T. Shet, and K. Dinshaw

Accelerated partial breast irradiation with interstitial brachytherapy as the sole modality of radiation for women with low risk early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10661. [Abstract]  

A. Modolell, J. I. Mayordomo MD, J. M. Garcia-Bueno, I. Machengs, I. Alvarez, M. Centelles, H. Palombo, M. Burillo, A. Yubero, L. Murillo, and R. Andrés

Multicenter phase II study of liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II - III breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10662. [Abstract]  

A. Karabelis, C. Kosmas, N. Mylonakis, G. Tsakonas, K. Evgenidi, E. Kallistratos, L. Sava, A. Nikolopoulou, A. Gassiamis, and C. Valavanis

Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1^st-line chemotherapy (chemo) in HER2/neu-positive (+) metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10663. [Abstract]  

I. Pavese, M. Di Palma, G. Capuano, and F. Satta

Continous low dose oral chemotherapy administration in heavily pretreated breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10664. [Abstract]  

A. J. Davis, C. R. Lewis, E. J. Moylan, F. X. Parnis, S. E. Brew, and S. P. Ackland

A phase II multicenter study of combination chemotherapy with capecitabine (C) and intravenous (iv) vinorelbine (V) in patients (pts) with pretreated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10665. [Abstract]  

M. Baranzelli, V. Cabaret, L. Vanlemmens, C. Desauw, S. Giard, M. Chauvet, Y. Belkacemi, A. Mailliez, L. Deschildre, and J. Bonneterre

Pathological response to neoadjuvant chemotherapy for inflammatory breast cancer (IBC). Critical evaluation of Chevallier’s and Sataloff’s classifications
J Clin Oncol (Meeting Abstracts) 2006 24: 10666. [Abstract]  

O. Pagani, M. Ruggeri, T. Rusca, R. Graffeo, E. Gallerani, M. Locatelli, M. Conti Beltraminelli, S. Longhi, L. Mazzucchelli, and A. Goldhirsch

Does HER2/neu expression affect adjuvant treatment choices in routine clinical practice?
J Clin Oncol (Meeting Abstracts) 2006 24: 10667. [Abstract]  

C. Isaacs, A. Wang, R. Warren, M. Wilkinson, G. Grana, M. C. Liu, V. Stearns, Y. H. Park, and A. Novielli

A phase II study of weekly gemcitabine and docetaxel in first and second line metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10668. [Abstract]  

E. Galligioni, R. Triolo, A. Lucenti, A. Ferro, M. Frisinghelli, G. Ambrosini, V. Murgia, and R. Micciolo

Clinical presentation and outcomes of 2,924 early breast cancer patients (br.ca. pts) treated in a single institution in a 10-year period with a long follow up
J Clin Oncol (Meeting Abstracts) 2006 24: 10669. [Abstract]  

I. Tusquets, Sr., M. Ramos, M. Gil, P. Sánchez-Rovira, J. R. Mel, A. Duque, L. García-Estévez, and A. Velasco

Preliminary results of docetaxel (T) and trastuzumab (H) combination administered every 21 days in metastatic breast cancer (MBC) and HER-2 over-expression patients (P)
J Clin Oncol (Meeting Abstracts) 2006 24: 10670. [Abstract]  

A. Montes-Worboys, A. Romero, A. M. Casas, E. Arellano, J. M. Juan, J. A. Moreno, and F. Rodriguez Panadero

Gene polimorphisms and biological factors as possible predictors for patients with pleural metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10671. [Abstract]  

R. De Boer, Sr., H. A. Burris, A. Monnier, H. Mouridsen, J. A. O’Shaughnessy, K. McIntyre, K. I. Pritchard, I. Smith, D. Yardley on behalf of the H2H trial steering committee

The Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10672. [Abstract]  

V. Lorusso, M. Spada, M. Giampaglia, A. Misino, R. Calabrese, A. Latorre, G. Monticelli, M. Guida, and D. Sambiasi

Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10673. [Abstract]  

M. Ruiz-Lopez-tejada, L. Tejedor-Cabrera, and C. Iradi-Martinez

Circulating tumour markers and time to progression in the chemotherapy treatment of metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10674. [Abstract]  

R. C. Zellars, D. Frassica, V. Stearns, J. H. Fetting, D. K. Armstrong, L. Myers, T. N. Tsangaris, L. Jacobs, J. R. Lange, and A. C. Wolf

Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial
J Clin Oncol (Meeting Abstracts) 2006 24: 10675. [Abstract]  

W. Han, Y. Zhao, Z. Wu, Y. Mu, L. Yu, Y. Meng, K. Huang, L. Zang, and Q. Li

Identification of estrogenically synthesized LRP16 as an ER coactivator and its role in ER-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10676. [Abstract]  

J. E. Freeman, S. Yang, S. V. Panasyuk, R. A. Lew, D. Ngo, D. V. Faller, and A. E. Rogers

In situ evaluation of residual breast tumor and tumor grade using medical hyperspectral imaging (MHSI)
J Clin Oncol (Meeting Abstracts) 2006 24: 10677. [Abstract]  

G. Perez Manga, M. Méndez, M. I. Palomero, R. Quibén, and J. Belón

Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10678. [Abstract]  

B. Xu, L. Tian, Q. Wu, M. Zhou, H. Wang, Z. Tong, H. Li, L. Li, G. Hu, and J. Shi

Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastastic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10679. [Abstract]  

A. Fabi, M. Milella, P. Malaguti, P. Papaldo, G. Ferretti, P. Carlini, A. Gelibter, A. Felici, I. Sperduti, and F. Cognetti

Pilot study of capecitabine combined with celecoxib (CapCel) for the treatment of far advanced metastatic breast cancer (MBC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 10680. [Abstract]  

M. Mion, F. Chierichetti, G. Liessi, S. Bissoli, E. Milan, F. Oniga, L. Sartor, M. Bortolin, G. Vicario, G. Sgarbossa, and P. Manente

Diagnosis of recurrent breast cancer: 18F-FDG PET/TAC as first choice
J Clin Oncol (Meeting Abstracts) 2006 24: 10681. [Abstract]  

N. S. El-Saghir, Z. Otrock, Z. Abdel Khalik, H. Yassine, M. Khalifeh, N. Bitar, M. Charafeddine, R. Jalloul, A. Dandashi, and A. Shamseddine

A clinical phase II study of combination Cisplatinum and Vinorelbine followed by Docetaxel as first-line chemotherapy in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10683. [Abstract]  

I. H. Shah, A. Shaharyar, A. Shahid, M. Hafeez, S. Perveen, A. Jameel, K. Shabbir, I. Randhawa, J. A. Gilani, A. I. Masood, and A. A. Javed

Phase II feasibility of concurrent docetaxel and post mastectomy radiation after four cycles of AC chemotherapy in patients with high risk operable breast cancer: A trial of the Cancer Research Group Pakistan
J Clin Oncol (Meeting Abstracts) 2006 24: 10684. [Abstract]  

S. X. Franco, A. Perez, E. Tan-Chiu, F. Gokce, C. Frankel, L. S. Schwartzberg, E. Krill, J. Jakub, N. Abramson, and C. Vogel

Updated results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10685. [Abstract]  

J. Hodgins and C. Hamm

Breast cancer wait times: Use of breast screening clinics affect presenting stage
J Clin Oncol (Meeting Abstracts) 2006 24: 10686. [Abstract]  

M. Guity, M. Mokri, M. Shakiba, and M. Atri

Introducing a new scoring system based on HER2/neu, p53 oncogenes results and mammographic findings for prediction of tumor grade in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10687. [Abstract]  

N. Yao, W. Kao, T. Chao, R. Hsieh, J. Lin, C. Su, and S. Lo

A phase II study of gemcitabine and liposomal doxorubicin (Lipo-Dox) as first line chemotherapy in the treatment of metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10688. [Abstract]  

G. Mustacchi, M. Mansutti, S. Barni, M. E. Cazzaniga, A. Farris, R. Ceccherini, C. Sacco, and C. Dellach

Exemestane (Exe) as primary treatment in hormonosensible early breast cancer of the elderly: Preliminary results of a phase II multicenter open Italian study
J Clin Oncol (Meeting Abstracts) 2006 24: 10689. [Abstract]  

W. Demey, H. Wildiers, G. Maleux, P. Clement, S. Heye, P. Debruyne, A. Van Oosterom, and R. Paridaens

Intrahepatic mitomycin C as treatment of breast cancer hepatic metastasis
J Clin Oncol (Meeting Abstracts) 2006 24: 10690. [Abstract]  

A. Rodriguez-Lescure, A. Llombart, R. Colomer, G. Gutierrez, J. Gayo, and I. Tusquets

Phase I-II study of IV vinorelbine (VRL) and oxaliplatin (OXP) every two weeks (q2w) in metastatic breast cancer (MBC): Results of the phase I trial
J Clin Oncol (Meeting Abstracts) 2006 24: 10691. [Abstract]  

J. L. Bayo, M. Lomas, J. Salvador, M. Ruiz, and A. Moreno

Docetaxel (T) followed by capecitabine (X) as first-line chemotherapy in patients (pts) with metastatic breast cancer (MBC): Preliminary findings from a phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10692. [Abstract]  

N. Batista, L. Estevez, P. Sánchez-Rovira, A. Velasco, M. Dómine, F. Lobo, J. Oramas, and J. Cruz

Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10693. [Abstract]  

S. Farjami, F. Waheed, D. Liu, K. Seiter, and T. Ahmed

High dose chemotherapy with autologous stem cell rescue as a part of combined modality therapy in stage IIIB inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10694. [Abstract]  

P. Cobb, L. S. Schwartzberg, K. Kulig, A. Johns, and B. Fortner

Patterns of adjuvant hormonal therapy (AHT) usage in early stage breast cancer (ESBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10695. [Abstract]  

S. R. Fanning, S. Short, K. Coleman, S. Andresen, G. T. Budd, H. Moore, A. Rim, J. Crowe, and D. E. Weng

Correlation of dynamic infrared imaging with radiologic and pathologic response for patients treated with primary systemic therapy for locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10696. [Abstract]  

K. Tauer, L. S. Schwartzberg, A. Epperson, and B. V. Fortner

Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10697. [Abstract]  

A. J. Fernandez Sagarra, C. Alvarenga, M. Alvarenga, M. L. Kraft, and L. C. Teixeira

Relationship between tumor characteristics and HER2/neu overexpression with response and outcome in locally advanced breast cancer (LABC) patients (pts) treated with neoadjuvant anthracycline-based chemotherapy (CHT)
J Clin Oncol (Meeting Abstracts) 2006 24: 10698. [Abstract]  

J. A. Bernstein, T. Schubbert, K. Kong, and R. S. Mehta

Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10699. [Abstract]  

G. E. Cassanello, F. Xynos, P. H. Capellino, A. Bacigaluppi, and P. Betti

Axillary recurrence after negative sentinel node biopsy in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10700. [Abstract]  

D. Serin, M. Namer, L. Cals, O. Rixe, C. Roussel, Y. Coscas, J. Blay, X. Pivot for the EDIFICE committee

Mammography screening in France: Results of EDIFICE study
J Clin Oncol (Meeting Abstracts) 2006 24: 10701. [Abstract]  

Y. Rai, T. Tajima, K. Tamura, Y. Morishita, T. Taki, K. Hisamatsu, Y. Ito, and T. Seriu

Weekly paclitaxel in Japanese women with metastatic or advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10702. [Abstract]  

L. R. Laufman, C. H. Spiridonidis, T. Parker, P. Boury, V. Maggard, and S. Miller

Gemcitabine and docetaxel for metastatic breast cancer—Further data
J Clin Oncol (Meeting Abstracts) 2006 24: 10704. [Abstract]  

N. Valeri, N. Battelli, C. Mariotti, A. Santinelli, W. Siquini, P. Gusella, C. Braconi, P. Lippe, and S. Cascinu Prof

CEA as a prognostic factor in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10705. [Abstract]  

P. Kumar, A. M. Ingle, B. Baney, K. Day, T. Dagen, A. S. Galley, and R. H. Dixon

Effect of microscopic residual tumor (MRT) at surgical margin of resection (SMR) in ductal carcinoma in-situ (DCIS) on survival of non-Hispanic white women in central Pennsylvania (PA)
J Clin Oncol (Meeting Abstracts) 2006 24: 10706. [Abstract]  

B. Mirtsching, T. Chidiac, T. Cosgriff International Oncology Network

First-line treatment of metastatic breast cancer with weekly abraxane (nab-paclitaxel: a 130 nm albumin-bound paclitaxel particle): A preliminary analysis of the phase II international oncology network ION-04–012 study
J Clin Oncol (Meeting Abstracts) 2006 24: 10707. [Abstract]  

E. Stickeler, M. Földi, A. Kummle, A. Hinke, P. C. Hartmann, J. Woll, D. O. Watermann, and G. Gitsch

Pegfilgrastim in dose-dense, sequential adjuvant chemotherapy for patients with breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10708. [Abstract]  

P. Zamora, M. Álvarez de Mon, L. Calvo, C. Jara, J. A. Virizuela, A. Yubero, J. Chacón, J. Mira, and M. González Barón

Phase II study of capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC): Final results
J Clin Oncol (Meeting Abstracts) 2006 24: 10709. [Abstract]  

R. Largillier, P. Fumoleau, C. Clippe, V. Dieras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, and L. Bobadilla

Long median survival with capecitabine (X) single-agent therapy for patients (pts) with anthracycline- and taxane-pretreated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10710. [Abstract]  

M. K. Chellama, S. A. Awadhi, V. Vyas, J. Nemec, A. Khodary, F. Enezi, and M. D. Delvadiya

Prevention of febrile neutropenia by prophylactic use of G-CSF with adjuvant TAC based on risk assessment—Single institute study
J Clin Oncol (Meeting Abstracts) 2006 24: 10711. [Abstract]  

B. Lex, M. Popovic, V. Russu, T. Gilster, H. Volkholz, and A. H. Tulusan

Addition of weekly paclitaxel (P) after dose intensified epirubicin/cyclophosphamide (EC) (NECTA-protocol) as primary systemic chemotherapy (PST) in locally advanced breast cancer (LABC) improves pathologic response rate (pCR) in comparison to peoperative dose intensified EC
J Clin Oncol (Meeting Abstracts) 2006 24: 10712. [Abstract]  

X. Hu, H. Guo, X. Yang, X. Zhao, Y. Cai, Z. Wang, S. Leaw, and J. Li

Phase II study of mitomycin-C and cisplatin in heavily pretreated advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10713. [Abstract]  

N. A. Othieno-Abinya, H. O. Abwao, P. Bird, R. Baraza, B. Byakika, and Y. Kodwavwalla

Experience with breast cancer in a single oncology clinic in Nairobi
J Clin Oncol (Meeting Abstracts) 2006 24: 10714. [Abstract]  

P. Ruff, R. Pienaar, A. Gudgeon, F. Michaelis, and H. Neethling

Docetaxel in advanced breast cancer (BC) in the community setting: Analysis of treatment and prognostic factors in 129 South African patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10715. [Abstract]  

J. H. Barton, W. Liggett, M. Mainwaring, J. D. Hainsworth, L. Simons, D. R. Spigel, H. A. Burris III, and D. A. Yardley

Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10716. [Abstract]  

H. Mukai, T. Watanabe, M. Mitsumori, H. Tsuda, S. Nakamura, N. Masuda, T. Asaga, N. Yamamoto, H. Kaba, and K. Aogi

Safety and efficacy trial of preoperative sequential chemo-radiation therapy for the surgery sparing treatment (SST) in early breast cancer (EBC): Japan Clinical Oncology Group trial (JCOG0306)
J Clin Oncol (Meeting Abstracts) 2006 24: 10717. [Abstract]  

S. Del Prete, L. Montella, V. Faiola, R. Guarrasi, G. Busto, and R. Addeo

Phase II study of pegylated liposomal doxorubicin plus vinorelbine in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10718. [Abstract]  

G. Orphanos, A. Alexopoulos, G. Ioannidis, C. Kandylis, A. Ardavanis, J. Stavrakakis, and G. Rigatos

High efficacy and low toxicity of the combination of vinorelbine and capecitabine as second line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
J Clin Oncol (Meeting Abstracts) 2006 24: 10719. [Abstract]  

M. Demiray, T. Evrensel, O. Kanat, E. Kurt, M. Arslan, S. Gokgoz, S. Tolunay, and O. Manavoglu

Open labeled phase II observation study of gemcitabine plus cisplatin plus trastuzumab (GCT) in metastatic breast cancer patients with prior anthracyclines and taxanes exposures: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 10720. [Abstract]  

M. Abu-Khalaf, R. Kim, M. Cohenuram, G. Chung, M. Digiovanna, B. Haffty, D. Carter, L. Horvath, F. Tavassoli, and B. Burtness

Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10721. [Abstract]  

C. Zamagni, S. Fanti, A. Bernardi, F. Sperandi, S. Quercia, D. Santini, A. Musto, P. Castellucci, M. Taffurelli, and A. Martoni

Evaluation of early response to primary systemic chemotherapy in breast cancer patients by ¹⁸FDG PET: Preliminary findings from the Arianna Project 01
J Clin Oncol (Meeting Abstracts) 2006 24: 10722. [Abstract]  

X. Liu, P. Fan, and Z. Wu

Study on the effects of c-erbB-2-specific antisense oligonucleotides on c-erbB-2 overexpressing breast cancer cells
J Clin Oncol (Meeting Abstracts) 2006 24: 10724. [Abstract]  

F. Moura Silva, C. Tosello, M. T. Laloni, C. M. Andrade, A. Bertozzi, P. Vernaglia, F. M. Correa, R. P. Moraes, and J. S. Goes

FEC 60 adjuvant chemotherapy (AdCT) in breast cancer (BC) patients (Pts): 10-year follow-up results
J Clin Oncol (Meeting Abstracts) 2006 24: 10725. [Abstract]  

C. Milandri, F. Calzolari, A. Passardi, E. Giampalma, C. Tison, L. Cecconetto, S. Calpona, and L. Ridolfi

Breast cancer (BC): May intra-arterial (IA) chemotherapy (CT) play a role in the treatment of locally advanced disease or liver metastases? Report of our experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10726. [Abstract]  

Y. Yap, A. Kendall, U. Banerji, G. Walsh, and I. E. Smith

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10727. [Abstract]  

S. F. Dent, S. Verma, J. Azzi, L. Vandermeer, J. Spaans Breast Cancer Disease Site Group

Trends in systemic management (SM) for the treatment of locally advanced breast cancer: Data from a regional cancer centre
J Clin Oncol (Meeting Abstracts) 2006 24: 10728. [Abstract]  

S. Giacchetti, M. Habdous, H. Hocini, C. Cuvier, A. De Roquancourt, F. Perret, and M. Espié

Neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel (ECT) in locally advanced and inflammatory breast cancer (BC): Saint Louis experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10729. [Abstract]  

D. R. Fescina, W. Gradishar, M. Orlando, J. Rubinsak, L. Haney, and Y. Wang

Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10730. [Abstract]  

D. Mintzer, L. S. Schwartzberg, P. Cobb, D. Henry, A. Epperson, and B. V. Fortner

Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10731. [Abstract]  

J. Ro, K. S. Lee, B. H. Nam, H. S. Lim, Y. Kwon, S. Y. Kong, J. A. Seo, and E. S. Lee

Aromatase inhibitors (AIs) with or without GnRH agonist as first-line hormone therapy in pre- and post-menopausal Korean women with metastatic breast cancer (MBC): Clinical outcomes in correlation with tumor ER/PR/HER2 status
J Clin Oncol (Meeting Abstracts) 2006 24: 10732. [Abstract]  

L. Tozzi, C. D’Addetta, M. Bisceglia, R. Murgo, G. Cilenti, M. El Jaouni, T. P. Latiano, G. Scaramuzzi, S. Parisi, and E. Maiello

Male breast cancer: Our experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10733. [Abstract]  

C. Gennatas, V. Michalaki, J. Psychogios, S. Gennatas, A. Kondi-Paphiti, E. Karvounis, and E. Kairi

Docetaxel and capecitabine as first-line chemotherapy in patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10734. [Abstract]  

A. Bensalem and K. Bouzid

Gemcitabine in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10735. [Abstract]  

Y. Suh, C. Chun, S. Oh, and S. Jung

Is the prophylactic use of colony stimulating factor and oral ciprofloxacin effective to prevent neutropenia in patients having docetaxel, doxorubicin, and cyclophosphamide for breast cancer as an adjuvant chemotherapy in Korea?
J Clin Oncol (Meeting Abstracts) 2006 24: 10736. [Abstract]  

A. Celebic, M. Halaska, O. Kosovac, D. Stojiljkovic, Z. Milovanovic, N. Miletic, and R. Dzodic

Differences on breast cancer management and surgical approach in six European breast cancer units
J Clin Oncol (Meeting Abstracts) 2006 24: 10737. [Abstract]  

P. Fedele, P. Rizzo, A. Cusmai, M. D’Amico, and M. C. Chetrì

Efficacy and safety of mitoxantrone-based chemotherapy as adjuvant treatment in elderly patients (EP) with node positive and high risk node negative breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10738. [Abstract]  

M. W. Ying, A. R. Green, A. Agrawal, C. E. Paish, D. A. Morgan, I. O. Ellis, and K. L. Cheung

Biological characteristics of oestrogen receptor positive early operable primary breast cancer in the elderly
J Clin Oncol (Meeting Abstracts) 2006 24: 10739. [Abstract]  

D. Choi, E. Kim, Y. Kim, M. Lee, and H. Park

Age is not a prognostic factor in Korean women with breast cancer treated with breast conservative surgery and radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10740. [Abstract]  

K. W. Jabboury, A. Wong, K. Sexton, L. Rogers, K. King, C. Reilly, S. Thomas, P. Curtis, O. Mangini, and R. Behar

Limited impact of tamoxifen following dose-intensive L-FAC multimodality therapy of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10741. [Abstract]  

A. E. Tomadoni, R. C. Wainstein, and M. N. Rondinón

Trastuzumab prolonged administration: Safety and toxicity profile in heavily pre-treated patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10742. [Abstract]  

B. Audhuy, C. Meyer, D. Nierges, J. C. Barats, and P. Straub

Monocentric retrospective analysis of locally advanced and inflammatory breast cancer (IBC) patients (pts) having received a neoadjuvant chemotherapy with docetaxel (D) and anthracyclines
J Clin Oncol (Meeting Abstracts) 2006 24: 10743. [Abstract]  

D. Amadori, G. Gasparini, M. O. Vannozzi, C. Milandri, P. Serra, F. Di Costanzo, B. Di Blasio, and G. Lunardi

First line treatment of HER-2/neu positive advanced breast cancer patients with liposomal doxorubicin (Myocet), docetaxel and trastuzumab. A phase I-II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10744. [Abstract]  

A. E. Alarcon-Rozas, R. Melendez, J. Ramirez, F. Salas, J. Ramirez, J. Guevara, A. Galarreta, E. Hernandez, F. Viayrada, and J. Torres

Pathological complete response (pCR) in stage II and III breast cancer patients treated with neoadjuvant chemotherapy (CT): Dose dense ACx4 followed by AT/Tx4 (weekly paclitaxel)
J Clin Oncol (Meeting Abstracts) 2006 24: 10746. [Abstract]  

H. Daw Sr., A. Muslimani, M. Ahluwalia, and M. Kundranda

Central nervous system metastases after trastuzumab therapy in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10747. [Abstract]  

C. F. Lobo, G. Lopes, O. Silva, and S. Gluck

Nanoparticle albumin-bound (Nab) paclitaxel (P) in combination with bevacizumab (B) with and without gemcitabine (G): Early experience at the Braman Family Breast Cancer Institute
J Clin Oncol (Meeting Abstracts) 2006 24: 10748. [Abstract]  

D. O. Bauerschlag, C. Schem, W. Jonat, and N. Maass

Clinical experience using fulvestrant in hormone responsive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10749. [Abstract]  

M. Kashiwaba, T. Inaba, Y. Hayakawa, I. Takiyama, and G. Wakabayashi

Early results of a phase I clinical trial of capecitabine in combination with CPT-11 for metastatic breast cancer (MBC) pre-treated with anthracycline and taxane
J Clin Oncol (Meeting Abstracts) 2006 24: 10750. [Abstract]  

M. Ruiz, J. L. Bayo, J. A. Moreno Nogueira, J. Dorta, A. M. Casas, and M. Morales

Randomized open label phase II study of pegilated liposomal doxorubicine (PLD) four or six-week scheduled in metastatic breast cancer (MBC) patients (p)
J Clin Oncol (Meeting Abstracts) 2006 24: 10751. [Abstract]  

I. Stojkovski, S. Kraleva, S. Smickoska, and S. Crvenkova

Three years follow up in patients with stage III breast cancer: Single institution experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10752. [Abstract]  

T. Puri, M. Malik, G. Gunabushanam, D. N. Sharma, P. K. Julka, and G. K. Rath

Infiltrating ductal carcinoma of male breast: A retrospective study
J Clin Oncol (Meeting Abstracts) 2006 24: 10753. [Abstract]  

S. A. Alawadi and M. D. Delvadiya

Pattern of breast diseases in Kuwait Cancer Control Center, Kuwait
J Clin Oncol (Meeting Abstracts) 2006 24: 10754. [Abstract]  

M. Lomas, J. Salvador, M. Ruiz, and J. L. Bayo

Safety of long-term administration of capecitabine in metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10755. [Abstract]  

M. Lux

MIX —The first results of the ongoing prospective multicentre phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10756. [Abstract]  

N. D. Bajic and D. D. Scepanovic

The analyses of disease free survival and overall survival in premenopausal and postmenopausal axillary node negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10757. [Abstract]  

G. Sulemanjee, S. Ristzert, and T. L. Cao

Docetaxel versus paclitaxel and "paclitaxel" versus paclitaxel: The optional therapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10758. [Abstract]  

A. Bova, H. Jennifer, S. Venkatappa, H. Ozer, and A. Tfayli

Epirubicin and docetaxel is an effective neoadjuvant therapy for breast cancer: Result of a phase II study
J Clin Oncol (Meeting Abstracts) 2006 24: 10759. [Abstract]  

P. Hupperets and M. E. Van Hoef

Combined modality treatment for breast cancer: Justification for integration of transplants at diagnosis
J Clin Oncol (Meeting Abstracts) 2006 24: 10760. [Abstract]  

M. Loewen, A. Ashikari, P. Kelemen, A. Salzberg, J. Savino, and R. Ashikari

Cowden Syndrome as an indication for bilateral prophyllactic mastectomy: A series of two cases
J Clin Oncol (Meeting Abstracts) 2006 24: 10761. [Abstract]  

J. Ordonez, C. Gomez Martin, and H. Cortes-Funes

Trastuzumab in combination with bevacizumab in advanced breast cancer patient resistant to chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10762. [Abstract]  

M. E. Van Hoef

Transplantation for breast cancer: Oncologists beware—a multicenter phase I-II study open to enrollment
J Clin Oncol (Meeting Abstracts) 2006 24: 10763. [Abstract]  

T. Singh, E. Tso, A. Kumar, and P. Ahrens

Axillary lymph node metastases from papilloma of the breast
J Clin Oncol (Meeting Abstracts) 2006 24: 10764. [Abstract]  

C. J. Tai, C. K. Pan, C. H. Wu, and C. S. Chen

Cost-effective treatment with half year of trastuzumab and chemotherapy as adjuvant treatment for overexpression of Her2/neu breast cancer patients: Two institutional experiences in Taiwan
J Clin Oncol (Meeting Abstracts) 2006 24: 10765. [Abstract]  

N. Fitzgibbon and A. Langtry

Providing information and support on all aspects of breast health and breast cancer in Ireland
J Clin Oncol (Meeting Abstracts) 2006 24: 10766. [Abstract]  

J. Samuel and D. Osafo

Rapid and prolonged palliation of symptoms with improved quality of life (QOL) with endocrine therapy (anastrazole) in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2006 24: 10767. [Abstract]  

F. Gago, D. R. Ciocca, B. Mendiondo, J. Orozco, and O. Tello

Clinical and pathological characteristics of basal -like breast carcinomas
J Clin Oncol (Meeting Abstracts) 2006 24: 10768. [Abstract]  

M. M. Magbanua, J. E. Lang, J. Scott, J. R. Crothers, S. Federman, C. Haqq, and J. Park

Gene expression profiling of circulating tumor cells from breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10769. [Abstract]  

A. Stojadinovic, J. Hooke, C. D. Shriver, A. Kovatich, A. Nissan, S. Ponniah, G. E. Peoples, and M. Moroni

Differential expression of the 150-kd oxygen-regulated protein (ORP150) in benign, pre-malignant and malignant breast tissue
J Clin Oncol (Meeting Abstracts) 2006 24: 10770. [Abstract]  

Z. Jiang, S. Zhang, X. Xie, J. Liu, J. Ren, H. Wang, Q. Sun, Y. Bai, Y. Cheng, X. Liang, and S. Jiao

A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10771. [Abstract]  

A. Ghaneie, J. B. Duhadaway, V. Zemba-Palko, and G. C. Prendergast

Bin1 expression is lost in breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10772. [Abstract]  

T. Palangie, P. Pouillart, H. Roche, P. Viens, C. Linassier FNCLCC study group

Five years update of sequential high dose doxorubicin, cyclophosphamide and docetaxel in inflammatory breast cancer; PEGAGE05 trial on behalf of FNLCC
J Clin Oncol (Meeting Abstracts) 2006 24: 10773. [Abstract]  

D. Grecea Sr., L. Neamtiu, C. Vasiliniuc, R. Tanasescu, A. Rancea, L. Resiga, M. Galatar, V. Popita, D. Daicoviciu, D. Postescu, and N. Ghilezan

Capecitabine (Xeloda) and quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC) relapsing after treatment with anthracycline and taxane containing–therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 10774. [Abstract]  

F. Morales-Vasquez, S. García, H. Lopez-Basave, and R. Altamirano-Ley

Detection of doxorubicin cardiotoxicity in patients with breast cancer by 99mTc-MIBI myocardial perfusion tomography
J Clin Oncol (Meeting Abstracts) 2006 24: 10775. [Abstract]  

N. Tagaya, R. Yamazaki, A. Nakagawa, S. Mori, K. Hamada, and K. Kubota

An intraoperative sentinel lymph node identification in breast cancer patients guided by near-infrared fluorescence imaging: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 10776. [Abstract]  

K. Yamada, N. Kohno, K. Endoh, D. Kimura, F. Ueno, A. Ogata, D. Ohta, H. Kaise, and H. Kato

The role of bisphosphonates and bone health issues in Japanese Breast Cancer patients: Efficacy of alendronate with aromatase inhibitors
J Clin Oncol (Meeting Abstracts) 2006 24: 10777. [Abstract]  

A. Iagaru, R. Masamed, H. Silberman, S. Keesara, and P. S. Conti

The role of F-18 FDG PET/CT and breast MRI in the management of breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 10778. [Abstract]  

H. R. Marana, J. M. Andrade, D. G. Tiezzi, F. E. Zola, H. H. Carrara, F. C. Reis, and S. Bighetti

Primary chemotherapy in breast cancer shows excellent clinical and pathological response with docetaxel and epirubicin
J Clin Oncol (Meeting Abstracts) 2006 24: 10779. [Abstract]  

R. Segal, S. F. Dent, S. Verma, C. M. Canil, J. Azzi, L. Vandermeer, and J. Spaans

Changing demographics of locally advanced breast cancer: Data from a regional cancer centre
J Clin Oncol (Meeting Abstracts) 2006 24: 10780. [Abstract]  

R. Jordan, H. Brzeski, W. P. London, R. Mural, M. N. Liebman, J. Hooke, C. D. Shriver, and H. Hu

Observations of differences in laterality imbalance of breast biopsies and breast disease between Caucasian and African American women
J Clin Oncol (Meeting Abstracts) 2006 24: 10781. [Abstract]  

M. Ortega, M. Ruiz-Echarri, E. Prats, R. Lastra, E. Aguirre, J. Lambea, E. Milastre, J. Mayordomo, P. Razola, A. Tres, and J. Banzo

What is the yield of regional lymph node dissection following sentinel lymph node involvement in patients with breast cancer?
J Clin Oncol (Meeting Abstracts) 2006 24: 10782. [Abstract]  

T. Tabei, K. Sato, K. Inoue, S. Nakano, T. Kai, K. Futsuhara, S. Yamashita, T. Saito, T. Kuroda, and K. Suemasu

Multicenter, prospective study of radiotherapy without surgery after AC followed by weekly paclitaxel for patients with inflammatory breast cancer: SBCCSG-04 study
J Clin Oncol (Meeting Abstracts) 2006 24: 10783. [Abstract]  

M. Hirata, H. Kawabata, and K. Tanaka

Sentinel lymph nodes navigation surgery for stage I or IIA breast cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 10784. [Abstract]  

S. Wang, K. Xu, X. Liu, Q. Zhou, Q. Geng, and Q. Geng

Experimental study on Chinese ink as the dye for the sentinel lymph node biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 10785. [Abstract]  

L. S. Maddali and S. Maddali

Multiple primary neoplasms involving the breast
J Clin Oncol (Meeting Abstracts) 2006 24: 10786. [Abstract]  

E. Millastre, M. Ruiz-Echarri Sr., M. Ortega, J. I. Mayordomo, R. Lastra, E. Prats, J. Lambea, E. Aguirre, P. Razola, R. Andrés, A. Tres, and J. Banzo

Axillary lymphadenectomy can be safely avoided in patients with breast cancer and negative sentinel lymph node biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 10787. [Abstract]  

S. Del Bianco and R. Rondinelli

Trastuzumab-containing therapies: Activity beyond disease progression in M.B.C.—A pivotal experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10788. [Abstract]  

G. Artioli, F. Bozza, G. Cartei, S. Zovato, R. Mencarelli, G. Zavagno, and M. Michelotto

A phase II study of gemcitabine (G), peghilated liposomal doxorubicin (PLD) and docetaxel (D) in locally advanced breast cancer (LABC): An interim analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 10789. [Abstract]  

C. P. Bowen-Wells, W. E. Sumner, F. Moffat, E. Avisar, and D. Fraceschi

Disparities in breast cancer among 236,101 patients in Florida
J Clin Oncol (Meeting Abstracts) 2006 24: 10790. [Abstract]  

R. S. Ahmed, J. B. Fiveash, R. A. Popple, S. A. Spencer, and J. F. De Los Santos

An IMRT technique to increase therapeutic ratio of breast irradiation in patients with early stage left breast cancer: Limiting second malignancies
J Clin Oncol (Meeting Abstracts) 2006 24: 10791. [Abstract]  

M. S. Reza, Q. Chowdhury, M. A. Hai, and M. A. Rahman

A phase II study of docetaxel-carboplatin as first line therapy in the patients with visceral metastatic breast cancer: A Bangladesh experience
J Clin Oncol (Meeting Abstracts) 2006 24: 10792. [Abstract]  

Cancer Prevention:

C. J. Fabian, B. F. Kimler, J. R. Anderson, C. Chamberlain, M. S. Mayo, C. M. Zalles, J. A. O’Shaughnessy, H. T. Lynch, K. A. Johnson, and D. Browne

Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene
J Clin Oncol (Meeting Abstracts) 2006 24: 1001. [Abstract]  

A. Bardia, A. H. Wang, L. C. Hartmann, J. E. Olson, C. M. Vachon, R. A. Vierkant, and J. R. Cerhan

Physical activity and risk of postmenopausal breast cancer defined by hormone receptor status and histology: A large prospective cohort study with 18 years of follow up
J Clin Oncol (Meeting Abstracts) 2006 24: 1002. [Abstract]  

N. D. Kauff, S. M. Domchek, T. M. Friebel, J. B. Lee, R. Roth, M. E. Robson, R. R. Barakat, L. Norton, K. Offit, T. R. Rebbeck PROSE Study Group

Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 1003. [Abstract]  

D. Euhus, R. Ashfaq, D. Bu, A. M. Leitch, and C. Lewis

Assessment of tumor suppressor gene methylation for breast cancer risk screening
J Clin Oncol (Meeting Abstracts) 2006 24: 1004. [Abstract]  

D. E. Brenner, Y. Su, D. P. Normolle, S. Syngal, R. Bresalier, N. Marcon, J. Baron, and T. Block

Detection of colorectal neoplasia associated K-Ras mutations in human urine
J Clin Oncol (Meeting Abstracts) 2006 24: 1005. [Abstract]  

N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiyama, and N. Moriyama

The adenocarcinoma-specific stage shift: Closely-repeated low-dose helical CT screening in a high-risk cohort for 10 years
J Clin Oncol (Meeting Abstracts) 2006 24: 1006. [Abstract]  

J. Kim, X. Wang, R. Babaian, L. Pisters, C. Pettaway, C. Wood, A. Sabichi, T. McDonnell, C. Logothetis, and P. Troncoso

A preoperative model evaluating the tissue effects of chemopreventive agents in low-volume prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 1007. [Abstract]  

T. F. Schwarz

An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old
J Clin Oncol (Meeting Abstracts) 2006 24: 1008. [Abstract]  

B. Bonanni, B. Santillo, D. Serrano, U. Veronesi, M. Rosselli Del Turco, P. Masullo, N. Monti, C. Andreoli, and A. Decensi

Initial results of a phase III study show safety of HRT and low dose tamoxifen
J Clin Oncol (Meeting Abstracts) 2006 24: 1009. [Abstract]  

B. Arun, V. Valero, G. Yin, G. Babiera, J. L. Murray, D. Browne, Y. Gong, E. Cook, G. N. Hortobagyi, and N. Sneige

Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 1010. [Abstract]  

Q. J. Khan, B. F. Kimler, E. J. Smith, A. P. O’Dea, P. Sharma, and C. J. Fabian

Correlation of mammographic breast density with Ki-67 expression in benign breast epithelial cells obtained by random periareolar fine needle aspiration of high risk women
J Clin Oncol (Meeting Abstracts) 2006 24: 1011. [Abstract]  

C. D. Figueroa-Moseley, G. C. Williams, G. R. Morrow, P. Jean-Pierre, J. Carroll, and J. Ryan

Empowered to stop smoking: The impact of a SDT smoking cessation intervention on economically disadvantaged whites and blacks
J Clin Oncol (Meeting Abstracts) 2006 24: 1012. [Abstract]  

A. R. Uyei, K. R. Broglio, T. L. Solomon, K. J. Vogel, C. I. Amos, K. Lu, F. Meric-Bernstam, L. Strong, and B. Arun

Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA1/2 genetic mutation
J Clin Oncol (Meeting Abstracts) 2006 24: 1013. [Abstract]  

A. Kendall, I. Smith, E. Folkerd, and M. Dowsett

Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention
J Clin Oncol (Meeting Abstracts) 2006 24: 1014. [Abstract]  

A. R. Bradbury, C. K. Daugherty, J. Dignam, C. Ibe, S. Auh, H. Fay, S. A. Cummings, M. A. White, and O. I. Olopade

Disclosure patterns and decision making preferences in BRCA 1/2 mutation carriers with young adult and minor children
J Clin Oncol (Meeting Abstracts) 2006 24: 1015. [Abstract]  

R. Surapaneni, R. Behm, and C. Wood

Effect of HMG CoA reductase inhibitors on the grade and recurrence of colonic polyps
J Clin Oncol (Meeting Abstracts) 2006 24: 1016. [Abstract]  

A. Alkhenizan and K. Hafez

The role of vitamin E in the prevention of cancer: Meta-analysis of randomized controlled trials
J Clin Oncol (Meeting Abstracts) 2006 24: 1017. [Abstract]  

C. C. Sun, S. K. Peterson, K. G. White, B. G. Watts, M. S. Daniels, S. G. Boyd-Rogers, K. M. Schmeler, D. C. Bodurka, and K. H. Lu

Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colectal cancer (HNPCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 1018. [Abstract]  

R. K. Gibb, J. D. Wright, R. Davila, M. A. Powell, J. S. Rader, F. Gao, and D. G. Mutch

Cervical cytologic screening: Optimal management of atypical squamous cells of undetermined significance in young women
J Clin Oncol (Meeting Abstracts) 2006 24: 1019. [Abstract]  

S. Dawson, J. McKinley, M. Jenkins, S. McLachlan, G. Lindeman, M. Friedlander, J. Hopper, and K. Phillips

Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab)
J Clin Oncol (Meeting Abstracts) 2006 24: 1020. [Abstract]  

C. P. Somkin, R. Gross, H. Liu, and L. Fehrenbacher

Automated data base screening of a population-based cohort of stage 1 colon cancer patients for eligibility in NSABP P-3, a polyp prevention study with celecoxib at Kaiser Permanente Northern California (KPNC)
J Clin Oncol (Meeting Abstracts) 2006 24: 1021. [Abstract]  

E. B. Lamont and L. E. Dias

NSAIDs, osteoarthritis, and colorectal cancer risk: Can administrative data provide a window into the effectiveness of a cancer prevention?
J Clin Oncol (Meeting Abstracts) 2006 24: 1022. [Abstract]  

S. R. Smiljanic and S. Gill

Patterns of diagnosis for colorectal cancer (CRC): Screening detected versus symptomatic presentation
J Clin Oncol (Meeting Abstracts) 2006 24: 1023. [Abstract]  

M. E. Wood, M. Stanley, and G. Leiman

Ductal lavage (DL) of affected and unaffected breasts in women with newly diagnosed breast cancer: Can this technique be used for risk assessment?
J Clin Oncol (Meeting Abstracts) 2006 24: 1024. [Abstract]  

S. Nishizawa, M. Inubushi, H. Okada, F. Ozawa, S. Kojima, S. Teramukai, and M. Fukushima

Cancer screening trial to evaluate the efficacy of FDG-PET in healthy subjects: 2-year results of the Hamamatsu Medical Imaging Center study
J Clin Oncol (Meeting Abstracts) 2006 24: 1025. [Abstract]  

L. L. Garland, H. S. Chow, J. Einspahr, R. B. Harris, J. Buckmeier, M. Tobar, S. Rodney, and I. A. Hakim

Phase III trial of chemoprevention of lung carcinogenesis using green tea beverage and tea polyphenols (Polyphenon E)
J Clin Oncol (Meeting Abstracts) 2006 24: 1026. [Abstract]  

A. Artmann, M. Heyne, M. Kiechle, and N. Harbeck

Breast self examination training and counseling as motivation strategies for breast awareness and participation in breast cancer screening programs
J Clin Oncol (Meeting Abstracts) 2006 24: 1027. [Abstract]  

H. T. Lynch, C. Snyder, J. Lynch, S. Ghate, and S. Thome

Family information service (FIS) in a BRCA1 extended family
J Clin Oncol (Meeting Abstracts) 2006 24: 1028. [Abstract]  

K. J. Mathews, D. Farria, B. C. Springer, and G. Randall

Initiatives to improve minority participation in cancer clinical trials
J Clin Oncol (Meeting Abstracts) 2006 24: 1029. [Abstract]  

S. Waheed and T. A. Linthacum

Preference and compliance of stool occult blood testing in a rural cancer-screening program
J Clin Oncol (Meeting Abstracts) 2006 24: 1030. [Abstract]  

P. Sharma, B. F. Kimler, T. Kennedy, E. J. Smith, Q. J. Khan, and C. J. Fabian

Correlation of statin use with breast random periareolar fine needle aspiration (RPFNA) cytomorphology in high risk postmenopausal women
J Clin Oncol (Meeting Abstracts) 2006 24: 1031. [Abstract]  

J. J. Zarba, S. Holgado, M. Sanchez Segura, A. Gonzalez, C. Lorente, C. Monroy, V. Cano Busnelli, A. Elias E. Programa de Detección Precoz de Cáncer Cervical Uterino

Outcome-impact of a cervical cancer (CC) screening program (SP) in a developing country
J Clin Oncol (Meeting Abstracts) 2006 24: 1032. [Abstract]  

A. F. Lazarev, V. D. Petrova, T. V. Sinkina, I. A. Selezneva, and S. A. Terekhova

Factor analysis in early detection of malignancies
J Clin Oncol (Meeting Abstracts) 2006 24: 1033. [Abstract]  

E. G. Shaw, B. Berkey, S. W. Coons, D. Brachman, J. C. Buckner, K. J. Stelzer, G. R. Barger, P. D. Brown, M. R. Gilbert, and M. Mehta

Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG)
J Clin Oncol (Meeting Abstracts) 2006 24: 1500. [Abstract]  

V. A. Levin and K. R. Hess

Study design considerations for phase II trials of anaplastic gliomas and its impact on phase III survival studies
J Clin Oncol (Meeting Abstracts) 2006 24: 1501. [Abstract]  

S. Holgado, M. Sanchez Segura, J. J. Zarba, C. Monroy, C. Lorente, and A. Elias

Frequency of biopsies (BX) and colposcopy (CP) of intraepitelial lesions (IL) in the cervical cancer screening program (CCSP)
J Clin Oncol (Meeting Abstracts) 2006 24: 11000. [Abstract]  

N. S. Markovic, O. Markovic, and E. S. Henderson

The power of the biomarker for cervical cancer control
J Clin Oncol (Meeting Abstracts) 2006 24: 11001. [Abstract]  

Central Nervous System Tumors:

C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry

Significance of necrosis in grading of anaplastic oligodendroglial tumors: A clinicopathological and genetic study of 916 high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2006 24: 1502. [Abstract]  

T. A. Kaleita, D. K. Wellisch, C. A. Graham, B. Steh, P. Nghiemphu, J. M. Ford, A. Lai, S. Peak, and T. F. Cloughesy

Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 1503. [Abstract]  

J. Li, S. M. Bentzen, M. Renschler, and M. P. Mehta

Improvement in neurocognitive function (NCF) correlates with tumor regression after whole brain radiation therapy (WBRT) for brain metastases (BM)
J Clin Oncol (Meeting Abstracts) 2006 24: 1504. [Abstract]  

R. B. Jenkins, K. V. Ballman, C. Giannini, R. M. Arusell, H. Blair, S. Passe, H. Flynn, P. Brown, E. G. Shaw, and J. C. Buckner

Diagnostic and prognostic significance of a t(1;19)(q10;p10) in patients (pts) with low-grade oligodendroglioma and astrocytoma: NCCTG 94–72–53
J Clin Oncol (Meeting Abstracts) 2006 24: 1505. [Abstract]  

J. J. Vredenburgh, A. Desjardins, J. E. Herndon, II, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman

Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas
J Clin Oncol (Meeting Abstracts) 2006 24: 1506. [Abstract]  

T. D. Nguyen, A. B. Lassman, E. Lis, N. Rosen, D. R. Shaffer, H. I. Scher, L. M. Deangelis, and L. E. Abrey

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2006 24: 1507. [Abstract]  

M. Bredel, C. Bredel, D. Juric, G. E. Duran, R. X. Yu, G. R. Harsh, H. Vogel, L. D. Recht, A. C. Scheck, and B. I. Sikic

Tumor necrosis factor--induced protein 3 down-regulates nuclear factor-B-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas
J Clin Oncol (Meeting Abstracts) 2006 24: 1508. [Abstract]  

J. N. Sarkaria, B. L. Carlson, P. A. Decker, M. J. Schroeder, G. J. Kitange, K. V. Ballman, and C. James

MGMT methylation status correlates with temozolomide-mediated radiosensitization in a panel of GBM orthotopic xenografts
J Clin Oncol (Meeting Abstracts) 2006 24: 1509. [Abstract]  

F. S. Lieberman, C. Tsien, B. Berkey, W. Curran, M. Werner-Wasik, R. Smith, L. Grossheim, E. Hug, and M. Mehta

Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04–20
J Clin Oncol (Meeting Abstracts) 2006 24: 1510. [Abstract]  

L. Buttolo, F. Giunta, V. D. Ferrari, S. Grisanti, G. Marini, and P. Mortini

Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6-year experience
J Clin Oncol (Meeting Abstracts) 2006 24: 1511. [Abstract]  

D. T. Blumenthal, M. Wade, C. J. Rankin, F. Fitzpatrick, K. Stelzer, A. Sloan, W. Ackerley, and E. J. Rushing

MGMT methylation in newly-diagnosed glioblastoma multiforme (GBM): From the S0001 phase III study of radiation therapy (RT) and O⁶-benzylguanine, (O⁶BG) plus BCNU versus RT and BCNU alone for newly diagnosed GBM
J Clin Oncol (Meeting Abstracts) 2006 24: 1512. [Abstract]  

M. C. Chamberlain, M. J. Glantz, L. Chalmers, A. Van Horn, and A. E. Sloan

Early necrosis following concurrent temozolomide and radiotherapy in adult patients with glioblastoma
J Clin Oncol (Meeting Abstracts) 2006 24: 1513. [Abstract]  

A. A. Brandes, A. Tosoni, G. Cavallo, L. Scopece, M. Gardiman, F. Berti, L. M. Pasetto, F. Ferrarese, V. Blatt, and M. Ermani

Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: A phase II GICNO study
J Clin Oncol (Meeting Abstracts) 2006 24: 1514. [Abstract]  

O. Chinot, M. Barrie, B. Calissi, S. Fuentes, P. Metellus, S. Honore, C. Boucard, A. Loundou, D. Figarella-Branger, and H. Dufour

Impact of Karnovsky performance status (KPS) on outcome of elderly patients (pts) with glioblastoma (GBM) and activity of temozolomide (TMZ) as first line therapy: Retrospective analysis of a cohort
J Clin Oncol (Meeting Abstracts) 2006 24: 1515. [Abstract]  

A. Berrocal, P. Perez-Segura, M. Gil, C. Balaña, R. Yaya-Tur, R. Yaya-Tur, J. Rodriguez, G. Reynes, J. Garcia-Lopez, and O. Gallego

Phase II study of extended schedule temozolomide in refractory gliomas
J Clin Oncol (Meeting Abstracts) 2006 24: 1516. [Abstract]  

M. A. Vogelbaum, B. Berkey, D. Peereboom, C. Giannini, R. Jenkins, J. Suh, P. Brown, D. Blumenthal, C. Biggs, and M. Mehta

RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival
J Clin Oncol (Meeting Abstracts) 2006 24: 1517. [Abstract]  

B. D. Ross, D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. Tsein, C. R. Meyer, S. Mukherji, L. Junck, A. Rehemtulla, and T. S. Lawrence

Assessment of the functional diffusion map (fDM) as an imaging biomarker for early stratification of glioma clinical response
J Clin Oncol (Meeting Abstracts) 2006 24: 1518. [Abstract]  

S. C. Pannullo, J. Burton, J. Serventi, P. Stieg, H. Subramanian, R. Elsoueidi, I. El-Jassous, and C. Balmaceda

Phase I/II trial of twice-daily temozolomide and celecoxib for treatment of relapsed malignant glioma: Final data
J Clin Oncol (Meeting Abstracts) 2006 24: 1519. [Abstract]  

J. C. Buckner, K. Ballman, P. Schaefer, A. F. Furth, C. Giannini, B. W. Scheithauer, E. Galanis, and K. A. Jaeckle

NCCTG 96–94–53: Clinical variables associated with overall survival (OS), progression-free survival (PFS), 6 month progression-free survival (PFS6), immediate progression (ImmProg), and response in patients enrolled in recurrent glioma clinical trials
J Clin Oncol (Meeting Abstracts) 2006 24: 1520. [Abstract]  

K. A. Jaeckle, P. A. Decker, K. V. Ballman, P. J. Flynn, C. Giannini, B. W. Scheithauer, R. B. Jenkins, and J. C. Buckner

Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival
J Clin Oncol (Meeting Abstracts) 2006 24: 1521. [Abstract]  

U. Bode, S. Buchen, G. Janssen, T. Reinhard, M. Warmuth-Metz, F. Bach, and G. Fleischhack

Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents
J Clin Oncol (Meeting Abstracts) 2006 24: 1522. [Abstract]  

H. Zhang, M. Tian, C. Zhao, X. Ye, and H. Zhan

11C-Methionine PET to predict survival of glioma patients treated by radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 1523. [Abstract]  

R. Yamanaka, N. Yajima, T. Mine, A. Yamada, M. Shigemor, and K. Ito

Immunological evaluation of personalized peptide vaccination for patients with malignant glioma: The results of a clinical phase I trial
J Clin Oncol (Meeting Abstracts) 2006 24: 1524. [Abstract]  

J. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck, and V. Heinemann

Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid
J Clin Oncol (Meeting Abstracts) 2006 24: 1525. [Abstract]  

C. Marosi, M. Vedadinejad, C. Haberler, J. A. Hainfellner, K. Dieckmann, K. Rössler, and M. R. Hassler

Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R
J Clin Oncol (Meeting Abstracts) 2006 24: 1526. [Abstract]  

A. Chakravarti, B. Berkey, H. I. Robins, A. Guha, W. J. Curran, D. Brachman, C. Shultz, and M. Mehta

An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma
J Clin Oncol (Meeting Abstracts) 2006 24: 1527. [Abstract]  

W. R. Shapiro, M. Schmid, M. Glantz, and J. J. Miller

A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis
J Clin Oncol (Meeting Abstracts) 2006 24: 1528. [Abstract]